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Abstract 
The overall aim of this thesis was to understand gender differences in obstructive sleep 
apnea (OSA) and use this information to develop a tailored therapy for female patients. 
Specific aims were to determine whether gender differences commonly reported in the 
literature are present in mild OSA and upper airway resistance syndrome (UARS) patient 
groups, and whether symptoms could be linked to respiratory parameters in these groups. 
The final aim was to develop, test and validate a new AutoSet treatment for female OSA 
patients.  
CHAPTER 1 of this thesis provides a detailed review of gender differences in the 
prevalence, symptoms, clinical experience, and health outcomes of OSA and UARS 
patients, with a focus on the implications of different scoring rules.  
CHAPTER 2 reviews of quality of life questionnaires from 259 untreated patients with mild 
OSA. Females reported statistically significantly higher levels of sleepiness, fatigue, 
insomnia, and anxiety/depression compared to males.  
CHAPTER 3 of this thesis reviews polygraphy data from patients with mild OSA.  Male 
patients were found to have significantly more breathing disturbances than females, however 
many of these difference disappeared when updated scoring criteria were used. Some weak 
correlations were found between respiratory parameters and symptoms; however, no clear 
conclusions could be drawn.  
CHAPTER 4 outlines the development of a new AutoSet device designed for female- 
specific breathing patterns. The remaining chapters (CHAPTER 5, and CHAPTER 6) of this 
thesis describe the testing and validation activities undertaken on the AutoSet F, including a 
clinical trial to test efficacy; a bench test to compare performance against other commercially 
available devices; a controlled product launch to validate the features of the algorithm; and 
finally a clinical trial which demonstrated improvements in sleep efficacy and quality of life 
over a three-month usage period.  
In summary, this thesis has shown that at the mild end of the OSA spectrum females are 
more symptomatic than males, even though respiratory differences in the genders are less 
pronounced than those described in moderate-to-severe patients. An AutoSet designed 
specifically for female OSA patients was successful in demonstrating efficacy and clinical 
effectiveness.     
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CHAPTER 1. INTRODUCTION – GENDER DIFFERENCES 
IN OBSTRUCTIVE SLEEP APNEA 
 
1.1. General introduction to the thesis 
The overall aim of this thesis was to understand gender differences in OSA and use this 
information to develop a tailored therapy for female patients. Specific aims were to 
determine whether gender differences commonly reported in the literature still exist in the 
mild OSA and UARS patient groups, and whether symptoms could be linked to breathing 
parameters in these groups. The final aim was to develop, test and validate a new AutoSet 
treatment for female OSA patients.  
The sections of this chapter are intended to provide a detailed background to this thesis, 
beginning with an overview of the difficulties in defining severity in OSA. In the next sections, 
the gender differences of OSA will be discussed, including prevalence, symptoms, clinical 
presentation, short and long-term health consequences, and suspected mechanisms. Mild 
OSA and UARS are then reviewed to determine whether gender differences are present in 
these patient groups. Gender differences in polysomnography data are then explored, along 
with mechanisms to explain why females appear to have different features of OSA. The final 
sections of this chapter describe the current treatments for OSA and options for female OSA 
patients, including the limitations of current treatments for female patients. 
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1.2. How should we define severity in OSA? 
Sleep disordered breathing (SDB) can be conceptualised as a continuum, ranging from 
simple snoring through to severe OSA (Figure 1).  
 
Figure 1: Continuum of sleep disordered breathing 
OSA is defined as repetitive closures of the upper airway during sleep. The airway closures 
can either be partial (hypopneas), or complete (apneas), and are associated with reduced 
airflow, oxygen desaturation, and arousal from sleep. The severity of OSA is determined 
from the number of breathing events occurring each hour (the apnea-hypopnea index [AHI)]. 
Patients are defined as having mild (AHI 5 to <15), moderate (AHI 15 to <30), or severe 
OSA (AHI >30). While the definition of obstructive apneas has remained relatively constant, 
the exact definition of what qualifies as a hypopnea has been one of considerable debate 
(1). Table 1 displays the recent history of hypopnea definitions according to the American 
Academy of Sleep Medicine (AASM).  
Table 1: Definitions of hypopneas 
 
Recommended Alternative 
AASM 
2012 (1) 
A hypopnea is scored when there 
is: 
 A decrease in oronasal airflow by ≥ 
30% from baseline AND 
 The event is ≥ 10 sec long AND 
 The event is associated with ≥ 3% 
SpO2 desaturation OR arousal 
Note: The AASM 2007 recommended 
definition may be used if the 
diagnosis is required for U.S. 
Medicaid or Medicare 
reimbursement. 
 
AASM 
2007 (2) 
A hypopnea is scored when there 
is: 
 A decrease in oronasal airflow by ≥ 
30% from baseline AND 
 The event is ≥ 10 sec long AND 
A hypopnea is scored when there 
is: 
 A decrease in oronasal airflow by 
≥ 50% from baseline AND 
 The event is ≥ 10 sec long AND 
Simple 
snoring
Upper 
Airway 
Resistance 
Syndrome 
(UARS)
Mild OSA
Moderate 
OSA
Severe 
OSA
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 The event is associated with ≥ 4% 
SpO2 desaturation 
 Associated with ≥ 3% SpO2 
desaturation OR an arousal 
AASM 
Chicago 
Rules 
(Classic 
criteria) 
1999 (3) 
Those with a > 50% decrease in a 
valid measure of airflow without a 
requirement for associated oxygen 
desaturation or arousal 
Those with a lesser airflow 
reduction in association with 
oxygen desaturation of > 3% or 
an arousal  
In 2007, the criteria of a ≥4% decrease in oxygen saturation during hypopneas was set due 
to the evidence at the time demonstrating the strongest links between oxygen saturation of 
≥4% and adverse cardiovascular outcomes (1). Further studies then showed that the risk 
was very similar with oxygen desaturation of ≥3%, and therefore in 2012 the taskforce 
recommended adoption of the ≥3% oxygen desaturation criteria for hypopneas (1). Arousals 
were added to the definition of hypopneas because the AASM wished to recognise the 
detrimental effects of repetitive arousals from sleep, regardless of oxygen saturation (1).  
1.2.1. Impact of changes in scoring rules  
It is well known that different hypopnea definitions result in different AHI values. The clinical 
consequence is that some patients may be denied treatment based on one set of scoring 
rules and provided treatment when using another set. This issue was discussed at length 
when the scoring rules changed in 2007. Guilliminault et al. found that up to 40% of patients 
who had been diagnosed with OSA based on the 1999 criteria would not have been 
diagnosed with OSA if they were scored according to AASM 2007 (4). Bahamman et al. (5) 
found that up to 45% (when using an AHI cut-off of 5) and 52% (when using an AHI cut-off of 
15) of patients would have not been diagnosed with OSA using AASM 2007 criteria, but 
were diagnosed when using AASM 2012 criteria. Table 2 displays the changes in number of 
patients diagnosed with OSA when using AASM 2007 and 2012 scoring techniques.  
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Table 2: Percentage of patients with positive sleep studies based on AASM scoring criteria of hypopneas  
Author n AASM 2007  
Recommended 
 (%) 
AASM 2007  
Alternative 
 (%) 
AASM 2012  
Recommended 
 (%) 
  AHI ≥ 5 AHI ≥ 
15 
AHI ≥ 
5 
AHI ≥ 
15 
AHI ≥ 
5 
AHI ≥ 
15 
Ruehland et al. (6)  328 59 38 76 50 - - 
Bahammam et al. (5) 100 24 11 31 21 19 31 
Ho et al. (7) 6,441 30.4 21.7 - - 38.15 44.8 
 
1.2.2. Where does Upper Airway Resistance Syndrome fit in?  
Upper Airway Resistance Syndrome (UARS) was first described by Guilleminault et al. in 
1993 (8), although the characteristics of the disease were first described in the late 1950s 
(9). Guilleminault et al. studied a group of 15 subjects who complained of daytime sleepiness 
and displayed breathing abnormalities during sleep, but did not have obstructive sleep 
apnea based on guidelines at the time. Guilleminault et al. described periods of flow 
limitation during which esophageal pressure continually increased until a short EEG arousal 
occurred. These events were termed Respiratory Effort Related Arousals (RERAs). In UARS 
patients RERAs occur multiple times during the night and significantly disrupt sleep. The key 
components of RERAs are: increase in respiratory effort with small decrease in flow (less 
than 30%) (10), cortical or autonomic arousal (10), and very little oxygen desaturation (11). 
The increase in respiratory effort can be measured directly by esophageal pressure, or 
indirectly from flow limitation via a nasal cannula (11). Although esophageal manometry is 
considered the gold standard for detecting respiratory effort, it can be poorly tolerated and is 
restricted to use within a clinical environment. The inspiratory flow shape seen when using 
nasal cannula is sufficient to identify flow limitation events and RERAs with similar accuracy 
than the detail provided by esophageal manometry (12, 13). 
The AASM has defined diagnostic criteria for RERAs and UARS (Table 3). 
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Table 3: Diagnostic criteria for RERAs and UARS 
Diagnostic Criteria  
RERA (AASM 2007) (2) A sequence of breaths lasting at least 10 seconds 
characterized by  
i. increasing respiratory effort or 
ii. flattening of the inspiratory portion of the nasal 
pressure (diagnostic study) or PAP flow 
waveform  
iii. which leads to an arousal from sleep and does 
not meet the criteria for an apnea or a 
hypopnea.  
 
UARS (AASM 2005) (14) Major criteria  
 Excessive daytime sleepiness 
 AHI< 5 
 RERA Index/ hr > 20 
Minor criteria 
 Snoring 
 Increase in the intensity of snoring 
before EEG arousal 
 Clinical response to CPAP therapy 
 
 
1.2.3. Differentiating between UARS and Mild OSA 
The main breathing events which contribute to UARS are RERAs. However, with the update 
to the hypopnea definition in 2012, RERAs and hypopneas terminated by arousal become 
very similar. In both classifications, the rules require the event to last at least 10 seconds, 
and to be concluded by arousal from sleep. The only difference is that hypopneas require a 
peak signal drop of ≥ 30%, while RERAs do not quantify the amount of flattening in the 
AASM definition (1). In clinical practice accurately measuring the reduction in flow is not 
common, and indeed the AASM stated that majority of RERAs can be re-classified as 
hypopneas when using 2012 scoring rules (10). This means that a significant proportion of 
patients previously identified as UARS may now be reclassified as having mild OSA.  
The differing definitions of hypopneas and associated changes in patient populations make it 
difficult to navigate the literature, particularly in the mild OSA/ UARS definitions where there 
may be considerable overlap in the patient groups and much less data is available.  
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1.3. Are there gender differences in OSA? 
Historically, OSA has been primarily regarded as a male disorder (15). The short and long-
term health consequences of OSA are heavily documented and well understood in a 
population which has largely consisted of male patients. More recently, studies have 
specifically looked at the consequences of moderate-to-severe OSA in female patients and 
found gender differences in prevalence, symptoms, clinical experience and health 
consequences of the disease.  
1.3.1. Prevalence of OSA by gender and severity 
The population prevalence of moderate-to-severe OSA, was estimated to be around 9% of 
males, and 4% of females in 1993 (16). The impact of rising global obesity along with 
stronger global recognition of OSA gave more recent estimates of 13.5% of males and 6% of 
females (17). When updated diagnostic criteria is used, as many as 49.7% of males and 
23.4% of females may have moderate-to-severe OSA, and 34% of males and 38% of 
females may have mild OSA (18) (Table 4).   
Table 4: Prevalence data for OSA in the general population  
Study 
Mild OSA  (AHI 
≥5/h) 
Moderate to severe 
OSA  (AHI ≥15/h) 
Males Females Males Females 
Young et al. (1993) (16) 24% 9% 9% 4% 
Redline et al.(1994) (19)* - - 26% 13% 
Bixler et al.(1998, 2001) (20, 21) 17% - 7% %2 
Duran et al.(2001) (22) 26.2% 28% 14% 7% 
Peppard et al.(2013) (17) - - 13.5% 6% 
Franklin et al.(2013) (15)^# - 50% - 26% 
Heinzer et al.(2015) (18)# 34% 38% 49.7% 23.4% 
*Respiratory Disturbance Index (RDI) rather than AHI given. 
^Women aged 20-70 years. 
#Updated scoring criteria (AASM 2012) used. 
 
1.3.2. Symptoms of OSA in moderate-to-severe patients  
The typical symptoms that males with sleep apnea present with are snoring, witnessed 
apneas and excessive daytime sleepiness. The most common symptoms that females 
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complain of are insomnia, fatigue, lack of energy, headaches, muscle pain, depression, and 
anxiety (23-27). Indeed, a population-based sample found that up to 40% of females with an 
AHI ≥15/h did not report any of the classic OSA symptoms (snoring, witnessed apneas, and 
daytime sleepiness) (28).  
1.3.2.1. Quality of life in women with OSA  
Comparisons of women and men with untreated OSA have found that women experience 
more mood disturbances such as anxiety and depression, impaired daytime mood, reduced 
sleep quality, and worsened neurobehavioral symptoms (29, 30). Ye et al. compared women 
and men with untreated OSA using the Functional Outcomes of Sleep Questionnaire 
(FOSQ). They found that women had significantly lower scores in daily activity level, general 
productivity and overall daytime functioning. They also found that women had significantly 
higher total mood disturbances, and performed significantly worse on the psychomotor 
vigilance task compared with men (29).  
1.3.2.2. Do women with OSA experience sleepiness?  
Excessive daytime sleepiness (EDS) is a common identifying symptom of male OSA. The 
Epworth Sleepiness Scale  (ESS) is a short questionnaire, developed in 1991 by Dr Murray 
Johns, which aims to assess levels of daytime sleepiness (31). Patients rate their likelihood 
to fall asleep in 8 different scenarios. The ESS has shown to be a reliable measure of 
sleepiness, with strong correlation to OSA severity and objective sleepiness, as well as good 
sensitivity to post-treatment changes (32-34).  
In women, sleepiness may not be a common OSA symptom. Women typically have lower 
scores than men on the ESS (28), and despite its widespread use, the ESS has never been 
properly validated as a tool to measure sleepiness in female OSA patients (31). The 
Wisconsin Sleep Cohort, a large population-based exploration of the prevalence and health 
outcomes of sleep disordered breathing (35), found that OSA was not strongly associated 
with subjective or objective sleepiness in women (36). Similar results were reported from 
another large population-based study, the Sleep Heart Health Study. This study found that 
women had similar levels of self-reported daytime sleepiness as men, but were less likely to 
report falling asleep in public. The authors concluded that the ESS was not a sensitive 
measure of subjective sleepiness in women (31). A more recent population-based study 
including 400 women aged 20-70 years found that daytime sleepiness was not related to 
obstructive sleep apnea in females (37). 
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It remains unclear whether women have a higher threshold for sleepiness, feel sleepy but 
are less likely to fall asleep in public situations, or are simply less inclined to report excessive 
sleepiness. It is also possible that women feel fatigued rather than sleepy, or interpret 
feelings of sleepiness as fatigue. There may also be some confusion around the meanings 
of the terms sleepy, fatigued and similar adjectives (Table 5).  
Table 5: Terms and definitions related to sleepiness  
Term Merriam-Webster’s Dictionary Definition  
Sleepy  Ready to fall asleep 
 Sluggish, as if from sleep 
 Sleep-inducing 
Lethargic  Characterized by laziness or lack of energy 
Tired  Drained of strength and energy 
 Fatigued often to the point of exhaustion 
Fatigue (d)  Weariness or exhaustion from labour, exertion, or stress 
 Drained of strength and energy 
Sluggish  Averse to activity or exertion 
 Indolent  
 Torpid 
 Slow to respond (as to stimulation or treatment)  
 Markedly slow in movement, flow, or growth.  
Weary  Feeling or showing extreme tiredness, especially as a result of 
excessive exertion 
In the ESS sleepiness is defined as “the likelihood of falling asleep in certain situations”. This 
is fairly easy to quantify; however, it doesn’t capture other feelings of daytime tiredness. 
Another short screening questionnaire which is similar to the ESS in length and ease of 
completion is the Fatigue Severity Scale (FSS). The FSS is designed to measure how 
feelings of fatigue impact an individual’s daily life in terms of motivation, exercise, daily 
activity, work, family and social life. The FSS requires patients to report how fatigued they 
felt at various times, but it does not define what is meant by fatigued. The FSS was 
developed by Dr Laurent Krupp in 1989 as a tool to facilitate research in medical conditions 
where fatigue is a prominent syndrome (38). The FSS has been utilised successfully for a 
number of health conditions, including sleep apnea (39-41). While it has not been validated 
in OSA patients specifically, it has been shown to have excellent internal consistencies and 
re-test stability in multiple health conditions, including chronic fatigue and multiple sclerosis 
(38, 42-44).  
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The literature states that women report fatigue rather than sleepiness as a common 
symptom of OSA (28). In order to better understand symptoms and post-treatment 
improvements in female patients, the FSS, along with the ESS, was included as part of 
clinical routine in two UK-based sleep clinics. Consecutive female patients were asked to 
complete the FSS, along with the ESS at their first clinic visit. When reviewing the outcomes 
of the screening questionnaires, 50% of symptomatic patients reported normal levels of 
sleepiness on the ESS, but high levels of fatigue on the FSS (45). This finding is consistent 
with the literature which states that females are more likely to report fatigue than sleepiness, 
and also highlights the importance of not relying solely on sleepiness when screening for 
OSA.  
1.3.3. Clinical experience of women with OSA 
OSA has been estimated to have a male to female ratio of between 3:1 and 5:1 in the 
general population and a much greater ratio of between 8:1 and 10:1 in some clinical 
populations (16, 23, 46). It is thought that the large discrepancy between the population 
prevalence of OSA and the clinical populations is due to females being frequently 
misdiagnosed (23, 47). 
Men often attend clinical appointments with their partner, whereas women are more likely to 
attend on their own (23, 46). This may mean that snoring and apneas in women are less 
frequently observed (46), or that male partners tend to be less concerned about the events 
(48). Women may also not know if they snore (37), or could be reluctant to complain about 
their own snoring as they consider it unladylike or embarrassing (23, 26). 
Less-frequent reporting of classic OSA symptoms (snoring, witnessed apneas and daytime 
sleepiness) plus a higher prevalence of atypical symptoms (insomnia, headache, anxiety 
and depression), means that physicians may not associate the complaint with OSA. Women 
with OSA are often misdiagnosed with depression or other illnesses (23, 24, 47). The result 
is lower referral rates to sleep clinics and an under-evaluation of OSA in women (47, 49), 
(23, 26, 49). It has been stated that recognizing the different features of SDB in women is 
central to effectively detecting and treating the condition (50). 
Young and colleagues found that even when women reported the classic symptoms of OSA 
(snoring, witnessed apneas and daytime sleepiness), they were still less likely to be referred 
to sleep clinics than men. This raised concerns that physicians tend to disregard these 
symptoms in women (47). Young et al. published this data in 1996, and therefore it is 
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plausible that this situation has improved due to increased awareness among primary care 
physicians and potential patients. However, data presented by Lindberg et al. during the 
2015 European Respiratory Society Congress showed that women who reported classic 
symptoms of OSA were significantly less likely to have a diagnosis or treatment for OSA 
than males with the same risk score (51).  
1.3.4. Health consequences of OSA in women 
The clinical impact of moderate-to-severe OSA (AHI ≥ 15) has been well documented in a 
male-dominated population. It is known to cause excessive daytime sleepiness, impaired 
cognitive function, and reduced quality of life (52, 53). Moderate-to-severe OSA is also 
associated with poor health consequences such as hypertension, diabetes, stroke, and 
cardiovascular morbidity and mortality (52, 54-57). Effective treatment with continuous 
positive airway pressure (CPAP) has been shown to improve symptoms and health 
outcomes in patients with moderate-to-severe OSA (53, 54, 57-61). 
Data comparing females with and without OSA has shown that those with OSA are at 
greater risk of reduced quality of life and impaired cognitive function. Yaffe et al. studied a 
group of women with OSA and found that they were more likely to develop cognitive 
impairment and dementia than women without OSA. Cognitive issues were more likely to 
develop in patients with increased oxygen desaturation and higher periods of time spent in 
apnea or hypopnea (62). Another study showed that female OSA patients experienced more 
brain white matter injury than their male counterparts (30). It is hypothesised that this change 
in white matter structure may be responsible for the long-term cognitive impairment found in 
some women with OSA (30). Further research in this area identified lateral and sex-specific 
volume differences in the hippocampus, demonstrating that females with OSA experience 
more volume decreases and injury in the brain compared to males with OSA (63).  
The correlation between OSA and sexual dysfunction in males has been explored in a 
number of studies (64, 65), with one meta-analysis estimating a pooled relative risk for male 
sexual dysfunction of 1.82 (95% CI: 1.12-2.97) (65). Female sexual health may also be 
impacted by OSA, although research in this area is scarce and no randomised controlled 
trials have been conducted. Small studies have reported that females with OSA have 
significantly more sexual distress and sexual dysfunction compared to females without OSA 
(66) (67). One meta-analysis of four small studies estimates the pooled relative risk of 
female sexual dysfunction in OSA patients as being 2.00 (95% CI: 1.29-3.08) (65).  
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Greenberg-Dotan et al. found that, compared to female controls, women with OSA were 
more likely to have a comorbid diagnosis of cardiovascular disease (OR 1.4) (68). Campos-
Rodriguez et al. followed 1116 females diagnosed with OSA between 1998 and 2007 in two 
Spanish sleep units. Patients with an AHI ≥ 10 were considered the OSA group while those 
with an AHI < 10 served as the control group. The study endpoint was cardiovascular death 
(including deaths from stroke, heart failure, arrhythmia, or myocardial infarction). The 
authors found that in women, untreated severe OSA is associated with cardiovascular death 
(adjust hazard ratio of 3.50, CI 1.23-9.98) (69).  
When reviewing the impact of OSA in females compared with males, studies have found that 
women with OSA are at increased risk of developing several health conditions. One study 
found that women with OSA have a higher odds ratio (OR) than men with OSA of developing 
hyperlipidemia (OR 1.5), hypothyroidism (OR 1.6), arthropathy (OR 1.6), diabetes (OR 1.6), 
asthma (OR 2.1), and reflux/gastritis (OR 2.5) (68). These women also experienced lower 
perceived health status, overuse of psychoactive drugs, and increased healthcare costs of 
1.3 times compared with men with OSA (68).  
Data from a cohort of 1,704,905 patients with matched controls taken from a collection of 
U.S. health insurance data found that overall comorbidities were more common in OSA 
patients than non-OSA patients (70). Compared with male OSA patients, hypertension was 
more prevalent in female OSA patients (70). It is possible that women with moderate-to-
severe sleep apnea are more susceptible to the adverse cardiovascular consequences of 
OSA than men. Females with OSA have more marked endothelial dysfunction (71), and 
respond less effectively to autonomic challenges than males, which may reduce the 
effectiveness of BP regulation (72).  
In summary, the limited data available suggest that although the prevalence and severity of 
OSA is lower in women than in men, the consequences of the disease in moderate-to-
severe females are at least the same, and potentially even worse in some quality of life and 
cardiovascular outcomes (29).  
1.3.4.1. Pregnancy and OSA 
Pregnancy is one area which highlights the importance of OSA recognition in women. 
Women are at increased risk of OSA during pregnancy due to a number of factors. The 
growing uterus elevates the diaphragm which changes pulmonary mechanics (73). During 
pregnancy neck circumference increases (74, 75), nasal patency is reduced (76), and 
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pharyngeal edema occurs (77). Substantial increases in snoring, snorting/gasping and 
witnessed apneas have been documented in pregnant women (75). Snoring during 
pregnancy appears to be a risk factor for both pregnancy-induced hypertension and 
intrauterine growth retardation (78). An observational study of 1.5 million pregnant women 
found significant associations between OSA and gestational diabetes (adjusted OR 1.51, 
1.34-1.72); pre-eclampsia (adjusted OR, 2.22, CI 1.94-2.54); and eclampsia (adjusted OR 
2.95, CI 1.08-8.02) (79). Similarly, a large observational cohort of nearly 3 million women 
found that OSA during pregnancy increased risk of preterm birth by 1.5 (O.R 1.2–1.8, 
P<.001, 15.5%) (80).  
A recently published prospective cohort study reviewed the prevalence and outcomes of 
OSA during pregnancy in 3705 women (81). Preliminary data from this group showed that 
OSA affects 8.1% of pregnant women by the second trimester, and that there was an 
association between OSA and hypertension and diabetes in this group (82). The final data 
set confirmed the findings that there is an independent association between OSA during 
mid-pregnancy and hypertension (OR 1.73, CI 1.19-2.52), pre-eclampsia (OR 1.95, CI 1.18-
3.23), and gestational diabetes (OR 2.79, CI 1.63-4.77) (83). 
1.4. Do the same gender differences exist in mild OSA and 
UARS? 
It is difficult to navigate the literature regarding gender differences in the milder patient 
groups for two reasons. The first is due to the changing definitions and overlap in patient 
groups described in Section 1.2. Secondly, there is a lack of research exploring these 
groups, with minimal data available on the gender differences. 
The literature available for moderate-to-severe patients implies that there are clear-cut 
symptomology differences between males and females with OSA. A conflicting hypothesis is 
that women do not suffer from different symptoms, but instead more women have mild OSA, 
and mild OSA itself, rather than gender, is responsible for the different symptoms reported 
by women. It is possible that characteristic symptoms such as snoring, witnessed apneas 
and excessive daytime sleepiness may be more prominent at higher AHIs, and perhaps 
patients with mild OSA dominated by flow limitation and constant arousals have different 
symptoms. 
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This hypothesis is supported by data from patients enrolled in the Wisconsin Sleep Cohort. 
Young et al. reported that snoring was the strongest and most sensitive predictor of OSA in 
both genders (47). Daytime sleepiness and pauses in breathing during sleep were reported 
equally by both genders with mild OSA. Reports of morning headache, depression and 
anxiety were reported equally by both genders across all severities of sleep apnea (47). 
Young et al. did, however, find that more females had mild OSA than males, and that 
females with an AHI of 2-5 had similar symptoms to females with an AHI of ≥ 15, while the 
same didn’t hold true for males (47). Similar analysis from the Wisconsin University Sleep 
Laboratory showed that lower rates of recognition of OSA in women compared with men 
only occurred in the subset of patients with an AHI of 5-20/h (84), again supporting the 
notion that symptoms may be based on severity rather than gender.  
1.4.1. Prevalence of OSA and UARS  
The prevalence of female OSA is consistently lower than male OSA, and as a group women 
have lower AHIs than men. Therefore, it is understandable if symptoms of mild OSA are 
attributed to females rather than the characteristics of the mild condition. When the updated 
(AASM 2012) hypopnea definition is used, which includes 3% oxygen desaturation and/or 
arousal from sleep, the prevalence of OSA in female patients becomes much higher. This is 
consistent with studies of UARS patients, where females represent close to 50% of the study 
population (85-87). 
The exact prevalence of UARS is not known. From the limited clinical trial data available, 
prevalence has been reported as 6% (88), 8% (89) 15% (90) 19% (87), and 32% (86) of 
patients reporting to sleep clinics with suspected OSA. However, as described in Section 1.2 
it seems that many of these patients may now be reclassified as OSA patients.  
1.4.2. Symptoms of mild OSA and UARS 
Common symptoms of mild OSA and UARS are reported as being similar to those of 
moderate-to-severe OSA: daytime sleepiness, snoring, nocturia, nocturnal awakenings, poor 
sleep efficiency and reduced cognitive function (11, 90). However, in the literature for these 
patient groups there are more complaints of sleep onset insomnia, sleep maintenance 
insomnia, and generally disrupted sleep (11, 85). Other symptoms which have been reported 
in the UARS group are irritable bowel syndrome and headaches (85).  
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Although snoring is commonly listed as a symptom of UARS, it does not occur in every 
instance. Guilleminault et al. reported snoring in only 67% (8) of patients during the original 
description of UARS. The same authors found in a later study that only 71% of men and 
11% of women with UARS reported snoring (91). A similar study reviewing the prevalence of 
OSA in military personnel found that 8.4% had UARS despite no reported snoring from the 
participants, and no significant snoring measured on the PSG (89). This indicates that 
snoring is not a reliable symptom of UARS, particularly in female patients.  
1.4.2.1. Quality of life in mild OSA 
The Sleep Heart Health Study found that quality of life in mild OSA subjects was significantly 
worse than in controls. This study also reported that patients with snoring, but an AHI < 5, 
reported significantly more sleepiness and quality of life issues than the control group (92). 
They found that females were more likely to report insomnia than males, and that mild OSA 
was associated with reduced vitality in both genders (92).  
A recent study of interest is the Apnea Positive Pressure Long Term Efficacy Study 
(APPLES) (93). A review of the mild patients in this study showed that, when compared with 
the participants with no OSA, the mild group did not have worse quality of life, as measured 
using the SAQLI questionnaire (no OSA vs Mild OSA: 4.5 ± 0.8 vs. 4.7 ± 0.7, p=0.39) (94).  
1.4.2.2. Quality of life in UARS 
An in-depth comparison of personality characteristics in UARS patients and OSA patients 
was recently conducted in a Korean population (87). Researchers compared 88 UARS 
patients to 365 OSA patients. They found that UARS patients reported very poor sleep 
quality, and were more likely to complain of insomnia and excessive daytime sleepiness, 
despite PSG studies showing that, objectively, their sleep efficiency and total sleep time was 
superior to that of OSA patients. They also found that UARS patients tended to rate 
significantly worse on a range of psychiatric scales, including: somatization, obsessive-
compulsiveness, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, 
paranoid ideation, psychoticism, global severity index, positive symptoms distress index, and 
total positive symptoms. They concluded that UARS patients had a higher degree of neurotic 
and sensitive tendencies than their OSA counterparts (87). 
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1.4.2.3. Do mild OSA and UARS patients experience sleepiness? 
There is no consensus as to whether mild OSA is associated with EDS. A review by the 
American Thoracic Society (ATS) of suitable studies comparing mild OSA to no OSA found 
that 20 studies reported no significant difference between sleepiness in mild OSA compared 
to no OSA (95). Conversely, 9 studies did show a significant relationship between mild OSA 
and sleepiness measured using the ESS tool (95).  
Daytime sleepiness is reported as a significant indicator of UARS (8). However, an 
investigation of military personnel with UARS found that only one third had a mean sleep 
latency significantly less than normal (86). This may indicate that the majority of UARS 
patients are not objectively sleepy. Insomnia is reported by approximately 20% of UARS 
patients (11), which may be a reflection of constant arousals and disturbed sleep throughout 
the night (11, 31).  
1.4.3. Clinical experience of mild and UARS patients  
1.4.3.1. Clinical experience of mild OSA patients 
There is no universal agreement on the appropriate treatment for mild OSA patients, or 
indeed if treatment at this stage of the disease is warranted. The definition of mild OSA was 
revised in 2012 by the AASM in an attempt to recognize the potentially detrimental effects of 
repetitive breathing-related arousals from sleep (1). An unintended outcome of the updated 
classification is that some healthcare providers, most notably the U.S. Centres of Medicaid 
Services (CMS), have taken the decision not to offer CPAP treatment based on AASM 2012 
guidelines, citing a lack of evidence that treatment of these is beneficial (1, 96). In many 
European countries, including France, Czech Republic, Belgium, and the Netherlands, 
treatment for mild OSA is not reimbursed by healthcare systems. The consequence of this to 
a patient with mild OSA is that they may not be offered treatment, depending on which 
scoring criteria is used, and where they are physically located. The MERGE clinical trial aims 
to provide evidence on the benefits of treatment mild OSA patients with CPAP, with a focus 
on AASM 2012 scoring (clinicaltrials.gov ID: NCT02699463; Appendix C). Results for this 
study are expected at the end of 2019. 
1.4.3.2. Clinical experience of UARS patients 
Clinical diagnosis of UARS is rare, partly due to the lack of use of the diagnosis in sleep 
clinics, and partly due to inconsistent definitions used. In their description of the syndrome, 
Guilleminault et al. listed complaints of daytime fatigue and/or sleepiness, increased upper 
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airway resistance during sleep, frequent arousals from the increased upper airway 
resistance, and no significant hypoxia (97). Pepin et al. placed more emphasis on the 
sleepiness of the patient, and described UARS as being present when a complaint of 
excessive sleepiness does not have any other causes (e.g. insomnia, periodic leg 
movements or obstructive sleep apnea) and when a sleep study shows that >50% of 
arousals during sleep are due to RERAs (11).  
Köktürk et al. (88) highlighted the importance of oxygen saturation during sleep, and defined 
UARS as being likely when AHI<5, RERA index >20 and excessive sleepiness was present 
without nocturnal oxygen desaturation.  
Bao et al. (98) reported that UARS patients are more likely to seek treatment for somatic 
functional syndrome than daytime sleepiness. As a result, they are often referred to 
psychiatrists, and consequently remain untreated.  
1.4.4. The importance of flow limitation 
One glaring omission from the AHI based definition of OSA is flow limitation. Currently, the 
percentage of flow limitation a patient experiences during the night does not influence their 
AHI. Flow limitation increases work of breathing, causes arousals and disrupted sleep, and 
impacts on daytime cognitive function (13). Upper airway resistance alone, without 
obstructive apneas, has been shown to produce clinical symptoms such as daytime fatigue 
and depression (99), both of which are symptoms reported by women with OSA. Women 
with partial upper airway obstruction have been shown to have similar symptoms, including 
sleepiness, to women with OSA, resulting in a call for partial upper airway obstruction to be 
clinically recognized in the same way as OSA in women (100).  
It is not clear at what level flow limitation, without OSA, becomes harmful. Flow limitation 
frequently occurs in normal patients to some degree, particularly during sleep onset (101). A 
population-based study of over 1000 individuals in Sao Paulo found that 95% of individuals 
with >30% flow limitation had symptoms of excessive daytime sleepiness and chronic fatigue 
similar to those with mild OSA (102). This was consistent with findings from a 
pathophysiological investigation, which found that >30% flow limitation was associated with 
nasal and palatal abnormalities (102). The authors concluded that >30% of flow limitation 
during the night may be a good measure of SDB in subjects with an AHI < 5 (102).  
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Hosselet et al. paired complaints of EDS with different measures of abnormal breathing 
patterns and found that an index which included inspiratory flow limitation provided better 
sensitivity and specificity for identifying subjects with SDB than AHI (103). 
1.4.5. Health consequences of mild and UARS patients 
There is some evidence to suggest that even minor sleep-related breathing disturbances 
have a negative impact on hypertension (104, 105), cognitive function (106, 107), quality of 
life (95, 108), and the risk of motor vehicle accidents (109). However, the evidence is mixed, 
with a recent review by the American Thoracic Society (ATS) stating that the impact of mild 
OSA on cognitive function, mood, vehicle accidents, cardiovascular events, stroke and 
arrhythmias is inconsistent (95). 
UARS appears to be associated with adverse cardiovascular consequences, in particular the 
development of hypertension, however the evidence is scarce. One study reported that 35% 
of UARS patients had drug resistant hypertension (110), and a similar investigation showed 
that 36% of UARS patients had systemic hypertension (111).  
1.4.5.1. What are the mechanisms for adverse cardiovascular outcomes in 
mild and UARS patients?  
The association between moderate-to-severe OSA and cardiovascular morbidity and 
mortality has been well documented, and repetitive hypoxia during sleep appears to play the 
most important role in this association (11). The potential mechanisms for how mild OSA and 
UARS could be associated with poor cardiovascular consequences are not clear, as these 
patients do not have significant oxygen desaturation (11, 111). It appears that flow-limited 
breaths and repetitive arousals from sleep are both harmful. In 1996 Guilleminault et al. 
demonstrated through continuous 24-hour blood pressure (BP) monitoring that flow-limited 
breaths without significant hypoxia were associated with increases in systolic and diastolic 
blood pressure (97). These findings were supported by a larger investigation of 448 subjects. 
Stradling et al. found that the level of respiratory effort was an independent predictor for the 
overnight change in systolic BP. The authors concluded that increased respiratory effort 
during sleep prohibits the normal nocturnal fall in BP, and this may be one mechanism for 
the development of hypertension in patients with nocturnal flow limitation (112). It has also 
been shown in a small group of patients that prolonged flow limitation increases CO2 (113). It 
has previously been established that any increase in CO2 stimulates the sympathetic 
nervous system (11).  
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The repetitive arousals seen in UARS and many mild OSA patients may also be responsible 
for increased BP. Arousals from sleep are shown to coincide with autonomic and 
cardiovascular activations during the night (11, 114). Guilleminault et al. showed that EEG 
arousal is significantly associated with an increase in heart rate, and that an increase then 
decrease in parasympathetic activity can be seen immediately after an arousal (115). The 
investigators demonstrated a relationship between RERA events and increases in systemic 
BP. They also found that the magnitude of the increase in BP was directly related to the 
severity of the arousal (116). Asker et al. demonstrated an association between arousals 
and uncontrolled hypertension in a small study of 14 patients (110). In their study they were 
able to establish a strong association between the patient’s arousal index and systolic BP 
(110). A study of healthy volunteers also provides evidence of the harmful effects of sleep 
disruption. In these healthy subjects, two nights of sleep fragmentation lead to a 20% 
decrease in insulin sensitivity and a significant reduction in glucose effectiveness (117). It 
was hypothesized that increases in sympathetic nervous system activation and 
adrenocortical activity were responsible for these metabolic consequences (117).  
Therefore, it appears that flow limitation during sleep combined with repetitive arousals lead 
to chronic increases in sympathetic activity, which may be responsible for hypertension, 
cardiovascular consequences, and potentially adverse metabolic outcomes (11).  
Another potential mechanism of cardiovascular damage may be through snoring, although 
the evidence for this hypothesis is mixed. Lee et al. found that snoring was an independent 
factor for the development of atherosclerosis (118). The researchers proposed that the 
vibrations generated during heavy snoring may be transmitted to the carotid artery wall. 
These vibrations may then cause endothelial damage which eventually leads to carotid 
atherosclerosis (118). However, a large population study of 380 participants over a 17-year 
period was unable to find any independent correlation between snoring and cardiovascular 
morbidity and mortality (119).  
1.4.6. Are mild OSA and UARS different from moderate and severe OSA? 
There is not universal agreement on whether UARS is simply a very mild form of OSA, or 
whether it should be considered a completely different condition. Gold et al. proposed that if 
UARS is an extension of OSA then there should be an increasing progression in 
somnolence from minor in UARS patients to extreme sleepiness in severe OSA patients 
(120). A small comparison of 12 symptomatic OSA subjects, 12 UARS subjects, and 12 
normal subjects found that the UARS subjects reported significantly worse tiredness and 
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daytime sleepiness than the normal subjects, although they were not significantly different 
from OSA patients (121). A larger study of 2783 patients with OSA, UARS, or snoring, found 
that patents with UARS described the highest degree of daytime impairment (90). UARS 
patients rated the quality of their daytime functioning as significantly worse than OSA 
patients. They also reported issues with daily functioning, such as difficulty concentrating 
and completing tasks, as well as depressed mood. They scored lower than OSA or snoring 
patients in their perception of sleep quality. The authors found that the female-to-male ratio 
was higher in the UARS group than those with OSA, although males still accounted for 60% 
of the group. The authors did not break down the study outcomes into gender differences 
(90).  
Stoohs and colleagues compared the reaction time of UARS patients with OSA patients to 
determine if UARS patients had the same high risk of motor vehicle crashes as OSA patients 
(122). They found that UARS patients had significantly worse results than the OSA patients 
on the majority of psychomotor performance tasks, including reaction time, vigilance and 
attention tests. They concluded that UARS patients may be at an increased risk of motor 
vehicle crashes compared with the already elevated risk of OSA patients (122).  
Taken together, the limited information available suggests that UARS patients experience 
much more excessive daytime sleepiness and reduced daytime functioning than expected if 
UARS was a very mild form of OSA. They also report high levels of insomnia not seen in 
severe OSA patients (120). This supports the hypothesis that patients with sleep disordered 
breathing characterised by flow limitation and frequent arousals from sleep have different 
symptoms than sleep disordered breathing characterised by obstructive apneas and severe 
oxygen desaturation. 
1.5. Are there polysomnography (PSG) differences between the 
genders? 
1.5.1. Gender differences in PSG data 
There are a number of gender differences in both the severity of OSA and its distribution 
across the sleep cycle. One of the largest reviews of PSG data, including 830 patients, found 
that women had a significantly lower overall AHI compared with men (20.2/h vs 31.8/h; 
p<0.001). AHI during non-REM sleep was also significantly lower in women vs men (14.6/h 
vs 29.6/h; p<0.001), but there was no difference between females and males with respect to 
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AHI during REM sleep (42.7/h vs 39.9/h, respectively), indicating a greater clustering of 
apneic events during REM sleep in women (123). This study also found that OSA in the 
supine position occurred almost exclusively in men, indicating that positional OSA is not an 
issue for women (123).  
PSG data from patients referred for suspected sleep disorders also showed that a difference 
between males and females in AHI was evident during stage 2 sleep, but not during REM 
sleep, further providing evidence that women often have mainly REM-based events (124). In 
addition, this data showed that women had shorter apnea events and less severe oxygen 
desaturations than men (both p<0.001) (124).  
Gender differences have also been observed in sleep architecture. A study of 307 patients 
found that women took longer to fall asleep than men. Women also had fewer awakenings 
and more slow wave (deep) sleep, despite no differences between the sexes in age, 
respiratory disturbance index or oxygen saturation (125). 
As a group, women with OSA have more episodes of upper airway resistance and flow 
limitation than men with OSA (126). This combined with the shorter apnea events and less 
severe oxygen desaturations (124) explains why more women are categorised as UARS and 
mild OSA than moderate-to-severe OSA. 
 
1.5.2. Why do these PSG differences occur? 
Overall females have less-severe OSA than males, which can be explained by several 
physiological differences. In women, the neck and upper airway are smaller in size than in 
men (23). Magnetic resonance imaging has shown that the airway length, tongue, soft 
palate, and total amount of soft tissue in the throat are all smaller in women (127). Intuitively, 
a smaller airway should occlude more easily than a larger one; however, this doesn’t seem 
to be the case. Men have a longer, softer oropharynx, and a larger, fatter, more posterior 
tongue, increasing the susceptibility of the large airway to collapse (23). Upper airway 
collapsibility, determined by the pharyngeal critical closing pressure, has been shown to be 
less in women compared with men with the same OSA severity (128). Gender differences in 
airway collapsibility are most evident during non-REM sleep, suggesting that women may be 
more susceptible to pharyngeal collapse during sleep transition and REM sleep but not 
during established sleep when some muscle tone is preserved (129). 
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Obesity is a well-recognized risk factor for OSA, and higher body mass index (BMI) is 
associated with increased severity of OSA for both sexes (130). However, for the same AHI, 
women tend to be more obese than men (128, 131). One potential explanation for this is 
differences in fat distribution between the sexes (132). For the same BMI, men have higher 
mean body weight, more free fat mass, and larger neck circumference compared with 
women (133). MRI studies have confirmed more pharyngeal fat and increased soft tissue 
volume in the neck in obese men compared with obese women (127). Upper airway fat 
distribution, particularly in the posterior tongue, is important in the pathogenesis of OSA. The 
increased weight and fat in the upper airway leads to more severe occlusion when muscle 
tone is lost during sleep (23). Additionally, upper body and visceral adiposity are associated 
with reductions in lung function, including total lung capacity, forced vital capacity and forced 
expiratory volume (134). This reduction in lung function impacts the body’s ability to achieve 
adequate ventilation, particularly during sleep when muscle tone is lost, and the positional 
load on the thorax is increased (135). 
Fat distribution might have physiological as well as mechanical effects in patients with OSA. 
Obese women, particularly those with OSA, have increased hypercapnic and hypoxic 
responses, whereas this was not the case in obese men (136). This increased sensitivity to 
changing blood gases means a better maintenance of optimal minute ventilation when the 
chest wall load is increased. 
Men and women have also been shown to respond differently to changing blood gases. Men 
experience respiratory instability from much lower levels of carbon dioxide in the blood, and 
as a result men are more susceptible to hypocapnic dysfunction during non-REM sleep than 
women (137), (138). There may also be gender differences in the arousal response to 
apneas. Jordan and colleagues found that during non-REM sleep men had a higher 
ventilatory response to apneas than women, but then they developed greater hypoventilation 
when they went back to sleep, especially in the supine position. This prolonged 
hypoventilation often leads to ventilatory instability upon returning to sleep. The study 
authors hypothesized that this may play a role in explaining why sleep apnea syndromes are 
more severe in men (139). 
A further explanation for these PSG differences may be related to hormones. Post-
menopause, the incidence of OSA markedly increases in female patients (21, 140, 141). 
Younger females (<30 years) are less likely to snore, have less severe OSA, and have a 
trend towards more upper airway resistance and flow limitation (50). Therefore, it has been 
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suggested that female sex hormones have some sort of protective effect on upper airway 
patency and/or ventilatory drive (24). The hormone progesterone is a known respiratory 
stimulant which increases chemoreceptor responses to hypercapnia and hypoxia, and has 
been shown to increase upper airway muscle tone (142). Progesterone levels increase 
during pregnancy and may play a protective role in maintaining ventilation against increasing 
weight of the developing fetus. Progesterone levels decrease after menopause. However, 
studies that have given males progesterone in an attempt to improve OSA have not yielded 
strong results (143).  
Hormones also play a role in the distribution of body fat. Post-menopausal women have a 
higher fat mass than prior to menopause, and fat distribution is more likely to be in the upper 
body and trunk area compared with the lower body (144, 145).  
In summary, women have less severe OSA. This is likely due to differences in body fat 
distribution, differing responses to blood gases, and the protective role of female sex 
hormones.  
1.5.3. Why do some patients have UARS or mild OSA and others have 
moderate-to-severe OSA? 
Individuals are susceptible to developing OSA due to a number of factors. In particular: 
upper airway anatomy; chemoreceptor responses to changes in blood oxygen and carbon 
dioxide levels; and the individual’s reaction to negative intra-oesophageal pressures and 
upper airway dilator muscle stimulus.  
UARS patients are commonly described as being younger with a lower BMI than OSA 
patients (87, 90, 110). Many UARS patients display defining craniofacial characteristics, 
including a long face with a short and narrow chin (11). In this patient group the mandible is 
retracted and the palate is narrow and high with reduced mouth opening (11, 146).  
Patients with UARS and mild OSA arouse from sleep very quickly in response to upper 
airway resistance. It is likely that the mechanoreceptors in the upper airway, coupled with 
increased sympathetic function, increase efferent activity in the central respiratory receptors 
which leads to arousal from sleep (114). This sleep disruption impacts daytime mood, 
function and quality of life. Conversely, patients with more severe OSA have longer 
obstructive events and more severe oxygen desaturation, but have less sleep arousals and 
fragmentation.  
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High levels of resistance in the upper airway, resulting in excessive amounts of flow 
limitation, are found in UARS patients (11, 147). UARS patients have a higher mean 
resistance at peak pressure in the upper airway during wake compared with OSA and 
normal subjects (147). The required forces to collapse the airway can be measured using 
the PCrit (critical closing pressure). PCrit is a continuum from normal, to UARS, to OSA 
(148-150). The amount of collapse that occurs in the upper airway is due to a combination of 
factors, including bony structures, retropalatal mechanical load, soft tissues and upper 
airway narrowing (146). In OSA patients, the blend of a collapsible airway with the loss of 
tonic input to the upper airway dilator muscle motor neurons during sleep leads to airway 
occlusion (151). UARS patients are able to maintain higher levels of upper airway resistance 
without collapse (147), despite employing the same amount of respiratory effort as severe 
OSA patients (152). It appears that UARS patients have preserved protective reflexes in the 
pharynx, which lead to increasing muscle activity to counteract the upper airway resistance 
and prevent further upper airway collapse (11). This idea is supported by research showing 
that upper airway sensitivity in UARS is not impaired, while it is severely impaired in OSA 
patients (153). 
Patients with UARS have much higher parasympathetic activation during sleep than OSA 
patients (115), which enables them to arouse quickly in response to small increases in 
respiratory effort (91). This appears to be because UARS patients respond efficiently to 
upper airway changes, while more severe OSA patients have dampened respiratory 
responses, which permits apneas to occur (98). While females as a group have less severe 
OSA and are more prone to flow limitation and respiratory-related arousals from sleep, it is 
not clear whether there are additional gender differences in the UARS and mild OSA groups. 
1.6. Continuous Positive Airway Pressure (CPAP) 
Continuous positive airway pressure (CPAP), first described by Sullivan et al. in 1981 (154), 
is considered the gold standard treatment for OSA. CPAP applies continuous positive 
pressure to the patient’s airway via tubing and a mask. The pressure provides a pneumatic 
splint to the upper airway which prevents the airway from collapsing (154).  
Effective CPAP treatment in compliant moderate-to-severe OSA patients has been shown to 
decrease elevated blood pressure, improve cardiovascular disease outcomes, and reduce 
the risk of cardiovascular fatal and non-fatal events (53, 155-157). CPAP treatment also 
eliminates excessive daytime sleepiness, improves quality of life, and restores cognitive 
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function to normal levels (53, 54, 57-61, 158). The majority of clinical trials of CPAP have 
included mainly male participants (159). 
1.6.1. The impact of CPAP on quality of life in women  
 
Studies that have split the results into genders found that CPAP improved symptoms and 
quality of life in both genders. A study by Ye et al. (160) compared a group of male and 
female patients presenting to sleep clinics. They found that despite similar age, BMI and 
AHI, women reported significantly worse scores in daily functioning measured by the 
functional outcomes of sleep questionnaire (FOSQ) (males 15 ± 2.9 vs females 12.8 ± 3.7, p 
= 0.002). Women also reported higher levels of sleepiness through the ESS (males 14.5 ± 
4.8 vs females 16.8 ± 4.1, p = 0.032), and more mood disturbance, measured using the total 
mood disorder (TMD) scale (males 11.9 ± 25.9 vs females 21.0 ± 17.6, p = 0.007). CPAP 
treatment significantly improved daily functioning, sleepiness and mood equally in both 
genders (160).  
A similar study which evaluated depression in OSA patients before and after treatment 
included 183 women with an average age of 52 ± 15 years and BMI of 32.1 ± 7.1 (161). 
Patients completed the PHQ-9, a questionnaire-based depression scale containing 9 items, 
asking about participants’ feelings of sadness, tiredness, sleepiness, lack of interest in 
activities, perceived personal successes, ability to concentrate, self-confidence, slow/fast 
speech patterns, and suicidal thoughts. Participants rate each item on a scale of 0-3, with 0 
indicating no symptoms and 3 indicating highly symptomatic. A total score of 27 is possible. 
Scores ≤ 4 are indicative of no depression; 5-9 is mild depression; 10-14 equals moderate 
depression; 15-19 is moderately severe depression; and ≥ 20 equals severe depression 
(162). In this study, the PHQ-9 in female patients at baseline was 10.4 ± 5.9, and after 3 
months of CPAP therapy this had decreased to 3.4 ± 2.8 (p < 0.001) (161).  
Campos-Rodriguez et al. published the first study to review quality of life in a female-only 
patient group. The authors studied 307 women diagnosed with moderate-to-severe OSA 
presenting concurrently to 19 sleep units throughout Spain. The average age was 57.1 + 
10.1 years with an average BMI of 33.7 (range 20.0 – 38.5). Women were randomized to 
receive CPAP therapy or conservative treatment for three months. The primary outcome was 
quality of life using the Quebec Sleep Questionnaire (QSQ). After three months CPAP usage 
all quality of life domains of the QSQ were significantly improved in the CPAP group 
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compared with the control group, including sleepiness (p<0.001), mood (p=0.012), anxiety 
(p=0.014) and depression (p=0.016) (163).  
1.6.2. The impact of CPAP on cardiovascular health in women  
Recently, Campos-Rodriguez et al. found that CPAP use for 3 months resulted in a 
significant decrease in diastolic blood pressure in female subjects (164). A prospective study 
by the same group evaluated the long-term outcomes of OSA in treated and non-treated 
female patients. They found that severe OSA was associated with increased cardiovascular 
mortality risk (adjusted hazard ratio 3.50, 95% CI 1.23-9.98), and that CPAP treatment may 
reduce this risk (25). 
1.6.3. CPAP in Pregnancy 
There are limited data on the treatment outcomes of OSA during pregnancy, and no 
adequately powered randomized controlled trials have been conducted in this area. Small 
studies have shown that CPAP treatment reduces blood pressure during pregnancy even 
when OSA is mild (165), and may improve pregnancy outcomes compared with untreated 
OSA (166, 167); however, more research is required in this area.  
1.6.4. CPAP compliance in women 
Gender differences in the use and response to CPAP devices have not been extensively 
studied to date. A review of a database of 4281 patients found that average daily CPAP 
usage in male patients was slightly higher than in female patients. Average nightly usage in 
both genders was high (6.3 ± 1.6 vs. 6.2 ± 1.6) (168). One study followed a group of 708 
women for a median of 6.2 (4.2-7.7) years. Long term compliance to treatment was good in 
these patients, with a median daily usage of 6 hours per day (IQR 4-7). 82.8% were still 
using CPAP after 5 years, and 79.9% were still using CPAP at 10 years (169). 
1.6.5. Non-CPAP treatments for women  
Non-CPAP treatments have rarely been studied for gender-specific effects. Weight loss is a 
common recommendation for mild patients; however, this may be more beneficial to males 
than females due to the increased fat distribution in the upper airway of males (170).  
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Mandibular Advancement Devices (MADs) are a treatment option for those with mild and 
moderate OSA or those who have rejected CPAP. One large study found female gender was 
a predictor of treatment success, particularly in the mild group (171). 
1.6.6. Treatment of Mild OSA with CPAP 
Effective treatment with CPAP has been shown to improve symptoms and reduce health 
risks in moderate-to-severe OSA patients (58). However, there is very little evidence 
regarding treatment of mild OSA, and the degree of severity at which symptoms are 
improved by treatment is not clear. Indeed, the few randomised controlled trials (RCT) in this 
area have yielded mixed results, potentially due to small sample sizes and methodology 
issues (58). Small studies in mild OSA subjects have generally shown that CPAP reduced 
AHI but did not improve objective sleepiness or blood pressure (BP) (58). Conflicting results 
were found for subjective sleepiness, neurobehavioral performance, mood and quality of life 
(58).  
One early trial from 2000 which aimed to evaluate the effectiveness of CPAP in mild OSA 
evaluated 142 consecutive patients in Spain. Patients with an AHI between 10-30 were 
entered into the trial and were randomised to receive either conservative care (sleep hygiene 
and weight loss) or conservative care in addition to CPAP treatment (172). Quality of life was 
assessed at 3 months and 6 months using the Sleep Apnea Hypopnea Syndrome (SAHS) 
questionnaire. The questionnaire measures how frequently the patient experiences 
symptoms including snoring, breathing pauses, nocturia, choking, morning headaches, non-
restorative sleep, morning drowsiness, and difficulty concentrating (173). The ESS, multiple 
sleep latency test (MSLT), FOSQ and Nottingham Health Profile (NHP) were also used to 
measure quality of life. The authors found improved quality of life in the CPAP group using 
the SAHS assessment (p <0.001). There were also improvements in quality of life measured 
by the FOSQ, although these did not reach significance (p = 0.06). No significant 
improvements were seen in any of the other quality of life assessments. When reviewing the 
gender differences in this study no clear conclusions can be made, as 91% of the control 
group and 81% of the CPAP group were male.  
A review of the trials using CPAP for mild OSA in 2006 by Gay et al., found that there was 
insufficient evidence regarding the effectiveness of treatment in the mild OSA group to draw 
conclusions (58). Following that review there have been two adequately powered studies in 
mild OSA populations. 
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The CPAP Apnea Trial North American Program (CATNAP) was conducted by Weaver et al. 
and published in 2012 (174). The rationale for the CATNAP trial was to understand the effect 
of CPAP on daily functioning in patients with daytime sleepiness (ESS >10) and mild to 
moderate OSA (AHI 5-30) (174). Patients were randomised to receive either CPAP 
treatment or sham-CPAP for a period of 8 weeks. The primary outcome was the FOSQ. 223 
patients completed the trial. The investigators found a significant improvement in daily 
functioning in the active CPAP group compared with the sham-CPAP group (174). The 
results of this study have not been broken down into gender.  
It remains unclear from the CATNAP study whether mild OSA patients without excessive 
daytime sleepiness would also benefit from CPAP treatment (174). The Multicenter 
Obstructive Sleep Apnea Interventional Cardiovascular (MOSAIC) clinical trial aimed to 
answer this question in an RCT of 391 patients who were diagnosed with OSA (ODI >7.5/h), 
but at a level not severe enough to warrant treatment (175). Patients were randomised to 
receive either CPAP therapy or standard care. The investigators found that CPAP improved 
daytime sleepiness (based on ESS scores), objective sleepiness and self-assessed health 
status, but not vascular health risk (175). A sub-group of the participants underwent 
endothelial function measurements. The study found a large improvement in brachial artery 
flow-mediated dilation in the CPAP group, particularly in those using CPAP for >4 hours per 
night. There was no effect on arterial stiffness. The authors concluded that minimally 
symptomatic OSA may be a cardiovascular risk factor (176). The improvement on ESS from 
CPAP was independent of gender, as was the 5-year vascular risk. In this study men 
accounted for 78% of the sample.  
The CATNAP and MOSAIC clinical trials used the AASM 2007 scoring criteria. No studies in 
the mild population have used the AASM 2012 scoring criteria, although the MERGE clinical 
trial is currently examining this population group (Appendix C). By definition, the AASM 2012 
scoring leads to inclusion of milder patients, so may yield different results.  
It is difficult to draw conclusions due to various definitions of mild OSA being used in studies 
as well as the predominance of males and lack of gender-specific results. Currently there is 
no global consensus on how mild OSA should be scored and whether mild OSA should be 
treated (177, 178), so it is not surprising that gender differences in mild OSA have not yet 
been properly explored.  
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1.6.7. UARS Treatment 
Very little data exists on the treatment of UARS with CPAP. Guilleminault et al. showed that 
CPAP was able to normalize breathing, significantly reduce nocturnal arousals, and 
eliminate daytime sleepiness in UARS (8). Non-randomised trials have examined the use of 
CPAP in UARS in subjects with an AHI <10 with positive results (114). Similarly, small 
studies have shown that CPAP can normalize breathing and assist in the control of BP in 
these patients (97, 110).  
Oral devices may be an alternative to CPAP in UARS patients. One investigation of 32 
patients found that treatment with a mandibular advancement device was able to 
significantly reduce daytime sleepiness, arousal index, and minimum oxygen saturation 
(179). 
1.7. Auto-adjusting CPAP devices and gender 
Auto-adjusting CPAP devices, commonly called AutoSet devices, monitor the patient’s 
breathing on a breath-by-breath basis and make calculations about the appropriate pressure 
response. If the patient’s breathing shows signs of obstruction, either through snoring, flow 
limitation or lack of breathing (apnea), the AutoSet algorithm is programmed to increase the 
pressure delivered to the patient until the obstruction is overcome and breathing is regular. 
Once breathing has been stable for a period of time, AutoSet devices then slowly decrease 
the delivered pressure to improve patient comfort. AutoSet devices have an advantage over 
fixed CPAP devices as they are able to overcome obstruction during changing 
circumstances, such as the intake of alcohol, supine sleeping, or weight gain. They can 
differentiate central apneas from obstructive apneas and only increase the pressure when 
obstruction is present. Theoretically, they are more comfortable and tolerable for patients 
because they keep the mean pressure lower.  
The first AutoSet devices were developed in the late 1990s. At this time OSA was viewed 
primarily as a male disease (15). Indeed, the patient population described in studies during 
the development and validation of AutoSet algorithms is typically 100% male (180-182). 
Personalised medicine, the practice of tailoring medical decisions and interventions to 
individual characteristics, has not yet penetrated OSA treatments. However, due to the 
different gender structures and pathologies of the disease, personalised diagnostic methods 
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and treatments may be a way to improve patient treatment and long term acceptance (183, 
184).  
1.8. Summary of the main themes and overall aims of the 
thesis 
Gender differences in the symptoms of OSA are frequently reported. Females do not present 
with the classic OSA symptoms, such as snoring, obesity and daytime sleepiness. Instead, 
females may complain of depression, anxiety, mood disturbance, reduced quality of life, 
insomnia and fatigue (29, 185-187). However, a detailed review of the research shows that 
these ‘female’ symptoms appear to be commonly reported in both genders in the mild OSA 
and UARS patient groups. However, there is limited data available on these patient groups 
and it often is not analysed by gender.  
What remains unclear is whether the gender differences described in moderate-to-severe 
OSA are present in the UARS and mild OSA patient groups.  
The first aim of this thesis is:  
1) Determine whether gender-related differences exist in symptoms of mild OSA 
patients (CHAPTER 2) 
The severity of OSA appears to differ between genders, with PSG examinations finding that 
females have less-severe OSA with overall lower AHI, shorter apneas, and a higher 
likelihood to have REM-only events (123). Younger women, in particular, often have more 
episodes of flow limitation and RERAs (50, 123). However, UARS and mild OSA are 
comprised largely of flow limitation and RERAs/hypopneas terminated by arousal. Therefore, 
it is not clear whether the reported gender-specific respiratory characteristics are present in 
the mild patient groups. Additionally, some mild OSA patients are reported as being 
symptomatic, despite having low AHI’s. It is hypothesised that the symptoms could be an 
outcome of flow limitation and arousals during the night rather than gender. 
The next aims of this thesis are: 
2) Determine whether gender-related respiratory differences exist in respiratory 
data of mild OSA patients (CHAPTER 3). 
 
3) Determine whether a relationship exists between respiratory data and patient 
symptoms in mild OSA patients (CHAPTER 3). 
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Effective CPAP treatment in adherent patients has been shown to improve sleepiness and 
quality of life, and reduce the cardiovascular health risk in patients (54, 57-60). However, the 
majority of clinical trials of CPAP have included mainly male participants (159), and indeed 
the development of AutoSet devices has been conducted on primarily male participants.  
As the final part of this thesis, the development of a new AutoSet device tailored specifically 
for females is outlined.  
The final aim of this thesis is: 
4) Develop and validate new AutoSet for the treatment of female-specific 
breathing characteristics (CHAPTER 4, CHAPTER 5, and CHAPTER 6).  
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CHAPTER 2. SYMPTOM COMPARISON IN MILD OSA 
PATIENTS  
 
2.1. Introduction 
As described in Section 1.3, the literature implies clear differences in symptoms between 
males and females with OSA. The typical symptoms that males with sleep apnea present 
with are snoring, witnessed apneas and excessive daytime sleepiness. The most common 
symptoms that females complain of are insomnia, fatigue, lack of energy, headaches, 
muscle pain, depression, and anxiety (23-27). However, detailed examination of patients 
with UARS and mild OSA indicates that symptoms attributed to females are common in both 
genders. To explore this further, this chapter examines a group of mild OSA patients to 
determine whether gender differences are present.  
The aim of this review was to determine whether gender-related differences exist in 
symptoms of mild OSA patients. The hypothesis is that clear gender differences will still exist 
even in these patients at the very mild end of the OSA spectrum.   
2.2. Methods  
Baseline questionnaire data from the MERGE clinical trial was used in this analysis. 
The full methodology for the MERGE study is contained in Appendix D. In summary, the 
MERGE study is a multi-centre, randomised, controlled study taking place in 11 centres in 
the UK Respiratory Sleep Research Network (clinicatrials.gov ID: NCT02699463). The 
MERGE study has been approved by South Central – Hampshire A Research Ethics 
Committee (approval reference 16/SC/0387). 
Polygraphy data from patients with mild OSA (AHI 5-15) is scored using both AASM 2007 
and AASM 2012 definitions. Patients are randomised to receive either CPAP treatment or 
standard care (sleep hygiene counselling) for three months.  
Primary Endpoint (AASM 2012 scoring): 
 Energy and Vitality Dimension of the SF-36 questionnaire 
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Secondary Endpoints (AASM 2007 & AASM 2012 scoring): 
 Short Form 36 (SF 36) 
 Epworth Sleepiness Scale (ESS) 
 Fatigue Severity Scale (FSS) 
 Functional Outcomes of Sleep Questionnaire (FOSQ) 
 Hospital Anxiety and Depression Scale (HADS) 
 Insomnia Severity index (ISI) 
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Patients who have either no OSA or mild OSA when scored with AASM 2007 scoring are 
entered into the trial. Those with no OSA are expedited for rescoring to see if they may have 
OSA when scored as per AASM 2012 scoring criteria (Figure 2). 
 
Figure 2: MERGE study methodology 
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In this chapter, baseline questionnaire data from the ESS, FSS, ISI, and HADS 
questionnaires were reviewed for gender differences. 
Statistical analysis of the data was performed using MiniTab statistical software (Version 
7.1.0). Data was split into genders in order to compare baseline questionnaires for females 
compared with males. Group means were first checked for normality, and then compared 
using the 2 sample T-test.  A value of P < 0.05 was considered statistically significant.  
A post hoc analysis of the data was undertaken to determine the power of the results. The 
minimally clinical important difference (MCID) of a questionnaire is the smallest change that 
would be expected to have clinical benefits.  The MCID for the ESS is 2 points. A power 
calculation using a sample size of 4.34 (found in this data review) shows that a sample size 
of 74 is needed to show a 2-point increase in the ESS with 80% power. Using this sample 
size of 259 participants, power is 99.9%. A similar calculation using the MCID of the FSS 
(0.74) and standard deviation found in this data set (12.9) shows that the power of the FSS 
result is 99%.  
2.3. Results 
Baseline ESS, FSS, ISI and HADS questionnaire data from the first 259 participants in the 
MERGE study were examined for differences based on gender. Data from 186 males and 73 
females was included in the analysis.  
On average, the females were significantly older with a higher BMI than the males (Table 6). 
Comparison of AHIs from these patients is presented in Section 3.3.  
Table 6: Demographics of the mild patient group 
 males females p-value 
Age (years)    
Mean ± SD 50.4 ± 12.1 54.9 + 9.8  
Min - Max 23 - 80 30 - 76  
   0.002 
BMI (units)    
Mean ± SD 29.5 ± 3.6 31.8 ± 5.2  
Min - Max 21 - 39 19.7 - 39  
   < 0.000 
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ESS scores are contained in Table 7. There were significant differences between the 
genders in ESS scores. The female patients in this study were sleepier as a group than the 
males. When using the ESS, scores of 10 or higher indicate problematic sleepiness. In this 
mild group of patients, 87/186 (47%) of males and 46/73 (63%) of females reported being 
excessively sleepy with a score ≥ 10. As can been seen Figure 3, the ESS data spread is 
fairly similar; however, females have a spike of scores at 11 and 14.  
Table 7: ESS Scores in mild patients 
 n min Mean ± SD Max p-value 
Males 186 0 9.13 ± 4.34 21  
Females 72 0 10.63 ± 4.34 20  
     0.014 
 
 
Figure 3: Histogram of ESS scores 
FSS scores are displayed in Table 8. There were significant gender differences. An FSS 
score of 36 or greater indicates high levels of fatigue. In this patient group 82/186 (44%) of 
males and 56/73 (77%) of females were excessively fatigued. Figure 4 shows the spread of 
data, and demonstrates that the female scores were clustered around 50-60. 
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Table 8: FSS scores in mild patients 
 n min Mean ± SD Max p-value 
Males 186 9 33.69 ± 13.94 63  
Females 73 9 43.10 ± 12.94 63  
     0.000 
 
Figure 4: Histogram of FSS Scores 
The ISI scores are displayed in Table 9. There were significant gender differences in the ISI 
scores.  
Table 9: ISI Scores of mild patients 
 n min Mean ± SD Max p-value 
Males 186 0 11.90 ± 5.48 24  
Females 73 1 14.62 ± 5.67 28  
     0.001 
Regarding the ISI questionnaire, scores of 0–7 indicate no clinically significant insomnia, 
scores 8-14 are indicative of subthreshold insomnia, and scores of 15 and over indicate 
clinical insomnia, with those above 21 being severe. Table 10 shows the breakdown of 
insomnia severity. 58% of females in this group had clinically significant insomnia, compared 
with only 31% of males. Figure 5 shows the spread of data and the higher scores from 
female participants.  
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Table 10: Insomnia severity in mild patients  
Category % of males % of females 
No insomnia 23 10 
Subthreshold 
insomnia 
46 33 
Clinical insomnia 28 44 
Severe insomnia 3 14 
 
 
Figure 5: Histogram of ISI scores 
The HADS scores from the data are displayed in Table 11. There were significant 
differences between males and females. Scores ≥ 11 indicate abnormally high levels of 
anxiety and depression. In this data set, 89/186 (48%) of males and 48/73 (66%) of females 
had high scores. As displayed in Figure 6, females had a pattern of higher scores than 
males.  
Table 11: HADS scores from mild patients 
 n min Mean ± SD Max p-value 
Males 186 0 11.03 ± 6.94 33  
Females 73 0 14.81 ± 7.57 37  
     0.000 
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Figure 6: Boxplot of HADS Scores  
2.4. Discussion 
Patients in the MERGE study were scored using AASM 2012 scoring criteria, which allows 
the inclusion of hypopneas with arousals. As per Section 1.2.3, if these hypopneas were 
rescored as RERAs (using AASM 2007 criteria), it is likely that many patients in the MERGE 
study may meet a diagnosis of UARS. However, no formal UARS diagnosis was made for 
these patients in this analysis.    
Of the first 259 patients enrolled in the study, only 73 were female. The literature suggests 
that in the mild OSA/UARS patient groups the gender split is almost 50/50. It would be 
reasonable to expect that females would make up close to 50% of the patient population in 
this study. The lower presentation of female patients supports the notion that females are 
underdiagnosed and present less often to sleep clinics (23, 47). 
Despite being considered a mild patient group, these patients experienced high levels of 
symptoms. Defining these patients as mild is misleading, and using AHI as the measure of 
severity categorisation may be inappropriate for this reason. Mild patients are often denied 
reimbursement for treatment. In many European countries a diagnosis of moderate-to-
severe OSA is required before CPAP treatment is provided to patients (1, 96).   
3
00.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
0 6 21 81 42 03 6
11.03 6.938 186
14.81 7.571 73
Mean StDev N
D
ytis
n
e
D
ata
m
elbairaV
SDAH elamef
SDAH ela
H
 lamroN
SDAH elamef ,SDAH elam fo margotsi
  
54 
 
There were significant gender differences in each of the baseline questionnaire scores, with 
females as a group being more symptomatic than males. Patients in this study had relative 
high ESS scores, especially for female patients and those with mild OSA. This contradicts 
the general consensus in the literature that females report less sleepiness than males (28). It 
is possible that females in the MERGE study are more symptomatic than those in other 
studies, as they have been referred from primary care to a sleep clinic due to suspected 
sleep apnea, and may have previously been investigated for other sleepiness causes.    
In this data set the groups were not completely matched. The females were older and 
slightly more obese. It is possible that this has driven the increased symptoms seen in these 
female patients. These relationships have been explored further in Section 3.3; however, 
future studies should match (or control for) participants on age and BMI.    
While this data set has clearly shown that mild OSA female patients are more symptomatic 
than male patients, it does not answer the question of why. It is not clear whether females 
perceive symptoms differently, or whether they describe them differently. Future studies 
could investigate the psychology behind symptom perception and reporting in mild OSA 
patients in order to better understand why these differences occur.  
2.5. Conclusion 
In this data set, females were found to suffer significantly higher levels of sleepiness, fatigue, 
insomnia, and anxiety and depression than males with the same severity of OSA. 
The literature regarding symptoms of OSA in females states that females with OSA do not 
often report daytime sleepiness (Section 1.3.2.2). However, in this patient group, 63% of 
female patients, compared to 47% of male patients had a score of ≥ 10 on the ESS, 
indicating excessive sleepiness. More female patients than male patients complained of high 
levels of daytime fatigue in this patient group, with 77% of females and 44% of males scoring 
highly on the FSS questionnaire. This is consistent with the literature cited in Section 1.3.2, 
which states that in females with OSA fatigue is commonly listed as a key symptom. Severe 
insomnia was present in 14% of females and only 3% of males. The literature also 
documents insomnia as a key symptom of female OSA. Insomnia is also frequently 
mentioned as a symptom of UARS. In this mild patient group clinically important levels of 
insomnia were present in 60% of females, and 31% of males, showing that insomnia impacts 
more females than males in the mild group. Anxiety and depression, scored using the HADS 
questionnaire, was high in both groups. Females reported more symptoms than males, and 
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clinically significant levels of anxiety and depression were found in 66% of females and 48% 
of males.  
This data set has shown that these patients experienced high levels of symptoms, despite 
being considered mild when using AHI as the measure of severity. There are significant 
symptom differences in the genders. A higher percentage of female patients were 
considered symptomatic in sleepiness, fatigue, insomnia and anxiety/depression. In this 
group a higher proportion of females than males experienced excessive daytime sleepiness, 
which is inconsistent with the literature.  
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CHAPTER 3. DETAILED ANALYSIS OF GENDER 
DIFFERENCES IN RESPIRATORY EVENTS  
3.1. Introduction 
Women with OSA are characterised as having more flow limitation, lower AHIs, and shorter 
apneas (Section 1.5.1). However, as described in Section 1.5.3, the literature on UARS 
indicates that that both genders may have similar amounts of airway obstruction. Therefore, 
the following chapter will explore whether mild OSA and UARS patients have clear gender 
differences in their respiratory data.  
As shown in CHAPTER 2, gender differences in symptoms still exist even amongst patients 
with mild OSA. What remains unclear is whether those symptoms are a result of gender, or 
whether they are related to different types of sleep disordered breathing events. This chapter 
will explore associations between the symptoms discussed in CHAPTER 2, and sleep study 
data taken from the PG studies of mild patients.  
The aim of this review was to determine whether there are gender differences in respiratory 
data from mild OSA patients, and whether respiratory data can be correlated with symptoms. 
The hypothesis is that gender differences will still exist in this respiratory data, and that 
worsening respiratory parameters will correlate with worsening symptoms.  
3.2. Methods 
The full methodology of the MERGE study is contained in Appendix D, and summarised in 
Section 2.2. 
PG data used in this review was collected using the Apnealink Air home sleep test 
(ResMed). Data including AHI, ODI, hypopnea index, flow limitation, and snore were 
analysed using both the AASM 2007 and AASM 2012 scoring criteria (see Section 1.2 for 
details on the different scoring criteria).  
The AASM 2007 analysis of the Apnealink Air was undertaken using AirView software 
(ResMed). Automated analysis of sleep studies using AASM 2007 criteria has been 
extensively validated and is closely correlated with manual PSG scoring (188-197). 
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The AASM 2012 analysis was done using a recently developed algorithm which estimates 
arousals from sleep. Although PSG is the most precise measure of arousals, surrogate 
measures such as pulse wave amplitude drops, respiratory changes, and movement have 
shown to accurately estimate arousals(198-200). The AASM 2012 scoring algorithm used in 
the MERGE study uses surrogate measures of arousal and machine learning to estimate 
arousals from sleep following hypopneas. This algorithm has been shown to have high 
sensitivity and specificity (92% and 80%) to rule in OSA at AHI ≥ 5, when compared with 
manual polysomnography scoring (201).Statistical analysis of the data was performed using 
MiniTab statistical software (Version 7.1.0). PG data was split into genders and compared 
using the Two-Sample T test. PG data was then analysed against baseline symptoms (as 
described in CHAPTER 2) using the Pearson’s Correlation Test to determine correlations. 
These relationships were further explored using the coefficient of determination (R2) in order 
to better understand the interactions between age, BMI, gender and symptoms.  
3.3. Results 
3.3.1. Gender comparison of PG data 
The first 259 consecutively enrolled participants in the MERGE study with full data sets were 
analysed. Of these 259 patients, 73 (28%) were female. Demographics for these participants 
can be found in Section 2.3.  
When PG studies were scored according to the AASM 2007 criteria, the males had more 
severe SDB in all respiratory categories (AHI, ODI at 4%, and number of hypopneas). 
However, when re-scoring with AASM 2012, the differences were much less obvious. 
When scored using AASM 2007 criteria, the males were found to have a higher AHI, ODI, 
and hypopnea index than the females (Table 12).  
Table 12: Mild patients scored with AASM 2007 criteria 
 males females p-value 
2007 AHI 7.17 ± 3.4 5.97 ± 2.71 0.004 
4% ODI 8.65 ± 2.3 7.06 ± 3.8 0.008 
Hypopnea index 5.31 ± 3.71 4.26 ± 2.71 0.015 
When scored using AASM 2012 criteria, the gender differences disappeared. The females 
did have slightly more hypopneas terminated by arousals; however, this was not statistically 
significant (Table 13). 
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Table 13: Mild patients scored with AASM 2012 criteria 
 males females p-value 
2012 AHI 12.52 ± 5.01 11.65 ± 4.69 0.197 
3% ODI 17.02 ± 4.96 15.6 ± 5.25 0.111 
Hypopneas terminated by arousal 3.2 ± 3.58 3.65 ± 3.58 0.370 
Hypopnea index 9.54 ± 3.97 9.03 ± 3.46 0.410 
Males had significantly more snore than females. The percentage of overall flow-limited 
breaths was similar between the genders; however, the females had significantly less flow-
limited breaths with snore (Table 14). 
Table 14: Flow limitation and snore in mild OSA patients  
 males females p-value 
% flow-limited breaths 39.8 ± 13.8 38.4 ± 15.6 0.598 
% flow-limited breaths without snore 33.2 ± 13.3 35.3 ± 14.3 0.348 
% flow-limited breaths with snore 6.55 ± 8.14 3.09 ± 4.69 0.001 
No. of snore breaths 1147 ± 1139 843 ± 845 0.022 
Patients who were classified as having no OSA at baseline (AHI < 5 by AASM 2007 scoring) 
were re-scored using AASM 2012 guidelines. Following the rescoring, 26/73 (36%) of 
females and 52/184 (28%) of males had an increased AHI sufficient to lead to diagnosis of 
OSA (AHI ≥ 5). 
The average AHI of this female group when scored with AASM 2007 was 5.97; it increased 
to an average of 11.65 when rescored according to AASM 2012 rules. The average AHI of 
the male group was 7.17, and it increased to 12.52 when rescored. The two groups were not 
significantly different regarding AHI changes between AASM 2007 and 2012 scoring.  
3.3.2. Relationships between PG data and symptoms 
There were correlations between AHI (scored with both AASM 2007 and AASM 2012) and 
daytime symptoms (Table 15). However, all the relationships were inverse: the higher the 
symptom, the lower the AHI. Flow limitation was only correlated with the ISI score, with an 
inverse relationship, with higher scores of insomnia being linked to lower percentages of flow 
limitation scores. Hypopneas terminated by arousals had no relationship with symptoms. 
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Table 15: Correlations between symptoms and respiratory parameters  
 2007 AHI 2012 AHI 
Percent of flow 
limited breaths 
Hypopneas 
terminated by 
arousal 
ESS 
r 
p-value 
 
-0.169 
0.007 
 
-0.158 
0.012 
 
0.047 
0.537 
 
0.025 
0.692 
FSS 
r 
p-value 
 
-0.152 
0.016 
 
-0.179 
0.004 
 
-0.10.2 
0.182 
 
-0.031 
0.622 
HADS 
r 
p-value 
 
-0.166 
0.008 
 
-0.144 
0.022 
 
-0.093 
0.228 
 
0.081 
0.202 
ISI 
r 
p-value 
 
-0.139 
0.027 
 
-0.156 
0.014 
 
-0.159 
0.037 
 
-0.029 
0.646 
When analysing the data by gender, there were far fewer correlations between SDB 
measures in the males than the females (Table 16). In the males, correlations were only 
found between AASM 2012 AHI, and FSS. In the female patients, correlations were found 
between AASM 2007 AHI and ESS, HADS, and ISI. In the female data scored with AASM 
2012 rules, correlations were found between AHI, and HADS, and ISI (Figure 11). There 
were no correlations between flow limitation and symptoms in the male group. In the female 
group correlations were found between percent of flow limited breaths and FSS, and ISI. 
Again these correlations were inverted, with higher symptoms being associated with lower 
percentage of flow limitation.  
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Table 16: Correlations between symptoms and respiratory parameters analysed by gender 
 2007 AHI 2012 AHI 
% flow limited 
breaths 
Hypopneas 
terminated by 
arousal 
Males 
ESS 
r 
p-value 
 
-0.093 
0.213 
 
-0.130 
0.083 
 
0.043 
0.633 
 
-0.042 
0.571 
FSS 
r 
p-value 
 
-0.074 
0.321 
 
-0.153 
0.040 
 
-0.006 
0.943 
 
-0.105 
0.160 
HADS 
r 
p-value 
 
-0.043 
0.563 
 
-0.026 
0.735 
 
-0.048 
0.598 
 
0.035 
0.637 
ISI 
r 
p-value 
 
-0.054 
0.468 
 
-0.103 
0.171 
 
-0.033 
0.712 
 
-0.085 
0.253 
Females 
ESS 
r 
p-value 
 
-0.317 
0.007 
 
-0.197 
0.099 
 
0.070 
0.639 
 
0.164 
0.171 
FSS 
r 
p-value 
 
-0.218 
0.068 
 
-0.192 
0.109 
 
-0.300 
0.040 
 
0.100 
0.408 
HADS 
r 
p-value 
 
-0.372 
0.001 
 
-0.381 
0.001 
 
-0.178 
0.231 
 
0.146 
0.224 
ISI 
r 
p-value 
 
-0.242 
0.042 
 
-0.240 
0.044 
 
-0.416 
0.004 
 
0.055 
0.648 
In male patients, the strongest relationship was seen between AASM 2012 AHI and FSS 
(Figure 7).  
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Figure 7: Relationship between AASM 2012 AHI and average FSS in male patients 
In the female patients the strongest relationships were seen between flow-limited breathing 
and ISI (Figure 8); AASM 2007 AHI and ESS (Figure 9); AASM 2007 AHI and HADS (Figure 
10); and AASM 2012 AHI and HADS (Figure 11).
 
Figure 8. Relationship between flow limited breaths and average ISI score in female patients 
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Figure 9: Relationship between AASM 2007 AHI and average ESS in female patients  
 
Figure 10: Relationship between AASM 2007 AHI and average HADS score in female patients  
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Figure 11: Relationship between AASM 2012 AHI and average HADS score in female patients  
 
3.3.3. Correlations between PG data, symptoms, gender, age and BMI  
When reviewing the data by the adjusted R², accounting for BMI and AHI, the FSS values of 
females are 33 points higher than that of males. They increase by 1.1 per unit of BMI 
increase and drop by 0.5 points for every one-unit increase in AHI. The increase of FSS per 
unit rise in BMI is 0.8 points lower in women than in men (Table 17, Figure 12).   
Table 17: Correlations between FSS and Gender, AHI, and BMI 
Dependent Variable:  FSS 
Variable  Estimated 
change per 
unit 
95%-C.I. p-value 
Female gender 33 [8.5 ; 57.5] 0.008 
BMI 1.1 [0.6 ; 1.6] <0.001 
2012AHI -0.5 [-0.8 ; -0.2] 0.004 
Female gender and 
BMI 
-0.8 [-1.6 ; -0.1] 0.037 
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Figure 12: Correlations between FSS, gender and BMI 
The HADS values of females are 11.1 points higher than that of males. In contrast to males, 
the values of females decrease with rising AHI by 0.6 per unit of AHI. There is a slight but 
significant decrease of 0.1 points per year of age (Table 18, Figure 13). 
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Table 18: Correlation of HADS, gender, age and AHI 
Dependent Variable:  HADS  
  
Variable  Estimated 
change per 
unit 
95%-C.I. p-value 
Female gender 11.1 [6 ; 16.1] <0.001 
Age -0.1 [-0.2 ; 0] 0.048 
2012 AHI 0 [-0.2 ; 0.2] 0.992 
Female gender and 
2012 AHI 
-0.6 [-1 ; -0.2] 0.005 
 
Figure 13: Correlations between HADS, AHI and gender 
Regarding sleepiness, in this group the risk of having an ESS of ≥11 is 90% higher in 
women than in men, and it decreases in both genders by 3 % per year of age (Table 19, 
Figure 14).  
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Table 19: Correlations between ESS, gender and age 
Dependent Variable: ESS 
Variable  Estimated 
change per 
unit 
95%-C.I. p-value 
Gender=Female 0.9 [0.3 ; 1.5] 0.002 
Age -0.03 [-0.06 ; -0.01] 0.005 
 
Figure 14: Relationship between ESS, age and gender 
The ISI values of females are 12.8 points higher than that of males. In contrast to females, 
the values of males increase with rising BMI values by 0.3 per unit. In both genders there is 
a small but significant decrease with increasing AHI values (Table 20, Figure 15, Figure 16). 
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Table 20: Correlations between ISI, gender, BMI and AHI 
Dependent Variable:  ISI 
Variable  Estimated 
change per 
unit 
95%-C.I. p-value 
Female gender 12.8 [2.8 ; 22.9] 0.012 
BMI 0.3 [0.1 ; 0.6] 0.001 
2012AHI -0.2 [-0.3 ; 0] 0.014 
Female gender and 
BMI 
-0.3 [-0.7 ; 0] 0.042 
 
Figure 15: Correlations between ISI, BMI and gender 
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Figure 16: Correlations between ISI, AHI and gender 
 
3.4. Discussion 
Many more male patients were enrolled in the MERGE study than female patients (72% vs. 
28%). Therefore, it appears true that more males are presenting to the clinics, even in this 
very mild group. Snoring was significantly more common in the male patients than females. 
It is possible that one reason female patients had worse symptoms is that their motivation for 
attending the sleep clinic was due to symptoms, whereas more males may have been 
referred due to snoring. The reasons for referral to sleep clinics were collected as part of the 
MERGE study (Appendix C). This will allow future analysis of the MERGE study data to 
describe any relationship between snoring as a reason for referral, and gender. 
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Figure 17: Gender and AASM scoring criteria 
This data found that males do have more severe OSA (more events with 4% desaturation) 
than females, however the differences were much less clear when using AASM 2007 scoring 
(Figure 17).   Changing the scoring criteria to AASM 2012 is more inclusive for females with 
OSA, as this allows for scoring of events with 3% desaturation, and also hypopneas 
terminated by arousals. The females did not have more of these types of hypopneas than 
the males; rather, they had a higher proportion of hypopneas terminated by arousal making 
up their AHI.  
Interestingly, this data did not show that females have more flow limitation than males. This 
was a surprising finding as this is commonly stated in the literature (section 1.5.1). It is 
possible this finding is due to how flow limitation is measured in different studies. It is difficult 
to get a consensus on what qualifies as flow limitation from manual scoring and different 
algorithms. The quality of the signal obtained, along with recognition of flow shapes, can 
lead to inconsistency. This is a known issue in sleep medicine, and in response the 
American Thoracic Society (ATS) workshop "Non-Invasive Identification of Inspiratory Flow 
Limitation in Sleep Studies” aims to standardise the methodology of visually identifying flow 
limitation (202).  
It is difficult to interpret the results correlating the patient symptoms and measures of SDB. 
Though some correlations were found, there was a wide scatter of data and no clear 
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conclusions can be drawn. The females, who were more symptomatic as a group, had more 
correlations, but the correlations were inverse. The higher the SDB measures, the less 
symptomatic the female patients were. In female patients, ESS was strongly correlated with 
age, with younger females much more likely to have high levels of daytime sleepiness. 
Female FSS scores were more strongly associated with BMI than AHI, whereas, in male 
patients increasing BMI was associated with worsening insomnia. Obesity, even without 
comorbid OSA, is associated with anxiety, depression and sleepiness (203). The underlying 
obesity in some of these participants may have a stronger impact on daytime symptoms than 
their OSA. The female patients, as a group, were more obese than the males, and were 
more symptomatic. In order to understand the different roles of obesity and OSA on daytime 
symptoms, treating the OSA in these patients and measuring any change in their BMI levels 
is important. The MERGE study (Appendix C) aims to do this, with results expected late 
2019.  
The literature comparing UARS to moderate and severe OSA patients has found that UARS 
patients are more symptomatic despite lower AHIs (section 1.4.6). In this data it was found 
that even within a mild patient population the less severe OSA patients had more symptoms. 
It was originally hypothesised in the introduction to this chapter that these symptoms may be 
correlated with other measures of SDB such as flow limitation, or hypopneas terminated by 
arousals, which appear more often in women. However, although some correlations did exist 
between measures of SDB and symptoms, the relationships were inverse. In this data there 
were no clear relationships between symptoms and sleep. Confounding factors such as age 
and BMI appear to have a large influence on symptoms. Additionally, there may be changes 
to symptoms over time, with patients becoming habituated to poor quality of life. Individual 
differences, including sensitivities to disrupted sleep and coping mechanisms, potentially 
play a large role and are difficult to quantify. It is also possible there are other SDB 
measures not collected during this study which correlate more strongly with symptoms.  
One limitation of this patient data is that it was gathered using PG rather than PSG. PG 
studies are less accurate than PSG studies, as they cannot definitively measure states of 
sleep and wake. This means that PG studies tend to underestimate AHI. This is a well-
known limitation of PG (204). As PGs are unable record to EEG waves, they cannot 
measure arousals from sleep, and therefore currently cannot identify hypopneas terminated 
by arousals. In the MERGE study a new PG algorithm was employed, which estimates 
arousals from surrogate measures such as pulse wave amplitude drops, respiratory changes 
and movement. The new algorithm has been shown to have high sensitivity and specificity 
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(92% and 80%) to rule in OSA at AHI ≥ 5, when compared with manual PSG scoring 
(201)(clinicaltrials.gov ID: NCT03470493). The benefits of PG studies are that they are 
simpler and more cost effective to use on large volumes of patients. Overall, studies suggest 
that home sleep testing is suitable for home diagnosis of OSA (204-206), and for the most 
part national sleep societies have recommended the use of PG studies for symptomatic 
patients at risk of moderate-to-severe OSA without other pathologies (207-209) (204, 210). 
However, the use of PG in mild patients has not been widely studied, and it is quite possible 
that AHI was underestimated in this study. Conversely, night-to-night variability in AHI is 
another known issue, which may have led to over-estimation of AHI in some of these 
patients (211). A single night study was used to facilitate a pragmatic trial design which is in 
line with majority of clinical pathways used in the diagnosis of OSA.  
 
3.5. Conclusion 
The gender differences in respiratory data described in the literature do still exist in this mild 
patient group; however, they are much less pronounced. When AASM 2012 scoring criteria 
is used, the gender differences in AHI are even less obvious. This indicates that women 
have less-severe oxygen desaturations, more flow limitation without snore, and more 
hypopneas terminated by arousals than men. There were some correlations between AHI, 
and flow limitation, and symptoms. These correlations primarily occurred in the female 
patient group and were inverse (higher SDB was correlated with lower symptom profile). 
Confounding factors including age, and BMI were also correlated with symptoms. High 
sleepiness was strongly correlated with age in younger patients. BMI was associated with 
increased FSS in female patients and increased ISI in male patients. No clear conclusions 
regarding symptoms and sleep measures could be drawn from this data. Future studies 
which investigate the changes in symptomology after application of OSA treatment will 
provide important insights into what level of symptoms can be attributed to OSA. 
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CHAPTER 4. DEVELOPMENT OF A FEMALE SPECIFIC 
AUTOSET DEVICE 
4.1. Introduction 
As described in Section 1.7, AutoSet devices have been developed for and validated with 
exclusively male patients. The aim of this chapter was to develop an AutoSet algorithm 
specifically for female patients.  
The differences in PSG data between males and females with OSA is described in Section 
1.5.1. In summary, females with OSA:  
 Have more episodes of upper airway resistance (flow limitation), and RERAs (126)  
 Have a higher occurrence of apneas during REM sleep (123)  
 Require lower CPAP pressures (212) 
 Have less severe OSA with lower apnea/ hypopnea index (AHI) (123)  
 Have shorter apneas/ hypopneas (124) 
 Take longer to fall asleep (125) 
 
The new AutoSet (described in this document as AutoSet F, and commercially released as 
AutoSet for Her [ResMed, Sydney]), was designed to appropriately treat these 
characteristics of female OSA.  
The AutoSet F algorithm was designed at ResMed. The first step in development was a 
thorough literature review to understand the differences in female and male OSA patients. 
As part of this review, detailed analysis of existing AutoSet algorithms was done to 
understand how they currently respond to female-specific breathing patterns. The next part 
of the algorithm development involved reviewing de-identified PSG files kept at ResMed 
from previous clinical trials to determine if the breathing patterns described in the literature 
could be quantified in PSGs from female patients compared with PSGs from male patients. 
Finally, in-house computer simulations were run to test various new algorithm learning and 
parameters in order to make final decisions about the behaviour of the algorithms. The 
following Sections describe the features of the algorithm and how they correspond to female-
specific breathing patterns. Clinical trials validating the algorithm and involving patients are 
described in CHAPTER 5. 
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4.2. Development of a new female-specific algorithm  
4.2.1. Modified Flow Limitation Response  
Females have more upper airway resistance, flow limitation, and hypopneas terminated by 
arousal (126). Therefore, the AutoSet F has a more sensitive flow limitation response. The 
algorithm will calculate and respond to a single breath of flow limitation (as opposed to the 3 
breath average used in the standard AutoSet algorithm). The purpose is to make it more 
responsive to flow limitation. This faster response allows the female patient’s flow limitation 
to be treated more efficiently, hopefully leading to a reduction in associated arousals from 
sleep.  
The algorithms’ response to flow limitation, although faster, has a gentler and lower pressure 
increase overall (Figure 18). This is to ensure the pressure changes remain comfortable for 
female patients and the pressure doesn’t increase too much or too quickly. 
 
Figure 18: The AutoSet F response to flow limitation (pink), compared to the standard AutoSet response to flow 
limitation (blue).  
4.2.2. Floor Pressure to protect against REM OSA 
As it is common for females with OSA to exhibit clusters of events during REM sleep (123), 
the AutoSet F contains a floor pressure. The floor pressure works by calculating a minimum 
pressure at which obstructive apneas no longer occur. If the algorithm detects two 
obstructive apneas occurring within one minute, then the pressure reached in response to 
the second apnea will become the new floor pressure. For example, when the algorithm 
senses a run of apneas and the patient requires a pressure of 8cm H2O to overcome the run 
of events, then for the remainder of the night the pressure will not drop below 8cm H2O.The 
floor pressure is capped so it will never increase higher than 10cm H2O. It is reset every time 
the device is stopped.  
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Figure 19 shows an example of a female patient with all her obstructive apneas occurring 
during REM sleep. If a standard AutoSet algorithm were used in this situation, the pressure 
would decay down to 4cm H20 during non-REM sleep when ventilation was stable. When 
the female patient requires higher pressure during REM sleep, the AutoSet may take some 
time to increase the pressure. During this pressure increase the patient may continue to 
have obstructive apneas. Once pressure is stable, REM sleep could be over, and the 
pressure would decay again before the next period of REM. In this case, the residual AHI 
could remain quite high.  
 
Figure 19: Female with obstructive events clustered during REM sleep 
4.2.3. Lower Mean CPAP Pressures 
Clinical trial data suggest that men require higher pressures during CPAP therapy than 
females, after adjusting for baseline OSA severity or BMI (168, 212, 213). To accommodate 
this, the AutoSet F algorithm has been designed to keep the CPAP pressure lower (and 
therefore more comfortable) while still adequately treating the majority of females. The 
maximum pressure that can be attained due to an obstructive apnea is 12cm H2O. In the 
standard AutoSet, the pressure increases from closed airway apneas were permitted up to 
20cm H2O. The AutoSet F therapy pressure can still rise above 12cm H2O for obstructions 
other than apneas (e.g. if the device detects flow limitation or snore). However, the algorithm 
includes logic to reduce the likelihood of reaching high pressures over short periods. 
The majority of research on women with CPAP has demonstrated the requirement for 
pressures at an average of around 10cm H2O (29, 212-214). The AutoSet F targets a 
pressure range of 8-12cm H2O and actively slows pressure increases as delivered pressure 
gets higher than 12cm H2O. 
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4.2.4. RERA Detection 
Respiratory Effort-Related Arousals (RERAs), have been described in Section 1.2.1. When 
scoring with AASM 2012 criteria, the majority of RERAs are likely to be reclassified as 
hypopneas terminated by arousals (1).  
Women tend to have short apneas and increased levels of flow limitation, and, as shown in 
CHAPTER 3, are more likely to arouse from sleep during a hypopnea rather than have 
continued lowering of their oxygen saturation. Therefore, the count of RERAs/hypopneas 
terminated by arousals is higher in female patients. An example of this event is shown in 
Figure 20.  
 
Figure 20: Example of a RERA (AASM 2007 scoring), or hypopnea with arousal  (AASM 2012 scoring). 
Device-scored AHIs are typically correlated with AASM 2007 scoring, and therefore do not 
include hypopneas terminated by arousals. To ensure that these events are still recognised, 
the algorithm detects and reports RERAs. RERA reporting is based on the following rules: 
 A minimum of two flow-limited breaths (flat/m-shape) AND 
 A reduction in the magnitude of these breaths. 
The RERA algorithm calculates three quantities: 
1. Flow limitation present in the three most recent breaths 
2. Flattening and length of event does not meet the criteria for a hypopnea  
3. Ventilation step change of at least 50% 
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If at least two breaths are flow-limited and a step change in ventilation of 50% from one 
breath to the next is identified, then a RERA is scored. 
 
Figure 21: Example of how the RERA detection algorithm identifies RERAs and avoids false positives.  
The purpose of the RERA index is to help physicians to review their patient’s treatment and 
ensure they are not having residual events. Figure 22 shows an example of a RERA 
occurring (scored as per AASM 2007 rules). In this case, the patient may require a higher 
minimum CPAP pressure to prevent partial airway closure.  
 
Figure 22: Example of a RERA from a CPAP download 
4.2.5. Automatic Ramp 
As women take longer, on average, to fall asleep than men (125), an automatic ramp has 
been introduced to the AutoSet F. Traditional ramp options work by starting at a minimum 
pressure and slowly increasing the pressure over a user-defined period of time until a 
suitable treatment pressure is reached. For example, a patient who uses a CPAP set to 
10cm H2O may find it difficult to fall asleep starting at 10cm H2O. Therefore, they may set a 
ramp period starting at 4cm H2O to increase to 10cm H2O over a period of 30 minutes.  
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The automatic ramp (AutoRamp, ResMed) measures the patient’s breathing and waits until 
sleep is established before increasing the pressure. Sleep onset is inferred via one of the 
following events: 
 Presence of 3 obstructive apnea or hypopnea events within 2 minutes 
 Presence of 5 consecutive snore breaths  
 Detection of stable metronomic (consistent) breathing indicative of sleep (30 
consecutive breaths which have similar breath durations, tidal volumes and peak 
flows). An example of this is available in Figure 23. 
 
Figure 23: Automatic ramp activated after 30 consecutive breaths inferring sleep onset. 
4.2.6. Gentle Pressure Adjustments 
There are anecdotal reports that some women may be disturbed by the changes in pressure 
when using standard AutoSet. The AutoSet F contains several modifications which 
effectively result in a slower (and lower) pressure rise and decay when compared to the 
standard AutoSet algorithm. An example is provided in Figure 24. 
The main changes from the standard AutoSet to the AutoSet F are:  
 The level of pressure increase has been dropped by 0.5 for every pressure rise, and 
the maximum increment per breath has been capped at 0.5 cm H2O. 
 The flow limitation response has been de-weighted linearly from 1 at 10 cm H2O to 
0 at 20 cm H2O. The higher the CPAP pressure goes, the less the AutoSet will 
increase in response to flow limitation. 
 The decay period has been increased 60 minutes (from 20 minutes in the standard 
AutoSet). When stable breathing is detected the algorithm will slowly decrease the 
pressure to the minimum over 60 minutes. 
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Figure 24: Example of the slower and more gentle female specific algorithm  
4.3. Summary of new algorithm features 
As demonstrated above, female-specific respiratory breathing patterns found in the literature 
have been used to for the development of a new AutoSet algorithm designed specfically for 
female patients.  
Table 21: Summary of AutoSet F algorithm features 
Parameter New female-specific algorithm Benefit to female patients 
Females have 
lower AHIs with 
shorter apneas 
and less severe 
hypopneas 
The algorithm reports a flow-
based RERA measure 
 
The RERA detector is a measure of 
events (RERAs and hypopneas 
terminated by arousals) which 
disturb the patient’s breathing 
during their sleep. This allows the 
clinician to understand residual 
breathing issues and modify 
treatment.  
Females have 
more upper 
airway 
resistance and  
flow limitation 
A single-breath index is used to 
calculate and respond to the 
patients flow limitation (as 
opposed to the 3-breath average 
used in the standard AutoSet 
algorithm). Additional changes 
have also been made to the 
algorithm to make it more 
sensitive to flow limitation.  
This change makes the AutoSet 
more responsive to flow limitation. 
The flow limitation is identified and 
the device responds quickly, 
avoiding long period of flow 
limitation or development into 
RERA or hypopnea.  
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Females have 
more REM-
based events 
The algorithm includes the 
addition of a closed airway apnea 
floor pressure.  
 
The floor pressure protects females 
against a string of REM-based 
events by setting a minimum 
pressure based on the patients 
breathing each night. 
Females take 
longer to fall 
asleep  
A smart ramp has been 
introduced. The therapy pressure 
will remain low until sleep onset 
occurs.  
The female patient can set a long 
ramp time (45 minutes) which will 
allow lower (more comfortable) 
pressure to be delivered while she 
falls asleep. The smart ramp 
means that if the female patient 
does fall asleep during this time the 
algorithm will identify and respond 
to obstructive events. 
Females require 
lower CPAP 
pressures  
The algorithm will increase the 
pressure to a maximum of 12cm 
H2O when an obstructive apnea 
occurs.  
NOTE: The therapy pressure can 
still go above 12 cmH2O as a 
response to snore or flow 
limitation. However, the algorithm 
includes logic to reduce the 
likelihood of reaching high 
pressures over short periods. 
 
As females require lower CPAP 
pressures than males, the new 
algorithm has been designed to 
keep the CPAP pressure lower 
(and therefore more comfortable) 
while avoiding large pressure 
increases.  
Some females 
may be 
disturbed by the 
standard 
AutoSet 
changes in 
pressure 
The pressure changes which 
occur in response to respiratory 
patterns have been programmed 
to be slower than those of a 
standard AutoSet.  
The AutoSet F increases and 
decreases pressure at a slower 
rate than a standard AutoSet, 
aiming to increase comfort and 
decrease therapy-related 
disturbances during the night. 
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4.4. Use of the AutoSet F in male patients 
When development was commenced on the AutoSet F, it was under the assumption that the 
literature pertaining to gender differences in OSA was accurate. That is to say that females 
with OSA have more flow limitation, more RERAs, more hypopneas terminated by arousals, 
lower AHIs, shorter events, less severe oxygen desaturations and require lower CPAP 
pressures. Further investigations in the areas of mild OSA and UARS indicated that the 
differences may not be as clearly defined as the literature first indicated. Findings from 
CHAPTER 2 support the notion that females are overall less severe, but shows that the 
differences are much less pronounced in the mild groups, with no gender differences found 
in the amount of flow limitation or hypopneas terminated by arousal.  
Despite these findings, the development of the AutoSet F focused solely on female OSA 
patients. An important driver for this was the clinical experience of female patients described 
in Section 1.3.3. Females are less likely to be referred to sleep clinics, and may feel 
embarrassed to be diagnosed with what was historically considered a male disease. 
CHAPTER 3 shows that, even in very mild patients, females with OSA have significantly 
worse symptoms than males with OSA. It is hoped that, by developing and commercialising 
a device for female with OSA, awareness is increased and the stigma that some female 
patients may feel is reduced.  
The AutoSet F is likely a suitable treatment for any patients with mild OSA dominated by flow 
limitation and RERAs, however exploring that area was outside the scope and purpose of 
the development of the AutoSet F.  
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CHAPTER 5. TESTING AND VALIDATION OF THE 
AUTOSET F  
5.1. Introduction  
As described in Section 1.5.1, female OSA patients have different breathing patterns from 
male patients. A new AutoSet algorithm was developed in order to optimally treat these 
differences to improve treatment for female patients. This chapter describes the methods for 
testing and validating that the AutoSet F was working as designed. The first validation 
activity was a clinical trial which evaluated efficacy, based on AHI and ODI, of the AutoSet F 
on 20 female patients. The second validation involved a bench test which was used to 
simulate the breathing of a standard female patient. The AutoSet F was evaluated on the 
bench test in order to review its performance on a standardised, repeatable test, compared 
with other AutoSet devices. Finally, the AutoSet F was commercially released in a controlled 
product launch where data was collected to ensure correct functioning and appropriate 
treatment of female OSA in uncontrolled conditions.  
5.2. Clinical trial to evaluate the efficacy of the AutoSet F 
5.2.1. Introduction  
Following on from development of the new algorithm designed for female patients, a clinical 
trial was conducted to evaluate treatment efficacy of the AutoSet F in female patients.   
5.2.2.  Methods 
The full methodology of this clinical trial is described in Appendix E.  
This was a single-blind, randomised, crossover, non-inferiority study comparing the efficacy 
of the new AutoSet F algorithm to the standard AutoSet algorithm undertaken at two West 
Australian sleep disorders research institutes.   
The study was approved by The University of Western Australia HREC (Approval No.: 
RA/4/1/5919) and by Sir Charles Gairdner HREC (Approval No.: 2013-042). All participants 
provided informed consent. 
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Female participants established on AutoSet treatment underwent consecutive 
polysomnography (PSG) studies in a randomised order where they received either the 
AutoSet F algorithm or the standard algorithm. At visit 1, baseline information was collected, 
including demographics and data from their diagnostic PSG. Following each treatment night, 
participants completed a questionnaire about the comfort of the device.  
PSG data was scored by an expert independent scorer from six lead EEGs.  
Primary Objective:  
1) To evaluate the efficacy of the new algorithm (AutoSet F) 
 Comparison of AHI and ODI of new algorithm compared with a standard 
algorithm to demonstrate non-inferiority 
 
Secondary Objectives:  
1) To evaluate whether sleep parameters are improved using the new algorithm 
(AutoSet F) compared with the standard algorithm 
2) To evaluate the patient’s subjective feedback of the modified algorithm (AutoSet F) 
compared with the standard algorithm 
 
5.2.3. Results 
5.2.3.1. 5.2.3.1. Participant demographics  
Twenty participants took part in the study. Table 22 displays participant demographics. 
Table 22: Participant demographics  
Participant Demographics and baseline characteristics 
Age (n=20) 44.85±5.02 years 
Ethnicity (n=20) 
Caucasian: 90% 
Aboriginal: 10% 
Height (n=20) 164.51±6.04 cm 
Weight (n=20) 104.02±20.45 kg 
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Diagnostic AHI (n=20) 19.08±8.69 events/hr 
Mask Type (n=20) 
Nasal Pillows: 35% 
Nasal: 55% 
Full Face: 15% 
Chin Strap (n=20) 
Yes: 15% 
No: 85% 
Duration of PAP Therapy (n=19)* 
23.3±34.5 months; range 1-144 
months 
 
5.2.3.2. Comparison of treatment efficacy 
No significant differences were found between participant AHI and ODI values when treated 
with the new algorithm compared to the standard AutoSet algorithm as shown by paired t-test  
(Table 23 and Table 24). 
Table 23: AHI comparison 
Efficacy Results – AHI (events/hr) 
 Valid N Mean Std. Dev. Min Max 
Standard AutoSet 20 0.96 1.40 0.00 4.34 
AutoSet F 20 0.91 0.90 0.00 2.84 
 Valid N 
Difference 
in means 
95% CI for mean diff p-value 
Paired t-test analysis 20 0.05  (-0.562, 0.658) 0.870 
 
Table 24: ODI comparison  
Efficacy Results – ODI (desaturations≥3%/hr) 
 Valid N Mean Std. Dev. Min Max 
Standard AutoSet 20 1.92 1.82 0.13  6.57 
AutoSet F 20 2.19  2.15   0.12  6.70 
 Valid N 
Difference 
in means* 
95% CI for mean diff p-value 
Paired t-test analysis 20 -0.28  (-1.072, 0.521) 0.477 
 
Further comparison analysis with patients’ diagnostic AHI values shows a statistically and 
clinically significant reduction in AHI with treatment of either the standard AutoSet [diagnostic 
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vs. standard AutoSet (19.07 vs. 0.95; p=0.000)] or AutoSet F algorithms [diagnostic vs. 
AutoSet F (19.07 vs. 0.91; p=0.000)] (Table 25 and Figure 25).  
Table 25: Comparison of untreated AHI vs. AutoSet F AHI  
AHI Comparison Analysis (Untreated vs. Standard AutoSet vs. AutoSet F) 
 Valid N Mean Std. Dev. Min Max 
Untreated 20 19.07 8.69 7.00 33.00 
Standard AutoSet 20 0.96 1.40 0.00 4.34 
AutoSet F 20 0.91 0.90 0.00 2.84 
Paired t-test analysis Valid N 
Difference 
in means 
95% CI for mean diff p-value 
Untreated vs. 
Standard AutoSet 
20 18.12  (14.01, 22.24) 0.000 
Untreated vs. 
AutoSet F 
20 18.17  (14.19, 22.14) 0.000 
 
 
Figure 25: Individual patient AHI comparison (Diagnostic vs. standard AutoSet vs. AfH (AutoSet F algorithm)).  
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5.2.3.3. Comparison of sleep parameters  
When comparing the sleep parameters, the data shows that flow limitation (% of breaths) was 
significantly lower when participants were treated with the new algorithm compared with the 
standard AutoSet algorithm (0.14% vs. 0.20%; p=0.003) as shown by paired t-test (Table 26). 
No other significant differences were found between sleep parameters.  
Table 26. Comparison of sleep parameters  
Sleep Parameter Results 
 
Therapy Valid N Mean 
Std. 
Dev. 
95% CI for 
mean diff 
p-value 
Sleep Efficacy 
(%) 
Standard 
AutoSet 
20 85.99 8.55 
 (-2.92, 6.62) 0.427 
AutoSet F 20 84.14 9.62 
Wake after 
Sleep Onset 
 (mins) 
Standard 
AutoSet 
20 47.52 34.57 
 (-29.72, 
9.92) 
0.309 
AutoSet F 20 57.42 43.31 
Sleep Latency 
 (mins) 
Standard 
AutoSet 
20 16.52 19.58 
 (-8.84, 9.39) 0.950 
AutoSet F 20 16.25 12.70 
# of 
Spontaneous 
Arousals 
 
Standard 
AutoSet 
20 85.55 40.88 
 (-12.30, 
20.60) 
0.604 
AutoSet F 20 81.40 33.91 
# of RERAs 
 
Standard 
AutoSet 
20 2.60 3.32 
 (-0.249, 
2.849) 
0.095 
AutoSet F 20 1.30 1.84 
Flow Limitation 
 (% of breaths) 
Standard 
AutoSet 
20 0.20 0.13 
 (0.0217, 
0.0937) 
0.003 
AutoSet F 20 0.14 0.09 
# of Hypopneas 
 
Standard 
AutoSet 
20 1.45 2.33 
 (-2.455, 
1.355) 
0.553 
AutoSet F 20 2.00 3.42 
# of Obstructive 
Apneas 
Standard 
AutoSet 
20 1.30 4.44 
 (-1.030, 
2.030) 
0.502 
AutoSet F 20 0.80 1.36 
# of Central 
Apneas 
Standard 
AutoSet 
20 3.55 7.45 
 (-1.94, 3.04) 0.649 
AutoSet F 20 3.00 3.78 
Standard 
AutoSet 
20 96.56 0.78 
 (-0.064, 
0.551) 
0.114 
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Mean SpO2 
 (%) 
AutoSet F 20 96.31 0.81 
Time in S1 
Sleep (%) 
Standard 
AutoSet 
20 6.05 4.63 
 (-2.40, 2.11) 
0.894 
 AutoSet F 20 6.20 3.33 
Time in S2 
Sleep (%) 
Standard 
AutoSet 
20 51.28 12.91 
 (-4.12, 7.81) 0.525 
AutoSet F 20 49.44 12.01 
Time in S3 
Sleep (%) 
Standard 
AutoSet 
20 24.83 11.58 
 (-3.32, 3.76) 0.898 
AutoSet F 20 24.60 10.77 
Time in REM 
Sleep 
 (%) 
Standard 
AutoSet 
20 17.93 11.05 
 (-7.07, 3.38) 0.469 
AutoSet F 20 19.77 7.54 
 
5.2.3.4. Comparison of device data  
The mean, median and 95th percentile pressures required to treat OSA in this female 
population was less with the AutoSet F algorithm compared with the standard AutoSet 
algorithm, although this did not reach statistical significance (Table 27 and Figure 26).  
Table 27: Comparison of device pressure  
Pressure Comparison (Standard AutoSet vs. AutoSet F)  
 
Valid N Mean Median 
95th 
%ile 
IQR Kurtosis 
Standard 
AutoSet 
20 8.34 8.31 11.63 2.48 4.38 
AutoSet F 20 7.89 7.94 10.56 2.35 4.99 
 Valid N 
Difference 
in means 
95% CI for mean diff p-value 
Kurtosis 
p-value 
Paired t-test 
analysis 
20 0.45  (-0.977, 0.077) 0.089 0.68 
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Figure 26: Mean mask pressure of AutoSet F (AutoSet F) and standard AutoSet  
Participants were asked to rate breathing comfort, ease of falling asleep, sleep disturbance 
caused by CPAP, and feeling of being refreshed, after using the standard AutoSet device and 
after using the AutoSet F using an 11 point Likert scale. One participant did not complete the 
questionnaires. No significant differences were found between the subjective ratings for both 
devices as shown by Mann-Whitney statistical analysis (Table 28). 
Table 28: Comparison of patients subjective ratings 
Patient Subjective Ratings 
 
Valid N Mean 
Std. 
Dev. 
Min Max Median p-value 
Standard AutoSet 
comfort of 
breathing 
19 8.21 1.32 6.0 10.0 8.0 
0.9405 
AutoSet F comfort 
of breathing 
19 8.05 1.78 4.0 10.0 8.0 
Standard AutoSet 
ease of falling 
asleep 
19 7.84 1.77 4.0 10.0 8.0 
0.5117 
AutoSet F ease of 
falling asleep 
19 7.26 2.05 2.0 10.0 8.0 
Standard AutoSet 
sleep disturbance 
19 8.26 1.70 4.0 10.0 9.0 
0.1171 
AutoSet F sleep 
disturbance 
19 7.47 1.71 4.0 10.0 8.0 
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Standard AutoSet 
feeling of being 
refreshed 
19 7.63 1.61 5.0 10.0 8.0 
0.0582 
AutoSet F feeling 
of being refreshed 
19 6.32 2.24 2.0 10.0 7.0 
 
5.2.3.5. Technical functioning of the AutoSet F algorithm  
The technical aspects of the new algorithm, including RERA-detection, slower and softer 
increasing and decreasing pressures, increased sensitivity and responsiveness to flow 
limitation, floor pressure and automatic ramp, were all monitored during the clinical study 
and found to be working as expected.  
RERAs scored by the AutoSet F algorithm were compared with RERAs scored by a blinded 
PSG scorer. This data was compared using the Wilcoxon Signed Rank non-parametric test. 
Analysis, comparing human (0.21 ± 0.3) and algorithm (0.22 ± 0.27) scoring showed no 
significant difference in the outcome, based upon the scoring method used (p = 0.87). The 
results gave a P-value of 0.87, which indicates that the RERAs scored by human and those 
scored by the AutoSet F are not statistically different.  
Table 29: Validation of RERA Index 
Parameter Score 
P-Val (2-tail) 0.87 
W-Score -7 
Z-Score -0.163314 
Figure 27 shows the algorithm-scored RERA index plotted against the human-scored RERA 
index. 
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Figure 27: RERA algorithm plotted against manually scored RERA data. 
 
5.2.4. Discussion 
This clinical trial has shown that there are no significant differences in AHI or ODI when 
female patients are treated with the AutoSet F algorithm, compared with the standard 
AutoSet algorithm, demonstrating that the two algorithms are equivalently efficacious in the 
treatment of OSA.  
The clinical benefit of this data is that the AutoSet F algorithm, like the standard AutoSet 
algorithm, effectively treats OSA in female patients, with a residual mean AHI <5/hr shown 
for both algorithms. Further comparison analysis with patients’ diagnostic AHI values shows 
a statistically and clinically significant reduction in AHI with treatment of either the AutoSet F 
or Standard AutoSet. 
Analysis of sleep parameters also showed a significant decrease in flow limitation (percentage 
of breaths) with the AutoSet F algorithm compared with the standard AutoSet algorithm. As 
females with OSA tend to exhibit greater amounts of flow limitation and upper airway 
resistance (159), the AutoSet F algorithm was designed to be more responsive to flow 
limitation than the standard AutoSet algorithm. A significant reduction in flow-limited breaths 
when patients were treated with the AutoSet F algorithm, compared with the standard AutoSet 
algorithm, suggests that female OSA patients are being treated more effectively with the 
AutoSet F algorithm. 
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Whilst no other statistically significant beneficial differences were seen in sleep parameters 
between the AutoSet F and standard AutoSet algorithms, non-statistical improvements were 
noted in the number of RERAs that occurred (1.30 vs. 2.60; p= 0.095) and the percentage of 
REM sleep (19.77 vs. 17.93; p=0.469) with the AutoSet F algorithm. Due to female OSA 
patients frequently exhibiting more REM-based apnoeic events(123), the standard AutoSet 
algorithm may decay below the critical airway pressure during REM sleep. To counter this, the 
AutoSet F algorithm contains a floor pressure (i.e. a set minimum the pressure decays toward 
during periods absent of respiratory events). This reduces the likelihood of obstructive events 
occurring due to insufficient pressure, which has the potential to increase periods of 
consolidated sleep (in particular during REM sleep). As such, the observed reduction in 
respiratory arousals and increased REM sleep is suggestive of more efficacious treatment of 
OSA in females with the AutoSet F algorithm, compared with the standard AutoSet algorithm. 
Whilst not statistically significant, the mean, median and 95th percentile pressure required to 
effectively treat OSA in this population was less with the AutoSet F algorithm compared with 
the standard AutoSet algorithm. This suggests that while both algorithms effectively treat OSA 
in female patients, the AutoSet F algorithm does so whilst utilising lower pressures, which may 
be attributed to the AutoSet F algorithm’s design of limiting pressure increases with a slower 
and more gentle response to obstruction. As research demonstrates that female OSA patients 
require less pressure than males (215), the AutoSet F algorithm may provide the benefit of 
increasing comfort of therapy by using a lower but still efficacious pressure response. 
Participant subjective feedback revealed no significant differences in regards to self-reported 
comfort of breathing, ease of falling asleep, sleep disturbance, and feeling of being refreshed 
between the AutoSet F and standard AutoSet algorithms. Median subjective ratings for all 
outcomes for both algorithms ranged from 7.0 to 9.0 on an 11-point Likert scale (10=good; 
5=OK; 0=poor) indicating that both algorithms were rated above average for all subjective 
outcomes.  
5.2.5. Conclusion  
This trial showed that the AutoSet F algorithm was non-inferior to the standard AutoSet 
algorithm, with both algorithms effectively reducing AHI and ODI in female patients. The 
AutoSet F algorithm reached a lower mean pressure than the standard AutoSet algorithm. 
Investigation of respiratory parameters showed that flow limitation was significantly 
decreased with the AutoSet F algorithm compared to the standard AutoSet algorithm. There 
were trends towards improvements in REM sleep percentage and RERAs. Taken together, 
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this data shows that the AutoSet F is able to effectively treat OSA in women, and may be a 
more suitable treatment option than a standard AutoSet.  
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5.3. Bench Testing of the AutoSet F 
5.3.1. Introduction  
The clinical trial outlined above demonstrated the efficacy of the AutoSet F in female 
patients. The next assessment of the AutoSet F was how it reacted on a controlled, 
repeatable model compared to other commercially available AutoSet devices.  
Professor Ramon Farré and colleagues at Barcelona University have developed a simulation 
patient bench model to test various AutoSet devices for their capability at treating OSA (216, 
217). Professor Farré was approached and asked to collaborate on the development of a 
new bench test designed to replicate a female OSA patient. The new model was then used 
for testing of the AutoSet F along with other AutoSet devices.  
5.3.2. Methods  
The original bench test model created by Farré and colleagues is described in detail in Rigau 
et al. (216), and Appendix F. The model (Figure 28) consists of one generator of breathing 
(flow generator) controlled by a computer. The flow generator can reproduce either pre-
designed flows, or it can reproduce the respiratory flow of a patient recorded during PSG. 
The model contains an obstruction valve, which introduce central or obstructive events. 
There are two additional valves, which allow for the simulation of mask leaks and mouth 
breathing. A loudspeaker provides vibrations to simulate snoring. The computer is able to 
control each of these elements. Standard tubing links a commercial CPAP device to the 
bench test. The response from the AutoSet algorithm is picked up by two sensors in the 
model, one pressure sensor and one flow sensor. The response from the CPAP is fed back 
into the computer which is then able to adjust the output accordingly.  
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Figure 28: Diagram of the bench test model 
PNT = pneumotachograph; EP = exhalation port; Obstr. = obstructive; Exhal. = exhalation V = flow; m = motor; p 
= pressure. Image reproduced from Rigau et al., 2006 (216) with permission. 
The original patient model used to create breathing flow in these bench tests was developed 
from typical male OSA patients. The simulated bench model is programmed to have 
obstructive apneas when the AutoSet pressure is between 0-5cm H2O. As the AutoSet 
algorithm increases the pressure to 5-7cm H2O, the obstructive apneas on the bench model 
develop into hypopneas. As the pressure is increased towards 10 cm H2O, the hypopneas 
are overcome and prolonged flow limitation remains. The AutoSet needs to reach a pressure 
of at least 12 cm H2O for normal breathing to resume (Figure 29). 
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Figure 29: Typical Male patient model and the required CPAP pressure needed to overcome obstructive 
breathing  
Image reproduced with permission from Rigau et al., 2006 with permission (216)(216)(215)(201). 
Professor Farre and colleagues developed an updated patient model based on 
characteristics of female OSA patients described in Section 1.5.1. Compared with the male 
patient model, the new female patient model had: 
 Lower AHI: less frequent events for each pressure range  
 More episodes of flow limitation: the pressure range in which prolonged flow 
limitation is reproduced was extended 
 Longer sleep onset: 30 minutes of normal breathing before sleep onset 
 Lower CPAP pressures required: pressure ranges were rescaled and normal 
breathing was achieved with pressures of 10cm H2O. 
The flow and obstructive breathing events used in the bench testing were extracted from 
several PSG recordings of typical female OSA patients. Period of sleep and wake, sleep 
onset, body position, and REM were added to the bench model to create a realistic night of 
sleep (Figure 30).  
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Figure 30: Description of the patient simulation implemented in the bench test model  
Image reproduced from Isetta et al., 2016 (218) with permission. 
The simulator would create breathing events at each pressure until the AutoSet device 
increased the pressure to overcome the events. The bench test patient model was tested 
using ten different AutoSet devices. Devices were all set to default AutoSet mode (minimum 
pressure 4cm H2O, maximum pressure 20cm H2O), and all devices were set to a starting 
pressure of 4cm H2O. In order to standardise the testing, optional comfort features such as 
expiratory pressure relief (EPR), humidification, ramp, and any additional optional settings 
were turned off.  Each device was tested twice, with the tests running for 4 hours and 15 
minutes each. The average of the two tests was taken as the result.  
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5.3.3. Results 
The results of the bench testing are shown in Figure 31. The AutoSet F is Device B. Only 
devices A, B and D were able to overcome obstructive events and overcome flow limitation, 
although the residual flow limitation in device D was 12% of sleep time compared with 2% of 
sleep time for the AutoSet F.  
 
Figure 31: Responses of AutoSet devices to the female OSA patient bench model.  
Image reproduced from Isetta et al., 2016 (218) with permission. 
 
5.3.4. Discussion 
AutoSet devices are often considered a ‘black box’, with their inner workings and decision-
making quite difficult to interpret (219). Comparing AutoSet devices is difficult as there is 
always night-to-night variability in patient breathing. A small number of studies have 
examined the technical functioning of AutoSet devices and found clinically important 
differences in each algorithm’s ability to treat OSA, and in patient compliance (220-222). 
The benefits of bench-testing compared to patient studies is that they allow review of 
algorithm functioning under a controlled environment. Individual patient differences are 
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removed, so the pure functioning of the algorithm can be examined. This allows comparison 
of different devices under the same conditions to better understand differences in how 
algorithms treat the same breathing patterns.   
 
In this bench test, we found significant differences in the way the AutoSet algorithms 
responded to the female breathing patterns. There was a high residual AHI (AHI > 5) at the 
end of the test from four of the devices. It is concerning that four commercially available 
devices were not able to reduce the residual AHI. A patient using these devices may only be 
partially treated and still experience daytime symptoms and longer-term health 
consequences.  
 
Only three of the devices were able to achieve full breathing normalisation, with prolonged 
flow limitation being an issue for seven devices. Considering the frequency with which flow 
limitation occurs in female patients, and the concern that it leads to RERAs, arousals and 
disruption from sleep, the ability of the AutoSet to treat flow limitation is something that 
clinicians should examine closely when reviewing the effectiveness of their patient’s 
treatment.   
Meurice et al. conducted an experiment in which two groups of patients diagnosed with OSA 
were treated with different CPAP pressures. Group 1 was treated with CPAP pressures 
targeted to eliminate flow limitation, while Group 2 was titrated with pressures to overcome 
apneas, hypopneas and snoring. Group 1 pressures were higher on average. This group 
had an increase in sleep time and more consistent improvement in maintenance of 
wakefulness. These results suggest that normalizing flow limitation, although frequently 
overlooked, may be a key part of effectively treating SDB (223).  
5.3.5. Conclusion  
The new bench test model provided a controlled, repeatable method of comparing different 
AutoSet devices and their treatment responses to female breathing patterns.  
The bench testing shows that the AutoSet F was able to overcome all obstructive events and 
flow limitation while keeping the pressure low, and that some commercially available devices 
may not provide optimal treatment for female patients.  
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5.4. Controlled product launch  
5.4.1. Introduction  
During the development of the AutoSet F, a clinical trial and bench testing (described above) 
were used to validate that the algorithm was functioning as intended and able to efficiently 
treat OSA. At the time of releasing the AutoSet F for commercial use, ResMed conducted a 
controlled product launch (CPL). During a CPL the devices are heavily controlled and 
monitored. The AutoSet F was provided to a selected number of clinics, and data was 
collected nightly to ensure correct functioning.  
5.4.2. Methods 
Devices were dispensed by multiple sleep clinics in Germany and France to patients 
diagnosed with OSA who qualified for CPAP treatment. Data was collected from devices 
used on female patients participating in the CPL. The device records de-identified 
information each time it is used, including usage, mask leak, AHI, and pressure. This 
information is stored on SD cards within the device, which were returned to ResMed on a 
regular basis during the CPL.  
The technical features of the algorithm were monitored to ensure they were working as 
intended. The data was also reviewed to check whether assumptions made during algorithm 
development were appropriate for treating female patients.  
5.4.3. Results 
De-identified device functioning information was collected from 163 devices, over 2272 
nights of use. Average daily usage was 5.9 hours per night. Residual AHI was 2.61 events 
per hour. The average 95th percentile pressure was 8.76cm H2O.   
The average number of RERAs for those patients prone to RERAs was 0.63 events/ hour 
(Table 30, Figure 32). 
Table 30: Activation of RERA index in female patients  
Parameter RERA Average SD 
All AutoSet F patients 0.30 0.63 
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AutoSet F patients with at least one RERA during 
the night 
0.63 0.79 
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Figure 32: Histogram of RERA Indexes occurring in female patients  
In this CPL data, the floor pressure had been activated in 50/401 (13%) sessions monitored 
(Table 31). Each session where the floor pressure had been activated was examined in 
more detail for further strings of apneas. No additional strings of apneas were found.  
Table 31: Review of floor pressure use in female patients  
Total sessions 
Number of sessions when floor 
pressure was triggered 
Average floor 
pressure (cmH2O) 
Median floor 
pressure (cmH2O) 
401 50 9.6576 10 
In the 2272 data sessions available from the CPL, the pressure cap was activated in only 
four cases.  
All devices were found to be functioning as intended during the CPL, with no software bugs, 
unexplained algorithm behaviour, or missing data reported.  
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5.4.4. Discussion 
Average daily usage was high, at 5.9 hours per night. Residual AHI was 2.61 events per 
hour, well below what is considered efficacious (<5). This efficacy was achieved with a group 
average 95th percentile pressure of 8.76cm H2O. 
The RERA index was used to alert the clinician of disrupted breathing during treatment. 
Almost half (45%) of AutoSet F sessions had at least one RERA during the night This shows 
that respiratory events with flow limitation leading to disruption from sleep are common in 
female patients. The residual RERA index remained low, at 0.63 events/ hour, 
demonstrating that the algorithm was effectively able to treat the flow limitation and avoid 
large RERA indexes. 
The floor pressure in the AutoSet F was designed to protect patients against strings of REM-
related events. The floor pressure was activated in 13% of cases. After each initial 
activation, no more strings of obstructive events occurred during the session, demonstrating 
that the floor pressure was working as intended to prevent untreated OSA during 
subsequent REM phases.  
The pressure cap was designed to keep the average pressures lower and more comfortable 
for female patients. Clinical trial data shows that women rarely require pressures above 
12cm H2O (168). The pressure cap was only activated in 4 of the 2272 data sessions 
recorded. An examination of those cases confirmed that obstructive apneas were still 
occurring above 12cm H2O. This confirms that majority of female patients do not need high 
CPAP pressures, although a very small proportion of female patients will continue to have 
obstructive apneas at or above 12cm H2O.  The AutoSet F was designed to provide lower 
and more gentle pressures by removing any response to obstructive apneas above 12cm 
H2O. The algorithm still responds to flow limitation and snore at these pressures, however 
the response is much more gentle with less pressure increases. For the patients who did 
require pressures above 12cm H2O, the algorithm increased the pressure and overcame 
obstructive events; however, this was done in response to flow limitation and snore, which 
resulted in a slower and more gentle pressure increase.  
The limitations of a CPL are that almost no demographic data is available on participants. 
This is the reality of a CPL compared with a clinical study. The benefits of a CPL compared 
with bench testing and clinical studies is that a CPL allows testing of the device in 
uncontrolled conditions. In a clinical trial, participants are carefully selected based on 
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inclusion and exclusion criteria. The participants’ medical history and comorbidities are 
known, and further investigations can be done if a device does not respond as expected. 
During a CPL, no information is available on users of the device. This allows the device to be 
challenged in a range of situations. The CPL also allows for assumptions made during the 
development of the algorithm to be tested in real-world conditions.  
5.4.1. Conclusion 
Data collected during the CPL showed that all technical aspects of the device were working 
as intended, and that the design of the algorithm was appropriate for treatment of female 
OSA patients. This data show that, in uncontrolled, real-world conditions, the AutoSet F is 
effective for treating female OSA.  
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Abstract 
Purpose Females with obstructive sleep apnea (OSA) have more flow limitation, lower 
apnea-hypopnea index (AHI), shorter apneas, and less severe oxygen desaturations than 
males. A female-specific auto-adjusting continuous positive airway pressure (fAPAP) 
algorithm has been developed to target these characteristics. This study investigated the 
effects of fAPAP therapy on quality of life (QoL) in women with OSA. 
Methods Female patients with AHI ≥15/h were eligible. Participants underwent polygraphy or 
polysomnography. The primary endpoint was change from baseline in Functional Outcomes 
of Sleep Questionnaire (FOSQ) score after 3 months’ fAPAP (AutoSet for Her, ResMed). 
Secondary endpoints included other sleep-related and QoL questionnaires.  
Results A total of 122 patients were enrolled in the study (age 53.7±9.5 years, body mass 
index 32.8±6.2 kg/m2, apnea-hypopnea index [AHI] 39.0±18.2/h); 111/122 completed the 
study. There was a significant improvement (p<0.0001) in FOSQ score from baseline 
(15.0±3.3) to 3 months (16.9±3.2). Significant improvements were also seen in the Patient 
Health Questionnaire-9 score (12.3±6.0 vs. 7.2±5.4), Epworth Sleepiness Scale score 
(10.8±4.9 vs. 7.3±4.7), EuroQol (EQ)-5D Index score (0.636±0.248 vs. 0.763±0.210), EQ-5D 
visual analogue scale score (54.4±21.7 vs. 64.5±21.5) (all p<0.0001), and Changes in 
Sexual Functioning Questionnaire score (38.7±9.5 vs. 42.4±8.5; p=0.001). In patients with 
PSG data, fAPAP improved other respiratory parameters (AHI, oxygen desaturation index, 
oxygen saturation; all p<0.0001), and increased time spent in rapid eye movement (REM) 
sleep (39.7±24.0 vs 48.1±24.5 min; p=0.022). Average daily fAPAP usage was 4.8±2.0 
h/night. 
Conclusion Usage of fAPAP significantly improved QoL and increased REM sleep, with good 
treatment compliance. 
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Introduction 
Obstructive sleep apnea (OSA) is a common disorder characterized by upper airway closure 
during sleep, resulting in disrupted breathing and arousals. Moderate to severe OSA (apnea-
hypopnea index [AHI] ≥15/h) is present in 4–23% of the female population (17, 224), and 
may impact as many as 26% of females aged between 20-70 years (17, 37, 224).  
There are well known gender differences in OSA. This includes both clinical 
manifestations and impact on quality of life (QoL). Females often do not present with classic 
OSA symptoms, such as snoring, obesity and difficulty staying awake during the day. 
Instead females with OSA may complain of depression, anxiety, mood disturbance, reduced 
QoL, insomnia and fatigue (29, 185-187). The presence of OSA in women appears to 
increase the risk of developing diabetes, dementia and cardiovascular diseases (62, 68, 69). 
Female sexual health may also be impacted by OSA, although this has not yet been fully 
explored. A recent study found that females with OSA had significantly more sexual distress 
and sexual dysfunction compared to those without OSA (67). 
The severity of OSA also often differs between genders, with polysomnography 
(PSG) data showing that females have less severe OSA with overall lower AHI, shorter 
apneas, and a higher likelihood of REM-only events (123). Younger women in particular 
often have more episodes of upper airway resistance rather than obstructive apneas (123).  
Continuous positive airway pressure (CPAP) is considered the gold standard 
treatment for OSA. CPAP applies a fixed pressure that acts as a pneumatic splint to the 
upper airway, preventing collapse. Auto-adjusting CPAP (APAP) devices monitor breathing 
on a breath-by-breath basis and respond by delivering the appropriate pressure throughout 
the night. Effective CPAP treatment in adherent patients has been shown to improve 
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sleepiness and QoL and reduce cardiovascular risk (58-60). However, the majority of clinical 
trials of CPAP have included predominantly male participants. Indeed, patient populations in 
studies during the development and validation of early APAP devices were typically 100% 
male (180-182). Only one study to date has examined QoL changes in an entirely female 
population of OSA patients treated with CPAP (163).  
A female-specific APAP (fAPAP) treatment algorithm has been developed with the 
goal of optimally treating the characteristics of OSA in women, including more sensitive 
treatment of flow limitation, and systems for overcoming REM-based events and lowering 
overall pressure. fAPAP has been shown to effectively control AHI while reducing residual 
flow limitation and lowering 95th percentile pressure in female OSA patients during a two-
night study (225), but longer term improvements in symptoms have not been determined. 
This study investigated changes in symptoms and sleep parameters in female OSA 
patients during 3 months’ treatment with fAPAP. 
Methods 
Study design 
This prospective, observational, open-label, single cohort study was conducted at one sleep 
clinic in Spain and two sleep clinics in Germany. The study was approved by local ethics 
committees and all participants provided informed consent.  
Patients 
Female patients who presented to the sleep clinic with suspected OSA were screened for 
OSA as per the usual clinical routine (home polygraphy (PG) in Spain or in-lab 
polysomnography (PSG) in Germany). Eligible patients were those aged ≥18 years who had 
an AHI of ≥15/h on diagnostic testing. Participants were excluded from the study if they were 
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unable to complete a one-hour CPAP run in. Additional exclusion criteria included: current 
use or experience with CPAP; use of supplemental oxygen; pregnancy or planned 
pregnancy in the next 3 months; pre-existing lung disease or condition predisposing to 
pneumothorax. 
Procedures and assessments 
At the first study visit, tolerance of CPAP was assessed with a one-hour run in on therapy.  
Baseline data, including height, weight, age, blood pressure and comorbidities, were 
collected from patients continuing in the study. Participants were then asked to complete the 
following questionnaires, with assistance from the nurse/clinician if required: Functional 
Outcomes of Sleep Questionnaire (FOSQ); Patient Health Questionnaire (PHQ-9); Epworth 
Sleepiness Scale (ESS); Changes in Sexual Function Questionnaire (CSFQ); and EuroQol 
5D (EQ-5D). Patients also provided information on subjective sleep quality based on a Likert 
scale from 0 (worst) to 10 (best). 
Participants were then initiated on fAPAP therapy (AutoSet for Her; ResMed), with 
humidification and an appropriately fitting mask, and instructed to use fAPAP every night 
while sleeping for the next 3 months. All participants were phoned during the first weeks of 
therapy to troubleshoot any issues. If necessary, the participant was invited back to the clinic 
for a face-to-face visit. All participants returned to the clinic after one month for a visit. During 
this visit study staff reviewed device usage and attempted to resolve any problems that the 
participant was experiencing. 
Three months after initiation of CPAP, participants returned to the clinic for a final visit. 
Patient data were downloaded from the device for analysis, including usage, AHI, mask leak, 
and pressures. At this time participants completed all questionnaires again. In addition, 
patients in Germany underwent an on-treatment PSG.  
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Endpoints 
The primary endpoint was change in QoL during fAPAP based on the FOSQ. Secondary 
endpoints included change in QoL and sexual function based on other questionnaires, 
change in sleep quality at 3 months versus baseline based on PSG data, and change in 
other respiratory parameters at 3 months versus baseline.  
Sample size 
Sample size was determined based on the results of the CATNAP-trial (174), which showed 
an unadjusted mean change in FOSQ total score from baseline to week 8 in the modified 
intention-to-treat population of 0.98±2.89. To achieve power of 80% at α=0.05 it was 
calculated that a total of 71 patients would be required to detect an increase in FOSQ total 
score in this study. Assuming a drop-out rate of approximately 10%, the target minimum 
sample size was set at 80 participants. 
Statistical analysis 
Differences in baseline characteristics and study endpoints between Germany and Spain 
were assessed using the t-test or Wilcoxon-Mann-Whitney test for continuous parameters, 
and Fisher’s exact test for categorical parameters. All study results were presented 
combined because pool-ability was confirmed (i.e. it was determined that there was no 
significant difference between the countries with respect to the primary study endpoint 
[change in FOSQ]). Primary and secondary endpoints are displayed separately when 
significant differences were detected. 
Demographic data, baseline characteristics, medical history, medications, baseline 
PG/PSG data, CPAP data, device usage and QoL endpoints for combined data were 
summarized descriptively. Number evaluated, mean, standard deviation (SD), median, 
minimum and maximum were generated for continuous variables. Number evaluated, 
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proportion of patients and 95% confidence intervals (CI) were calculated for categorical 
variables. 
Changes in quality of life scores from baseline to 3 months were analyzed for 
combined data using a paired t-test, testing the null hypothesis that there is no change in 
QoL scores. Wilcoxon paired signed rank tests were also generated when a non-parametric 
test was warranted. For comparison of EQ-5D dimensions between baseline and 3 months, 
a Mantel-Haenszel test was performed with modified ridit scores. All statistical analyses 
were performed using SAS version 9.4.  
Results 
Study population 
A total of 122 patients (25 from Spain and 97 from Germany) were enrolled in the study (age 
53.7±9.5, body mass index [BMI] 32.8±6.2, 56% with hypertension) (Table 1). The majority 
of patients (74%) used an AirFit P10 for Her mask as the device interface (Table 1). Of the 
122 enrolled patients, 111 completed the study.  
 Participants from Spain and Germany were similar for most baseline 
characteristics, but those from Spain versus Germany had a significantly higher BMI 
(36.07.8 vs. 31.95.5 kg/m2; p=0.02), and were significantly more likely to have comorbid 
insomnia (36% vs. 9%; p=0.002), anxiety (44% vs. 3%; p<0.0001) or depression (36% vs. 
7%; p=0.001).  
Questionnaire results 
The change in FOSQ total score for participants in Spain versus Germany was not 
significantly different (2.63.7 vs. 1.83.2; p=0.31), thus primary and secondary endpoints 
are presented as pooled results. FOSQ total score (primary endpoint) improved significantly 
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from baseline to 3 months (Table 2). Significant improvements from baseline were also seen 
in total scores for the PHQ-9, ESS, CSFQ, indexed EQ-5D (based on country-specific 
reference values), and EQ-5D health status visual analog scale (Table 2). When individual 
EQ-5D dimensions were assessed, patients reported a significant improvement in their 
ability to perform usual activities, significantly fewer participants reported extreme pain or 
discomfort at 3 months compared with baseline, and patients also reported significant 
improvements in the Anxiety and Depression dimension after 3 months’ fAPAP therapy 
(Table 3). 
 Improvements in the majority of secondary outcome questionnaires 
were similar in the Spanish and German subgroups. The exception was the ESS score, 
which improved to a significantly greater extent in Spain versus Germany (mean  SD 
change from baseline to 3 months of –6.95.7 (median –4) vs. –2.74.4 (median –3); 
p=0.002).  
 None of the mean questionnaire scores reached normal population 
values after 3 months of fAPAP, but changes from baseline were greater than the minimal 
clinically important difference (MCID) (Table 4).  
Respiratory and sleep parameters 
Patients from the Spanish center had OSA diagnosed using PG. Baseline PG data and 
device data after 3 months of fAPAP in these patients are shown in Table 5. OSA and 
related respiratory events were largely eliminated in all patients. Participants enrolled in 
Germany underwent full PSG at baseline and after 3 months of fAPAP. There were no 
significant changes in total sleep time, sleep efficiency or time in slow wave sleep from 
baseline to 3 months, but the time spent in stage 1 sleep decreased significantly and time in 
REM sleep was significantly increased (Table 6). Combined 3-month device data from all 
participants showed that OSA was effectively treated (AHI 1.3±1.7/h, respiratory event-
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related arousals 0.2±0.5/h) with low mean mask leak (2.4±4.1 L/min, range 0–23). The 95th 
percentile pressure was 10.2±1.8 cmH2O.  
Device usage 
For the 111 patients who completed the study, average device usage was 4.8±2.0 h/night 
(median usage 5.1 h/night), and 75% of patients used their device for at least 4 h/day (Table 
7). For those calculations, zero hours usage was assumed for the duration of the study in 
patients who stopped using the device prior to the 3-month visit, providing a conservative 
estimate of device usage. In analyses that included only days where the device was used, 
average device usage was 5.2±1.9 h/night (median 5.5 h/night) and 83% of patients used 
their device for at least 4 h/day. There was a trend towards greater use of the fAPAP device 
in Spain versus Germany (calculated average usage 5.51.4 vs. 4.62.2 h/day); findings 
were similar for the proportion of days with usage >4 hours (78.221.4 vs. 63.131.6%).  
Subjective sleep quality 
Subjective sleep quality improved from baseline after fAPAP therapy, as did the number of 
hours patients reported that they slept each night (Table 8).  
Discussion 
This is the first appropriately-powered study to examine the impact of a new female-specific 
APAP device on QoL in female OSA patients. The results showed that APAP therapy using 
a female-specific algorithm was associated with improvements in a range of QoL measures.  
Our population was, on average, middle-aged and moderately obese with a 
moderate level of sleepiness at baseline and low levels of anxiety and depression. The 
primary endpoint, FOSQ score, improved significantly from baseline during the 3-month 
study in this group of women. Weaver et al. described a FOSQ score cut-off value of 17.9 
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as being normal (226). Based on this, the proportion of patients with normal FOSQ values at 
baseline in our study was 23%. After treatment, this had increased to 53%, but 47% of 
patients still had FOSQ scores below normal. These results are similar to another study of 
CPAP patients, where only 35% of patients had normal scores after treatment (227). The 
MCID for the FOSQ is 0.75. The average improvement in our patient group during fAPAP 
therapy was 1.9 points. Thus, although QoL was not normalized in all patients, 
improvements were of a magnitude that would result in a relevant improvement in clinical 
symptoms. Clinically relevant improvements (based on the MCID) were also seen in the 
ESS, PHQ-9 and EQ-5D index scores in our study, while the CSFQ score MCID has not yet 
been defined.  
We used the CSFQ in this study to better explore the area of female sexual heath 
and function in OSA. In men, untreated OSA is associated with erectile dysfunction and low 
sexual hormone levels, which are improved by treatment with CPAP (228). However, there 
are comparatively few data on the implications of OSA for female sexual health. Two small 
questionnaire-based studies in female patients (n=22 and n=25) found that women with OSA 
score lower on sexual function questionnaires compared with controls (229, 230). One study 
found that women with untreated OSA (n=80), regardless of severity, were at higher risk of 
having sexual difficulties, and rated higher on the sexual dysfunction and sexual distress 
scales than a population-based sample of women without OSA (67). In the current study, we 
also showed that females with OSA rated lower than the population average on the CSFQ. 
During the conduct of our study, it was emphasized that completion of the CSFQ was 
optional. This was done to avoid any feelings of embarrassment for participants. The 
response rate to the CSFQ was significantly lower than the other questionnaires. Therefore, 
future studies will need to carefully consider the methodology used to collect female sexual 
function information. Our findings that the CFSQ score improved from outside the normal 
range to the lower end of what might be considered normal, suggest that fAPAP has the 
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potential to improve sexual function in female patients with OSA. Increases in the CFSQ 
score reached statistical significance versus baseline, and this beneficial effect of fAPAP 
warrants further investigation. 
The questionnaires used in our study had been validated in both the German and 
Spanish languages. Therefore, it is reasonable to conclude that the improvements reported 
between countries were referring to the same symptoms. However, we did see some 
regional differences. At baseline, patients from Spain had a higher BMI and reported more 
sleepiness, anxiety and depression than those from Germany, although rates in Germany 
were particularly low compared with similar studies [4-7]. They also showed a significantly 
greater improvement in sleepiness (ESS score). It is possible that the higher BMI in the 
Spanish group was responsible for the higher levels of sleepiness, anxiety and depression, 
as obesity is associated with these symptoms even in the absence of OSA (203). Greater 
sleepiness at baseline may also have meant greater potential to improve. In addition, device 
usage was greater in the Spanish group (average 5.5±1.4 vs. 4.6±2.2 h/night; p=0.02), 
which may have been due to the higher levels of baseline sleepiness, and also may have 
contributed to the greater improvement in sleepiness seen in this group. It has been 
suggested previously that CPAP usage for ≥5 h/night is required to achieve significant 
improvements in daytime sleepiness (231), a finding supported by our results.  
Only one previous clinical study focused on QoL in female-only CPAP users (163). 
Campos-Rodriguez et al. used the Quebec Sleep Questionnaire as a primary endpoint, plus 
the Hospital Anxiety and Depression scale (HADS), the abbreviated Profile of Mood Stages 
(POMS), and the Short Form Health Survey (SF-12), none of which were used in our study. 
Our questionnaires were selected, in part, due to the availability of validation in both the 
German and Spanish languages. Despite the different questionnaires used, the study by 
Campos-Rodriguez et al. reported significant improvements in all QoL measures in females 
using fixed CPAP compared with the control group, consistent with our findings. In addition, 
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both studies showed a similar improvement in ESS scores during CPAP therapy (by 3 points 
in the Campos-Rodriguez et al. study and 3.6 points on average in this study). The findings 
of these two trials strengthen the limited pool of data evaluating females during CPAP 
therapy. 
Women in our study showed adequate compliance with fAPAP therapy, with mean 
daily usage of 4.8±2.0 hours. Generally, device usage of >4 h/night is considered 
acceptable. An analysis of female CPAP compliance published in 2013 found that females 
were generally compliant with CPAP, with 79.9% still using CPAP after 10 years and median 
usage of 6 h/day (232). In our study population, median usage of fAPAP was nearly as high, 
at 5.5 h/day in Spain and 4.6 h/day in Germany.  
Use of fAPAP in our study resulted in patients spending significantly less time in 
stage one sleep and significantly more time in REM sleep compared with baseline, as 
measured by PSG in Germany. Time spent in slow wave sleep was also increased, but this 
did not reach statistical significance. REM sleep is thought to be important for consolidation 
of procedural memories, while slow wave sleep may help patients feel rested and benefit 
declarative memories (233).  
The most important limitation of this study was its design (single cohort rather than 
randomized trial) and the resulting lack of a comparator group (e.g. APAP with a standard, 
rather than female-specific, algorithm). It is therefore not possible to categorically state that 
the improvements in QoL that occurred during fAPAP treatment were due to optimization of 
therapy based on the female-specific algorithm or whether standard APAP therapy would 
have had similar effects.  
In conclusion, this study showed significant improvements in QoL in female OSA 
patients treated for 3 months with a female-specific APAP device. This included 
improvements in sexual function, which have been rarely studied in these patients. The 
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female-specific algorithm evaluated in this study represents one approach to targeting 
therapy for individual patients (personalized medicine). The majority of existing data relate to 
OSA populations with a predominance of males, particularly with respect to treatment. A 
growing body of evidence suggests that there are substantial differences between females 
and males in the symptoms, diagnosis and consequences of OSA. Better knowledge of 
gender differences in OSA will help to improve the awareness and diagnosis of OSA in 
women. In addition, the development and availability of therapeutic options that take into 
account differences in the physiology and presentation of OSA in women could have the 
potential to improve outcomes for these patients. 
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Table 1. Baseline characteristics of the study population. 
Parameter 
Spain 
(N = 25) 
Germany 
(N = 97) p-value 
Age (years)    
       n 25 97 0.37 [1] 
       Mean ± SD (Median) 52.1 ± 8.6 (54.0) 54.1 ± 9.8 (55.0)  
       Min, Max 39, 68 25, 76  
 
 
BMI (kg/m2)    
       n 25 95 0.02 [1] 
       Mean ± SD (Median) 36.0 ± 7.8 (35.0) 31.9 ± 5.5 (32.0)  
       Min, Max 22, 51 18, 49  
 
Systolic blood pressure (mmHg)    
       n 25 91 0.08 [1] 
       Mean ± SD (Median) 137.6 ± 13.7 
(140.0) 
143.7 ± 19.5 
(142.0) 
 
       Min, Max 110, 165 100, 214  
 
Diastolic blood pressure (mmHg)    
       n 25 91 0.07 [1] 
       Mean ± SD (Median) 87.0 ± 11.0 (90.0) 92.7 ± 14.4 (94.0)  
       Min, Max 70, 114 11, 122  
 
Comorbidities n/N (%):     
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Parameter 
Spain 
(N = 25) 
Germany 
(N = 97) p-value 
Heart Disease  
Hypertension  
Diabetes 
Anxiety 
Depression  
Insomnia  
Other 
2/25 (8.0%) 
12/25 (48.0%) 
2/25 (8.0%) 
11/25 (44.0%) 
9/25 (36.0%) 
9/25 (36.0%) 
22/25 (88.0%) 
2/97 (2.1%) 
56/97 (57.7%) 
9/97 (9.3%) 
3/97 (3.1%) 
7/97 (7.2%) 
9/97 (9.3%) 
33/97 (34.0%) 
0.19 [3] 
0.38 [3] 
1.00 [3] 
< 0.0001 [3] 
0.0007 [3] 
0.002 [3] 
< 0.0001 [3] 
 
Mask Type, n/N (%)    
       AirFit N10 for Her 1/25 (4.0%) 0/97 (0.0%) < 0.0001 [3] 
       AirFit N10 11/25 (44.0%) 1/97 (1.0%)  
       Mirage FX For Her 0/25 (0.0%) 1/97 (1.0%)  
       AirFit P10 for Her 13/25 (52.0%) 95/97 (97.9%) 
 
 
[1] Independent samples t-test [2] Wilcoxon-Mann-Whitney test [3] Fisher’s exact test (or Chi-square where applicable) 
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Table 2. Change in questionnaire scores after 3 months’ female-specific auto-titrating 
positive airway pressure therapy. 
 Baseline fAPAP (3 months) Change from baseline p-value 
FOSQ total score (n=121) (n=111) (n=110)  
Mean ± SD (range) 15.0±3.3 (6–20) 16.9±3.2 (6–20) 1.9±3.3 (–14, 13) <0.0001 
PHQ-9 total score (n=119) (n=111) (n=108)  
Mean ± SD (range) 12.3±6.0 (1–27) 7.2±5.4 (0–24) –5.0±4.9 (–16, 5) <0.0001 
ESS score (n=122) (n=108) (n=108)  
Mean ± SD (range) 10.8±4.9 (1–24) 7.3±4.7 (0–20) –3.6±5.0 (–20, 6) <0.0001 
CSFQ total score (n=87) (n=70) (n=63)  
Mean ± SD (range) 38.7±9.5 (21–63) 42.4±8.5 (22–63) 2.4±5.9 (–12, 16) 0.001 
EQ-5D index score  (n=115) (n=108) (n=102)  
Mean ± SD (range) 0.64±0.25 (0.1–1.0) 0.76±0.21 (0.1–1.0) 0.12±0.21 (–0.4, 0.6) <0.0001 
EQ-5D health status 
(VAS score) 
(n=108) (n=110) (n=98)  
Mean ± SD (range) 54.4±21.7 (5–100) 64.5±21.5 (7–100) 9.7±21.5 (–45, 75) <0.0001 
CSFQ: Changes in Sexual Function Questionnaire; ESS, Epworth Sleepiness Scale; fAPAP: female-
specific auto-titrating positive airway pressure; FOSQ: Functional Outcomes of Sleep Questionnaire; 
PHQ-9: Patient Health Questionnaire-9; SD: standard deviation; VAS: visual analog scale. 
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Table 3. Change in EuroQol 5D dimensions after 3 months’ female-specific auto-titrating 
positive airway pressure therapy. 
Dimension; n (%)  Baseline fAPAP (3 months) p-value* 
Mobility  (n=116) (n=109)  
No problems in walking about 91 (78.4) 89 (81.7) 
0.55 Some problems in walking about 25 (21.6) 20 (18.3) 
Confined to bed  0 0 
Self-care  (n=117) (n=111)  
No problems with self-care 108 (92.3) 106 (95.5) 
0.32 Some problems with washing or dressing 9 (7.7) 5 (4.5) 
Unable to wash or dress myself 0 0 
Usual activities  (n=117) (n=111)  
No problems performing usual activities  64 (54.7) 78 (70.3) 
0.02 Some problems performing usual activities  51 (43.6) 32 (28.8) 
Unable to perform usual activities  2 (1.7) 1 (0.9) 
Pain/discomfort  (n=115) (n=110)  
No pain or discomfort 22 (19.1) 32 (29.1) 
0.002 Moderate pain or discomfort 64 (55.7) 69 (62.7) 
Extreme pain or discomfort 29 (25.2) 9 (8.2) 
Anxiety/depression  (n=115) (n=111)  
Not anxious or depressed 40 (34.8) 57 (51.4) 
0.005 Moderately anxious or depressed 62 (53.9) 49 (44.1) 
Extremely anxious or depressed 13 (11.3) 5 (4.5) 
fAPAP: female-specific auto-titrating positive airway pressure. 
*p-values generated using Mantel-Haenszel test with modified ridit scores. 
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Table 4. Questionnaire scores in relation to healthy populations and minimal clinically 
important difference. 
Questionnaire 
Healthy 
population 
scores 
Baseline score 
(mean ± SD) 
fAPAP 
(3 months)  
(mean ± SD) 
Change from 
baseline with 
fAPAP 
MCID 
FOSQ ≥17.9 15.0±3.3 16.9±3.2 1.9±3.3 0.75 
ESS ≤9 10.8±4.9 7.3±4.7 –3.6±5.0 2–3 
PHQ-9 ≤4 12.3±6.0 7.2±5.4 –5.0±4.9 5 
CSFQ 47.8±9 38.7±9.5 42.4±8.5 2.4±5.9 Unknown 
EQ-5D Index 1 0.636±0.248 0.763±0.210 0.12±0.21 0.074 
CSFQ: Changes in Sexual Function Questionnaire; ESS, Epworth Sleepiness Scale; fAPAP: female-
specific auto-titrating positive airway pressure; FOSQ: Functional Outcomes of Sleep Questionnaire; 
MCID: minimal clinically important difference; PHQ-9: Patient Health Questionnaire-9; SD: standard 
deviation. 
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Table 5. Respiratory data at baseline (polygraphy) and 3 months (device) for patients from 
Spain. 
 
Baseline 
(n=25) 
fAPAP (3 months)  
(n=23) 
AHI, /h 39.2±20.5 (17–76) 0.9±0.7 (0–3) 
ODI, /h 39.8±21.5 (13–79) - 
RERA, /h - 0.2±0.3 (0–1) 
OAI, /h 8.2±10.6 (0–36) 0.3±0.3 (0–1) 
CAI, /h 0.4±1.1 (0–5) 0.2±0.3 (0–1) 
Mean SaO2, % 97.1±1.6 (92–99) - 
Minimum SaO2, % 77.3±8.3 (52–88) - 
Total sleep time, min 381.5±56.5 (273–486) - 
Mean leak, L/min - 3.8±3.8 (0–16) 
95th percentile leak, L/min - 18.7±8.2 (5–35) 
Median pressure, cmH2O - 9.1±1.4 (7–11) 
95th percentile pressure, cmH2O - 11.0±1.1 (9–13) 
Values are mean  standard deviation (range). 
AHI: apnea-hypopnea index; CAI: central apnea index; fAPAP: female-specific auto-titrating positive 
airway pressure; OAI: obstructive apnea index; ODI: oxygen desaturation index; RERA: respiratory 
event-related arousals; SaO2: oxygen saturation. 
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Table 6. Polysomnography data at baseline and 3 months for patients from Germany. 
 
Baseline 
(n=97) 
fAPAP (3 months) 
(n=87) 
p-value 
Respiratory parameters    
AHI, /h 39.0±17.7 (14-100) 3.3±6.0 (0-50) <0.0001 
ODI, /h 19.1±18.0 (1-86) 4.3±7.0 (0-56) <0.0001 
OAI, /h 27.2±34.4 (0-289) 0.9±2.4 (0-14) <0.0001 
CAI, /h 1.1±3.1 (0-27) 1.2±3.0 (0-25) 0.03 
Basal SaO2, % 93.5±2,2 (87-97) 94.6±2.2 (89-98) <0.0001 
Minimum SaO2,% 79.9±8.3 (53-95) 86.7±4.8 (69-96) <0.0001 
Sleep parameters    
Total sleep time, min 321.0±63.9 (160–568) 326.5±72.2 (116–478) 0.80 
Sleep efficiency, % 79.4±12.6 (34–99) 79.7±14.7 (25–99) 0.91 
Time in S1 sleep, min 39.1±38.1 (5–260) 29.4 ± 25.2 (3–150) 0.02 
Time in S2 sleep, min 197.2±57.9 (38–326) 193.4±49.0 (25–296) 0.50 
Time in SWS, min 40.0±26.3 (0–132) 47.0±29.4 (0–113) 0.07 
Time in REM sleep, min 39.7±24.0 (0–142) 48.1±24.5 (0–110) 0.02 
Values are mean  standard deviation (range). 
AHI: apnea-hypopnea index; CAI: central apnea index; fAPAP: female-specific auto-titrating positive 
airway pressure; OAI: obstructive apnea index; ODI: oxygen desaturation index; REM: rapid eye 
movement; SaO2: oxygen saturation; SD: standard deviation; SWS: slow-wave sleep. 
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Table 7. Device usage (completed cases)  
 
fAPAP (3 months)  
(n=111) 
Average usage, h/day  4.8±2.0 (0.1–8.2) 
Days with usage >4 h/day, %  66.2±30.4 (1.9–100.0) 
Average usage 4 h/day, n (%)  75 (67.6) 
Values are mean  standard deviation (range) or number of patients (%). 
fAPAP: female-specific auto-titrating positive airway pressure. 
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Table 8. Subjective sleep quality 
 Baseline 
fAPAP 
(3 months) 
Change from 
baseline 
p-value 
How easy/difficult was it to fall 
asleep? 
(n=120) (n=107) (n=106)  
Mean ± SD (range)* 5.2±2.9 (0–10) 6.3±2.5 (0–10) 1.1±2.7 (–5, 7) <0.0001 
How well did you feel like you 
slept most nights? 
(n=119) (n=109) (n=107)  
Mean ± SD (range)* 3.5±2.4 (0–10) 6.1±2.3 (1–10) 2.6 ± 2.7 (–3, 8) <0.0001 
How refreshed did you feel in 
the mornings on waking? 
(n=120) (n=108) (n=107)  
Mean ± SD (range) 2.4±2.0 (0–10) 6.3±2.4 (0–10) 3.8±3.0 (–5, 10) <0.0001 
On average, how many times did 
you wake up each night? n (%) 
(n=119) (n=109)   
None  7 (5.9)  19 (17.4)   
<0.0001** 
1-2  43 (36.1)  58 (53.2)   
3-4  56 (47.1)  31 (28.4)   
5-6  12 (10.1)  1 (0.9)   
More than 6  1 (0.8)  0   
*Score on a scale from 0 (worst) to 10 (best).  
**Mantel-Haenszel test (modified ridit scores). 
SD: standard deviation.  
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CHAPTER 7. GENERAL CONCLUSION TO THE THESIS 
 
7.1. Summary of thesis aims 
The overall aim of this thesis was to understand gender differences in OSA and use this 
information to develop a tailored therapy for female patients.  
Specific aims of this thesis were to:  
1) Determine whether gender-related differences exist in symptoms of mild OSA 
patients (CHAPTER 2) 
 
2) Determine whether gender-related differences exist in respiratory data of mild 
OSA patients (CHAPTER 3). 
 
3) Determine whether correlations exists between respiratory parameters and 
patient symptoms in mild OSA patients (CHAPTER 3). 
 
4) Develop, test and validate a new AutoSet for the treatment of female-specific 
breathing characteristics (CHAPTER 4, CHAPTER 5 and CHAPTER 6).  
 
7.2. Summary of the literature review 
CHAPTER 1 of this thesis provides a detailed review of OSA and UARS, with a focus on 
gender differences. OSA is a common disorder characterised by repetitive nocturnal 
complete collapses (apneas) or partial collapses (hypopneas) of the upper airway during 
sleep. These events are associated with oxygen desaturation and/or arousal from sleep. The 
severity of OSA is measured by the number of occurrences of airway collapse per hour (the 
apnea-hypopnea index [AHI]). Measuring the severity of OSA is complicated due to changes 
in scoring rules introduced by the American Association of Sleep Medicine (AASM) in 2007 
and 2012. In 2012 the definition of a hypopnea was modified, which increases the number of 
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patients achieving diagnostic criteria. In particular, many patients who may have previously 
been diagnosed with UARS are likely to qualify for an OSA diagnosis if later scoring criteria 
are used.  
OSA is less prevalent in females than males. When AASM 2012 scoring criteria is used, as 
many as 49.7% of males and 23.4% of females may have moderate-to-severe OSA (18). 
Females present with different symptoms than males. While the typical OSA symptoms are 
snoring, witnessed apneas and daytime sleepiness, females are more likely to complain of 
fatigue, insomnia, depression and anxiety (23-26). Females with moderate-to-severe OSA 
have significantly worse quality of life and mood disturbances than males with OSA (29, 30). 
It is not clear whether women with OSA experience daytime sleepiness. Women consistently 
score lower on questionnaires assessing daytime sleepiness, and are more likely to 
complain of fatigue and tiredness than sleepiness (36, 37). Females with OSA are frequently 
misdiagnosed with depression and other illnesses, most likely due to the atypical symptoms 
they report (23, 24, 47). However, even when women do report the typical OSA symptoms 
they are still less likely to be referred to sleep clinics, indicating that OSA in female patients 
is often overlooked (47). Compared to males with OSA, females have a higher likelihood of 
developing a range of health conditions including diabetes (68) and hypertension (70). 
Women with OSA are more likely than those without OSA to be diagnosed with 
cardiovascular diseases (68), and severe untreated OSA in females has been associated 
with cardiovascular death (69). 
As defined by the AHI, females have less-severe OSA compared to males (126). Females 
have lower AHIs, comprised of shorter events and less-severe oxygen desaturations, than 
males (124). Females are more likely to have clusters of obstructive events during REM 
sleep (123), and less likely to experience positional OSA (123). Less severe OSA in females 
appears to be due to a combination of anatomical, hormonal, and chemoreceptor differences 
(23, 137, 138, 142).  
The gender differences in prevalence, symptoms, clinical experience, and health 
consequences of OSA patients appear to be clearly defined. However, a review of patients 
with mild OSA and UARS shows that the proportion of females reporting to sleep clinics is 
much closer to 50% (85-87). The symptoms that mild OSA and UARS patients report are 
similar to those attributed to female OSA patients, including insomnia, poor quality of life, 
and daytime tiredness (11, 85). Patients with mild OSA and UARS experience large amounts 
of flow limitation during sleep. Flow limitation alone, with obstructive apneas, has been 
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shown to produce clinical symptoms such as fatigue and depression (99). It is therefore 
possible that symptoms of OSA may be more closely related to severity of the disease than 
gender.  
The most effective treatment for OSA is continuous positive airway pressure (CPAP). CPAP 
provides a pneumatic splint by applying pressurized air from a device to a patient’s airway 
via a mask and tubing. Effective CPAP treatment in women has been shown to improve 
quality of life (160), sleepiness (163), anxiety (163) and depression (161). CPAP also 
appears to reduce the risk of cardiovascular mortality in adherent female patients (25).  
AutoSet is a mode of CPAP therapy which automatically adjusts the pressure delivered to 
the patient based on a breath-by-breath assessment of ventilation. AutoSet devices assess 
the patient’s breathing for flow limitation, snore, and reduction or lack of ventilation 
(hypopnea or apnea). The AutoSet devices then increase the pressure to overcome 
obstruction until ventilation is stable. AutoSet devices are also able to reduce pressure 
during periods of stable breathing to improve patient comfort. An advantage of AutoSet 
devices is their ability to provide efficacious treatment for patients during changing 
circumstances, for example after alcohol intake or weight gain. AutoSet devices have been 
developed and validated in patient groups consisting of 100% male patients (180-182). As 
female-specific characteristics have not been considered during the development of AutoSet 
devices, they may not be optimal for treatment of women with OSA.  
7.3. Summary of the main findings of this thesis 
CHAPTER 2 of this thesis aimed to determine whether the literature-reported female 
symptoms of OSA (fatigue, insomnia, anxiety and depression) are still a gender-specific 
phenomenon in UARS and mild OSA patients. Patient data from the MERGE clinical trial 
(Appendix C) was used for this analysis. Patients were entered into this clinical trial if they 
had mild OSA (AHI 5-15) according to either AASM 2007, or AASM 2012 criteria. At the first 
trial visit patients were asked to complete a range of quality of life questionnaires, including 
the Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hospital Anxiety and 
Depression Scale (HADS), and Insomnia Severity Index (ISI). Baseline questionnaire scores 
of the males and females were compared to see if gender differences were present in this 
mild patient group. 
Included in this analysis were 186 males and 73 females. On average, the females were 
significantly older (54.9 + 9.8 vs. 50.4 ± 12.1, p = 0.002), and had a higher BMI (31.8 ± 5.2 
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vs. 29.5 ± 3.6, p < 0.000). There were significant gender differences in each questionnaire 
response. The female patients reported significantly higher sleepiness according to the ESS 
(10.63 ± 4.34 vs. 9.13 ± 4.34, p = 0.014). Females also reported significantly higher levels of 
fatigue (FSS scores 43.10 ± 12.94 vs. 33.69 ± 13.94, p = 0.000), insomnia (ISI scores 14.62 
± 5.67 vs. 11.90 ± 5.48, p = 0.001), and anxiety/depression (HADS scores 14.81 ± 7.57 vs. 
11.03 ± 6.94, p = 0.000).  Overall, this data from 259 mild OSA patients shows that, even at 
the lower end of the OSA spectrum, the symptoms of females are still significantly worse 
than those of males.   
CHAPTER 3 of this thesis aimed to determine whether the gender differences reported in 
respiratory parameters of moderate-to-severe patients also exist in mild OSA and UARS 
patients. Females are reported to have more flow limitation, shorter apneas, less-severe 
oxygen desaturation, and more RERAs/hypopneas terminated by arousal. UARS is 
characterised by excessive flow limitation and RERAs. It is not clear if females have less-
severe sleep disordered breathing (SDB) within the mild OSA and UARS groups. Patients 
enrolled in the MERGE study (Appendix C) underwent polygraphy (PG) home sleep testing. 
PG data from the participants was analysed according to gender to assess for differences. 
PG data was then correlated with patient symptoms to determine whether there were 
relationships between SDB events and symptoms.  
PG studies from 259 patients (73 females) were collected. Studies were scored both with 
AASM 2007 and AASM 2012 scoring criteria. When scored according to AASM 2007 criteria, 
the male patients had significantly higher AHI (7.17 ± 3.4 vs. 5.97 ± 2.71, p = 0.004). This 
difference disappeared when the studies were rescored with AASM 2012 criteria (male vs. 
female AHI 12.52 ± 5.01 vs. 11.65 ± 4.69, p = 0.197). There were no significant differences 
in the number of hypopneas terminated by arousals (male vs. female score 3.2 ± 3.58 vs. 
3.65 ± 3.58, p = 0.370). There was also no significant difference in the percentage of flow 
limited breaths between the genders (males vs. female percentage 39.8 ± 13.8 vs. 38.4 ± 
15.6, p = 0.598).  
In the male patient group, correlations were only found between AASM 2012 AHI, and FSS 
(r = -0.153, p = 0.040). In the female patients, correlations were found between AASM 2007 
AHI and ESS (r = -0.317, p = 0.007), AHI and HADS (r = -0.372, p = 0.001), and AHI and ISI 
(r = -0.242, p = 0.042). In the female data rescored with AASM 2012 rules, correlations were 
also found between AHI and HADS (r = -0.381, p = 0.001), and AHI and ISI (r = -0.240, p = 
0.044). In all correlations found, the relationship was inverse, meaning that the symptoms 
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were higher for lower AHIs. There were no correlations between flow limitation and 
symptoms in the male group. In the female group correlations were found between percent 
of flow limited breaths and FSS (r = -0.300), and percent of flow limited breaths and ISI (-
0.416, p = 0.004). Again, these correlations were inverted, with higher symptoms associated 
with lower percentages of flow limitation. In the female patients, ESS was strongly 
associated with age, with younger females more likely to report excessive sleepiness. BMI 
was associated with FSS increases in females, and ISI increases in males.  
This data confirmed that, even in this mild patient group, females have less-severe SDB, 
with lower AHIs and a higher proportion of hypopneas terminated by arousals. There was no 
significant difference in the percentage of flow limitation between genders. It was not 
possible to draw clear conclusions from the associations between symptoms and measures 
of SDB.  
CHAPTER 4 of this thesis outlined the development of a female-specific AutoSet device. 
Females are reported as having different breathing patterns to males, including more flow 
limitation, shorter and less-severe apneas, lower AHIs, less severe-oxygen desaturations, 
more events during REM sleep, and a longer sleep latency. Traditionally, AutoSet devices 
were developed and tested on male patient groups and therefore may not appropriately 
recognise and respond to female-specific breathing events and may not provide optimal 
treatment for female patients.  
Development of the new AutoSet (AutoSet F) involved designing a new algorithm which 
would detect and respond to female-specific breathing patterns. The AutoSet F algorithm 
includes a sensitive flow limitation detection and response, a floor pressure to protect 
against strings of OSA in REM, lower overall mean pressures than a standard AutoSet, a 
new RERA detection algorithm, gentle and slow pressure increases and decreases, and an 
automatic ramp feature which keeps delivered pressure low until sleep onset is detected.  
CHAPTER 5 of this thesis detailed the testing and verification activities undertaken on the 
AutoSet F. The first activity was a clinical trial conducted on 20 female OSA patients to test 
device efficacy. Female patients with a diagnostic AHI ≥ 15 were randomised to receive 
AutoSet F or standard AutoSet on consecutive nights while undergoing PSG. The primary 
objective was to compare the AHI and ODI of the AutoSet F to the standard AutoSet to 
demonstrate non-inferiority. Secondary outcomes were sleep parameters and patient 
satisfaction.  
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Female participants were primarily Caucasian with a mean age of 44.85 ± 5.02 years and 
diagnostic AHI of 19.08 ± 8.69. No significant differences were found between the standard 
AutoSet and AutoSet F in AHI (0.96 vs. 0.91, p = 0.870); or ODI (1.92 vs. 2.19, p = 0.477). 
When comparing the sleep parameters, the data shows that flow limitation (% of breaths) 
was significantly lower when participants were treated with the AutoSet F compared with the 
standard AutoSet (0.14% vs. 0.20%; p=0.003). This study shows that the AutoSet F is able 
to efficaciously treat OSA in female patients and may be a more suitable option than 
standard AutoSet. 
The next activity for validating the AutoSet F was testing using a bench test designed to 
simulate a female OSA patient. The primary objective of this activity was to test the 
performance of the AutoSet F compared to other commercially available devices, on a test 
which is controlled and repeatable. The bench test in this study was developed Professor 
Farré and colleagues at Barcelona University.  
In this bench test, the simulated patient was designed to replicate a typical female OSA 
patient with a lot of flow limitation, short apneas, mild hypopneas and a requirement for 
overall lower treatment pressures.  
From the ten AutoSet devices tested, only the AutoSet F and two other AutoSet devices 
were able to completely overcome obstructive events and flow limitation. There was a high 
residual AHI (AHI > 5) at completion of the testing for four of the devices. This bench testing 
demonstrated that the AutoSet F was able to completely normalize breathing of a simulated 
female patient, while several other commercially available AutoSet devices were unable to 
normalize breathing.  
The next validation test for the AutoSet F was a controlled product launch (CPL). During a 
CPL, product commercial release is carefully controlled and data from participants is 
collected and analysed for correct device functioning. De-identified device functioning 
information was collected from 163 devices, over a total of 2272 nights of use. Average daily 
usage was high, at 5.9 hours per night. Residual AHI was 2.61, well below what is 
considered efficacious (< 5). This efficacy was achieved with a group average 95th percentile 
pressure of 8.76 cm H2O. During the CPL, the technical features of the AutoSet F were 
found to be working as intended, and the internal algorithm was able to treat female patients 
in real world, uncontrolled conditions.  
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CHAPTER 6 of this thesis reported a clinical trial evaluating quality of life in female patients 
before and after using the AutoSet F for three months. The literature, as well as data in this 
thesis, has shown that female OSA patients experience worse symptoms, including fatigue, 
quality of life, anxiety and depression, insomnia, than males with OSA. The purpose of this 
study was to evaluate whether ongoing use of the AutoSet F was able to improve these 
symptoms in female patients. 
Participants underwent PG (Spain) or PSG (Germany) at study entry. Those with a 
diagnostic AHI of ≥ 15/h were eligible to participate. The primary endpoint was change in 
baseline in the Functional Outcomes of Sleep Questionnaire (FOSQ) score after 3 months’ 
AutoSet F use. Secondary endpoints included other sleep-related and QoL questionnaires.  
A total of 122 patients were enrolled in the study (age 53.7 ± 9.5 years, body mass index 
32.8 ± 6.2 kg/m2, apnea-hypopnea index [AHI] 39.0±18.2/h); 111/122 completed the study. 
There was a significant improvement (p<0.0001) in FOSQ score from baseline (15.0 ± 3.3) 
to 3 months (16.9 ± 3.2). Significant improvements were also seen in the Patient Health 
Questionnaire-9 score (12.3 ± 6.0 vs. 7.2±5.4), Epworth Sleepiness Scale score (10.8 ± 4.9 
vs. 7.3 ± 4.7), EuroQol (EQ)-5D Index score (0.636 ± 0.248 vs. 0.763 ± 0.210), EQ-5D visual 
analogue scale score (54.4 ± 21.7 vs. 64.5 ± 21.5) (all p<0.0001), and Changes in Sexual 
Functioning Questionnaire score (38.7 ± 9.5 vs. 42.4 ± 8.5; p=0.001). In patients with PSG 
data, AutoSet F improved other respiratory parameters (AHI, oxygen desaturation index, 
oxygen saturation; all p<0.0001), and increased time spent in rapid eye movement (REM) 
sleep (39.7 ± 24.0 vs 48.1 ± 24.5 min; p=0.022). Average daily usage was 4.8 ± 2.0 h/night. 
This study showed significant improvements in quality of life in female OSA patients treated 
for 3 months with the AutoSet F device. This included improvements in sexual function, 
which have been rarely studied in these patients. Significant improvements were seen in 
respiratory parameters as well as time in REM sleep. Taken together, this data shows that 
the AutoSet F can improve sleep and quality of life in female OSA patients.  
7.4. Conclusion to this thesis and future direction  
During this thesis I aimed to determine whether gender differences described in OSA 
patients still exist in those patients on the mild end of the spectrum. I found that significant 
gender differences do exist in mild OSA patients, with females suffering from significantly 
worse sleepiness, fatigue, insomnia, and anxiety/depression. It was clear that these patients 
were extremely symptomatic, and defining them as mild is misleading, as is only looking at 
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AHI as a measure of severity. The reasons that female patients express worse symptoms 
remain unclear, and future studies should investigate the psychology behind how females 
perceive and report symptoms of OSA compared with males.  
Gender differences in the severity of OSA are also present in mild OSA patients, although 
they are far less pronounced than those in moderate-to-severe patients, with no significant 
differences found between the percentage of flow limitation or number of hypopneas 
terminated by arousal. I was unable to conclusively find relationships between measures of 
SDB and symptoms. Although correlations were found between some measures of SDB and 
symptoms in female patients, they were inverse, meaning that lower SDB scores were 
associated with higher symptoms. There were also strong confounding factors, including 
BMI and age, which were associated with symptoms for both genders. Future research 
should review symptom improvement following OSA treatment, as this will provide further 
insights as to which symptoms are caused by untreated OSA. The MERGE trial (Appendix 
C) aims to investigate this area further, with results expected late 2019.  
The final aim of this thesis was to develop a new AutoSet treatment for female patients. 
Using respiratory parameters commonly found in female patients, I developed an 
appropriate AutoSet which I then tested for efficacy, effectiveness, and long-term use in 
female patients. The studies demonstrated that the AutoSet F is able to significantly improve 
OSA and improve symptoms of female patients, and may provide more optimal treatment 
than other commercially available AutoSet devices. This work has contributed to the field of 
sleep medicine by bringing awareness to the gender differences that exist in OSA, and 
introducing personalised medicine for female OSA patients. It is hoped that through this work 
it will be easier for female OSA patients to be identified and treated for obstructive sleep 
apnea, which will then improve their quality of life.  
Further research in this area should compare the AutoSet F to standard AutoSet in a longer 
clinical trial to see if PAP acceptance and compliance can be improved with the use of the 
AutoSet F. Future research may also investigate the use of the AutoSet F on male patients 
with mild OSA and excessive amounts of flow limitation to see if similar improvements are 
seen in the male population.  
Female patients may benefit from introducing new definitions of OSA which move away from 
traditional AHI measures. As shown in this thesis, the AASM 2012 definition of OSA appears 
to be more beneficial to female patients as it recognises more respiratory events, however 
prolonged flow limitation and some RERAs are still not included in this definition. Finally, 
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new therapies emerging to treat OSA, including mandibular advancement devices, phrenic 
nerve simulation, and combinations of new drugs, should all be separately analysed on 
female patients. These therapies could then be optimised for the female patients, who have 
been shown to be very different from the male patients. 
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Abstract 
Obstructive sleep apnea (OSA) has traditionally been seen as a male disease. However, the 
importance of OSA in women is increasingly being recognized, along with a number of significant 
gender-related differences in the symptoms, diagnosis, consequences, and treatment of OSA. 
Women tend to have less severe OSA than males, with a lower apnea-hypopnea index (AHI) and 
shorter apneas and hypopneas. Episodes of upper airway resistance that do not meet the criteria for 
apneas are more common in women. Prevalence rates are lower in women, and proportionally 
fewer women receive a correct diagnosis. Research has also documented sex differences in the 
upper airway, fat distribution, and respiratory stability in OSA. Hormones are implicated in some 
gender-related variations, with differences between men and women in the prevalence of OSA 
decreasing as age increases. The limited data available suggest that although the prevalence and 
severity of OSA may be lower in women than in men, the consequences of the disease are at least 
the same, if not worse for comparable degrees of severity. Few studies have investigated gender 
differences in the effects of OSA treatment. However, given the differences in physiology and 
presentation, it is possible that personalised therapy may provide more optimal care. 
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1. Introduction 
Obstructive sleep apnea (OSA) is characterized by 
repetitive nocturnal complete collapses (apneas) or 
partial collapses (hypopneas) of the upper airway 
during sleep. These events are associated with 
oxygen desaturation and/or arousal from sleep. The 
severity of OSA is measured by the number of 
occurrences of airway collapse per hour (the apnea-
hypopnea index [AHI]). OSA is the most common 
form of sleep disordered breathing (SDB) and its 
prevalence has been increasing steadily, in part due 
to the global rise in obesity and in part due to 
changes to the recommended OSA scoring 
ruleswhichwereupdatedin2012toallowabroaderdefini
tion of OSA [1]. Table 1 summarizes prevalence data 
for OSA in the general population. 
OSA has been estimated to have a male-to-female 
ratio of between 3 : 1 and 5 : 1 in the general 
population and a much higher ratio of between 8 : 1 
and 10 : 1 in some clinical groups [2–4]. Perhaps not 
surprisingly then, OSA has historically been regarded 
as a male disease [5]. Prevalence data do show that 
more men than women are affected by OSA; 
however, these differences are not reflected in 
clinical populations. This indicates that females are 
being diagnosed and treated for OSA less frequently 
than males. 
2. OSA Classification, 
Diagnosis, and Symptoms 
2.1. Sleepiness. It has been suggested that 
discrepancies between males and females in the 
prevalence of OSA could be a result of women 
frequently being misdiagnosed or underdiagnosed 
due to reporting different symptoms [4]. In the past, 
sleepiness has been seen as a key component of 
OSA. Obstructive sleep apnea syndrome (OSAS), 
which refers to OSA with accompanying symptoms, 
has been the main focus 
Table 1: Estimated population prevalence of OSA. 
Mild OSA (AHI ≥ 5/h) 
Study 
Moderate-to-severe 
OSA (AHI ≥ 15/h) 
 Males Females Males Females 
Young et al. 
[2] 
24% 9% 9% 4% 
Redline et al. 
[21]∗ 
— — 26% 13% 
Bixler et al. 
[22, 23] 
17% — 7% 2% 
Duran et al.´ 
[24] 
26.2% 28% 14% 7% 
Peppard et al. 
[25] 
— — 13.5% 6% 
Franklin et al. 
[5]∧# 
— 50% — 26% 
Heinzer et al. 
[26]# 
34% 38% 49.7% 23.4% 
∗Respiratory disturbance index (RDI) rather than AHI given. 
∧Women aged 20–70 years. 
#Updated scoring criteria (AASM 2012) used. 
of treatment in the past. Furthermore, because the 
majority of clinical trial participants with OSA have 
been sleepy, it is still not clear whether 
asymptomatic OSA should be treated. 
The Epworth Sleepiness Scale (ESS) is a tool used to 
measure the likelihood of falling asleep in certain 
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situations and is commonly used to screen for OSA 
[5, 6]. Despite its widespread use, the ESS has not 
been validated for use in female OSA patients and 
has not been strongly associated with daytime 
sleepiness in female patients in population based 
studies [5, 6]. In fact, even women who report similar 
levels of daytime sleepiness to men are less likely to 
have an ESS score >10 [6]. It is not clear why these 
differences occur; however, it is possible that women 
have a different threshold for feeling sleepy and/or 
complain differently about sleepiness compared with 
men [4]. 
2.2. Other Symptoms. Making a differential diagnosis 
of OSA in women might be more difficult given that 
they tend to present with more generalized daytime 
symptoms than men [4]. Women with OSA complain 
of symptoms such as insomnia, restless legs, 
depression, nightmares, palpitations, and 
hallucinations whereas men are more likely to report 
snoring and apneic episodes [7]. Women may 
consider their own snoring “unladylike” and 
therefore be less likely to mention it [4]. In addition, 
women are more likely to attend clinical 
appointments on their own, whereas men often 
attend with their partner [3]. Therefore, information 
from a partner on snoring and witnessed apneas may 
not be as readily available for women versus men. 
Less frequent reporting of “typical” OSA symptoms 
such as sleepiness and snoring by women, plus a 
higher prevalence of atypical symptoms such as 
insomnia, headache, anxiety, and depression, could 
contribute to the under-evaluation of OSA in women, 
lower referral rates to sleep clinics, and 
underrepresentation in clinical studies [8, 9]. 
In a community-based sample, women with OSA 
reported the same symptoms as men across a range 
of severities, and snoring was the most significant 
predictor of OSA for both sexes [9]. However, a 
similar study of a population-based sample found 
that up to 40% of women with an AHI > 15/h did not 
report any of the classic OSA symptoms (snoring, 
witnessed apneas, and daytime sleepiness) [7]. 
2.3. Recognition and Diagnosis. It is clear that many 
women do report classic OSA symptoms, suggesting 
that factors other than symptoms also contribute to 
gender disparity in OSA populations [9]. These 
include failure of women to acknowledge OSA 
symptoms and seek medical help or failure of 
medical professionals to respond to OSA symptoms 
in women [4, 9]. Adding to the difficulty in correctly 
diagnosing female patients is the reporting of 
symptoms such as depression and anxiety, which are 
also more common in female than male patients 
without OSA [10]. 
Data from the Wisconsin University Sleep Laboratory 
showed that lower rates of recognition of OSA in 
women versus men only occurred in the subset of 
patients with an AHI of 5–20/h [11]. Their findings 
led the study authors to hypothesize that there may 
be greater gender-related differences in OSA 
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symptom expression at lower AHI values, particularly 
with respect to characteristic symptoms such as 
snoring, witnessed apneas, and excessive daytime 
sleepiness. 
Another difficulty in correctly diagnosing and treating 
OSA is understanding where the disease becomes 
significant and at what point treatment should be 
initiated. Large studies have typically shown an 
association between moderate severe OSA and poor 
cardiovascular outcomes, whereas the same 
association has not been found in mild OSA [12]. 
Growing evidence suggests that mild OSA is 
associated with reduced quality of life, including 
general tiredness, fatigue, daytime impairment, 
difficulty concentrating and completing tasks, 
depressed mood, poor sleep quality and insomnia, 
and poor psychomotor performance [1, 13–17]. 
3. Gender Differences in the 
Upper Airway, Fat 
Distribution, and 
Respiratory Stability 
Definitive explanations for differences between men 
and women in the symptoms, characteristics, and 
severity of OSA are not yet available, but various 
factors may contribute. 
The focus of a number of studies has been on the 
upper airway. Magnetic resonance imaging has 
shown that airway length, the tongue, the soft 
palate, and the total amount of soft tissue in the 
throat are all smaller in women than in men [18]. 
Although, intuitively, a smaller airway might be 
expected to occlude more easily than a larger one, 
this does not seem to be the case. It appears that 
men have a longer, softer oropharynx and a larger, 
fatter, more posterior tongue, increasing the 
susceptibility of the large airway to collapse [4]. 
Upper airway collapsibility, determined by the 
pharyngeal critical closing pressure, has been shown 
to be less in women versus men when the severity of 
OSA is the same [19]. Sex differences in airway 
collapsibility were most evident during non-REM 
sleep, suggesting that men may be more susceptible 
to pharyngeal collapse than women during 
established sleep, but not during sleep transition 
[20]. 
Obesity is a well-recognized risk factor for OSA, and 
higher body mass index (BMI) is associated with 
greater severity of OSA for both sexes [18]. However, 
for the same AHI, women tend to be more obese 
than men [19, 27]. One potential explanation for this 
is differences in fat distribution between the sexes 
[28]. For the same BMI, men tend to have higher 
mean body weight, free fat mass, and neck 
circumference compared with women [29]. MRI 
studies have confirmed less pharyngeal fat and lower 
soft tissue volume in the neck for obese women 
versus obese men [30]. Upper airway fat distribution, 
particularly in the posterior tongue, appears to be 
important in the pathogenesis of OSA and is related 
to gender [4]. Upper body and visceral adiposity have 
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been associated with reductions in lung function, 
including total lung capacity, forced vital capacity, 
and forced expiratory volume [31]. In addition, the 
independent effects of body fat distribution on lung 
function were more pronounced in men than in 
women [32]. 
Fat distribution might have physiological as well as 
mechanical effects in patients with OSA. Obese 
women, especially those with OSA, have been shown 
to have significantly increased hypercapnic and 
hypoxic responses, whereas this was not the case in 
obese men [33]. This adaptation might maintain 
adequate minute ventilation when the chest wall 
load is increased. In addition, men and women have 
been shown to require different levels of carbon 
dioxide in the blood to cause respiratory instability, 
and men were more susceptible to hypocapnic 
dysfunction during non-REM sleep than women. It is 
possible that women preserve ventilation output 
during hypocapnia more efficiently than men [34]. 
Indeed, the ventilatory response to hypercapnia has 
been shown to be greater in men than in women 
[35]. Thus, reduced lung function and decreased 
chemoresponsiveness are additional reasons why 
men are more susceptible to OSA than women. 
There may also be gender differences in the arousal 
response to apneas. Jordan and colleagues found 
that during non-REM sleep men had a higher 
ventilatory response to apneas than women, but 
then they developed greater hypoventilation when 
they went back to sleep, especially in the supine 
position. This prolonged hypoventilation often leads 
to ventilatory instability upon returning to sleep. The 
study authors hypothesized that this may play a role 
in explaining why sleep apnea syndromes are more 
severe in men [36]. 
4. Manifestations 
There are a number of gender differences in the 
manifestations of OSA; both the severity of OSA and 
its distribution across the sleep cycle differ in males 
and females. In patients with existing OSA, women 
had a significantly lower overall 
AHI compared with men (20.2/h versus 31.8/h; p < 
0.001); AHI during non-REM sleep was also 
significantly lower in women versus men (14.6/h 
versus 29.6/h; p < 0.001) but there was no difference 
between females and males with respect to AHI 
during REM sleep (42.7/h versus 39.9/h, resp.), 
suggesting greater clustering of apneic events during 
REM sleep in women [37]. This study also showed 
that OSA in the supine position occurred almost 
exclusively in men, indicating that positional OSA is 
not really an issue for women [37]. 
Polysomnographic data from patients referred for 
suspected sleep disorders also showed that a 
difference between males and females in AHI was 
evident during stage 2 sleep, but not during REM 
sleep [38]. In addition, women had shorter apnea 
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events and less severe oxygen desaturations than 
men (both p = 0.001) [38]. 
An interesting finding is that women are 
symptomatic at lower AHI cut-off values compared 
with men with the same AHI [9]. Females with an AHI 
of 2–5/h had a similar level of symptoms to men with 
an AHI of ≥15/h. In contrast, males with an AHI of 2–
5/h were indistinguishable from those with an AHI of 
0–2/h with respect to symptoms. One possibility is 
that the long-term effects of REM sleep disruption 
contribute to greater symptomatology at lower AHI 
values in women compared with men [39]. 
Another theory is that women may be more 
symptomatic because they have more episodes of 
upper airway resistance during sleep. Obstructive 
events can be thought of as a continuum from partial 
to complete upper airway obstruction. Upper airway 
resistance occurs early in this spectrum and 
describes events where resistance to airflow in the 
upper airway increases during sleep, presenting as 
flow limitation during polysomnography [40]. This 
increase in upper airway resistance could increase 
work of breathing, cause arousals and disrupted 
sleep, and impact daytime cognitive function [40]. 
Upper airway resistance alone, without complete 
obstructive apnea or respiratory disturbance, has 
been shown to produce clinical symptoms such as 
daytime fatigue and depression [41], both of which 
are symptoms reported by women with OSA. 
Sleep architecture is another aspect that has been 
shown to differ between males and females. A study 
of 307 patients found that women took longer to fall 
asleep than men and, once asleep, had fewer 
awakenings and more slow wave (deep) sleep, 
despite no differences between the sexes in age, 
respiratory disturbance index, or oxygen saturation 
[42]. 
The occurrence of multiple episodes of upper airway 
resistance without frank apneas means that an AHI 
value may not provide a physician with a true 
indication of the degree of sleep fragmentation being 
experienced by patients. As a result, episodes during 
sleep where flow is reduced, respiratory effort 
increases, and the episode is terminated by an 
arousal have been termed respiratory effort-related 
arousals (RERAs) [40] (Figure 1). The importance of 
measuring and reporting RERAs has been 
emphasized by a task force of the American Academy 
of Sleep Medicine (AASM) [43]. 
Women with partial upper airway obstruction have 
been shown to have similar symptoms, including 
sleepiness, to women with OSA, resulting in a call for 
partial upper airway obstruction to be clinically 
recognized in the same way as OSA in women [44]. It 
has also been suggested that recognizing and 
understanding the different features of SDB in 
women are central for effectively detecting and 
treating the condition [45]. An update to the AASM 
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scoring criteria in 2012 broadened the definition of 
OSA, and this may 
 
Figure 1: Respiratory effort-related arousals (RERAs). Trace shows 
a sustained period of flow limitation leading to increasing 
respiratory effort and arousal typical of RERAs. EEG: 
electroencephalography. 
theoretically increase the number of patients with 
mild OSA. The AASM felt that there was sufficient 
evidence that hypopneas without associated oxygen 
desaturation, but rather hypopneas associated with 
arousal from sleep, were associated with significant 
daytime impairment and impacted quality of life to 
the point where treatment may be of benefit [1]. 
This is particularly relevant for female OSA patients 
because they are more likely to experience milder 
OSA with less severe oxygen desaturations. In 
addition, RERAs are now very rare with the new 
definition because most events of this nature can 
now be classified as hypopneas [1]. No prospective 
studies have investigated continuous positive airway 
pressure (CPAP) treatment in this newly defined 
group of patients with mild OSA; however, there is 
one randomized controlled trial underway which 
aims to do so (merge study, NCT02699463). 
5. Menopause and 
Pregnancy 
Differences between men and women in the 
prevalence of OSA decrease as age increases, largely 
as a result of a marked increase in the prevalence 
and severity of SDB in women after menopause [22, 
46, 47]. Therefore, it has been suggested that female 
sex hormones have some sort of protective effect on 
upper airway patency and/or ventilatory drive [39]. 
The hormone progesterone is a known respiratory 
stimulant which increases chemoreceptor responses 
to hypercapnia and hypoxia and has been shown to 
increase upper airway muscle tone [48]. 
Progesterone levels decrease after menopause. 
Hormones may also play a role in the distribution of 
body fat. Postmenopausal women have a higher fat 
mass compared to the period prior to menopause, 
and fat distribution is more likely to be in the upper 
body and trunk area compared with the lower body 
[49, 50]. In female volunteers, activity of the 
genioglossus muscle during wakefulness was lower in 
postmenopausal women compared with 
premenopausal women and significantly increased 
after 2 weeks of hormone replacement therapy [51]. 
Women may be at increased risk of OSA during 
pregnancy due to a number of factors. The growing 
uterus elevates the diaphragm, changing pulmonary 
mechanics [52]. In addition, during pregnancy, neck 
circumference increases [53, 54], nasal patency is 
reduced [55], and pharyngeal edema occurs [56]. 
Substantial increases in snoring, snorting/gasping, 
and witnessed apneas have been documented in 
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pregnant women [54]. Snoring during pregnancy 
appears to be a risk factor for both pregnancy-
induced hypertension and intrauterine growth 
retardation [57]. An ongoing study in this area will 
enrol 3702 women to understand the prevalence and 
outcomes of OSA during pregnancy [58]. Preliminary 
data from this group found that OSA affects 8.1% of 
pregnant women by the second trimester and that 
there was an association between OSA and 
hypertension and diabetes in this group [59]. 
There are limited data on the treatment outcomes of 
OSA during pregnancy, and no randomized 
controlled trials have been conducted in this area. 
Small studies have shown that CPAP treatment 
reduces blood pressure during pregnancy even when 
OSA is mild [60] and may improve pregnancy 
outcomes compared with untreated OSA [61, 62]; 
however, more research is required in this area. 
6. Quality of Life 
Several comparisons of women and men with 
untreated OSA have found that women report 
impaired quality of life. Women complain of more 
mood disturbances such as anxiety and depression, 
report low quality of life scores on a range of 
questionnaires, and display increased daytime 
fatigue, reduced sleep quality, and worsened 
neurobehavioral symptoms [63–66]. One limitation 
of these studies is that females were generally 
compared to males with OSA, rather than matched 
controls, meaning that there are no data on how 
female OSA patients differ from those in the general 
female population, where mood disturbances such as 
anxiety and depression can be common. 
7. Health Consequences of 
OSA and Effects of 
Treatment 
OSAS has been associated with elevated 
cardiovascular risk and increased morbidity and 
mortality [67]. Observational studies have shown 
that adequate treatment of OSA with CPAP can 
reduce the incidence of cardiovascular events in 
patients with any severity of symptomatic OSA [68, 
69]. The evidence for non-sleepy patients is mixed, 
with two short-term randomized studies showing no 
cardiovascular improvement in non-sleepy patients 
[70, 71]. However, a recent study by Barbe et al. 
included 725 non-sleepy patients´ with an AHI ≥20/h 
who were randomized to CPAP or a control group. 
There were fewer cases of new hypertension and 
cardiovascular events in the CPAP group, although 
this did not reach statistical significance (CPAP versus 
control group incidence density ratio (IDR) 0.81, 
confidence interval [CI] 0.61–1.06; 𝑝 = 0.13). 
However, an analysis of those using PAP for ≥4 
hours/night compared with the control group had an 
IDR of 0.69 (CI 0.50–0.94; 𝑝 = 0.02) compared with an 
IDR of 1.12 (CI 0.77–1.64; 𝑝 = 0.55) for those using 
CPAP <4 hours/night [72]. Due to the associations 
between OSA and harmful cardiovascular 
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consequences, many researchers advocate for CPAP 
treatment of all patients, regardless of symptoms 
[73]. 
It has been postulated that non-sleepy patients will 
not be adherent to treatment; however, a recent 
large prospective trial has shown that long-term 
CPAP treatment is feasible in non-sleepy moderate-
to-severe OSA patients [74]. 
7.1. Gender Differences in the Health Consequences 
of OSA. In the past, the belief that OSA was primarily 
a male disorder meant that clinical trial populations 
were comprised almost entirely of males [5]. 
Recently, studies have focused more specifically on 
the unique consequences of OSA in female patients. 
Greenberg-Dotan et al. found that, compared to 
female controls, women with OSA were more likely 
to have a comorbid diagnosis including 
cardiovascular disease (odds ratio [OR] 1.4), 
hyperlipidemia (OR 1.5), diabetes (OR 1.6), asthma 
(OR 2.1), hypothyroidism (OR 1.6), arthropathy (OR 
1.6), and reflux/gastritis (OR 2.5) [65]. 
Yaffe et al. studied a group of women with SDB and 
found that they were more likely to develop 
cognitive impairment or dementia than those 
without SDB. Cognitive issues were more likely to 
develop in patients with increased oxygen 
desaturation and higher periods of time spent in 
apnea or hypopnea [75]. Another study showed that 
female OSA patients experienced more brain white 
matter injury than their male counterparts [64]. It is 
hypothesized, though not yet known, that this 
change in white matter structure may be responsible 
for the worsened quality of life reported by women. 
Sympathetically mediated responses to autonomic 
challenges in patients with OSA are blunted to a 
significantly greater extent in women versus men 
with OSA; this deficit is likely to reduce the 
effectiveness of BP regulation and brain perfusion 
[76]. In addition, it is possible that women with 
moderate sleep apnea are more susceptible to the 
adverse cardiovascular consequences of OSA than 
men, having been shown to have more marked 
endothelial dysfunction [77]. Certainly, untreated 
severe OSA has been independently and significantly 
associated with cardiovascular death in women [78, 
79]. Conversely, the contribution of OSA to 
hypertension has been shown to be lower in women 
versus men [80]. 
The ability of CPAP treatment to improve outcomes 
in females has not been studied as extensively as in 
males. A prospective study by Campos-Rodriguez et 
al. evaluated the long-term outcomes of OSA in 
treated and non-treated female patients. They found 
that severe OSA was associated with increased 
cardiovascular mortality risk (adjusted hazard ratio 
3.50, 95% CI 1.23–9.98) and that adequate CPAP 
treatment may reduce this risk [78]. 
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In summary, the limited data available suggest that 
although the prevalence and severity of OSA may be 
lower in women than in men, the consequences of 
the disease are at least the same, if not worse [63]. 
8. OSA Treatment 
In 2006, the American Academy of Sleep Medicine 
(AASM) reviewed all available evidence for CPAP and 
concluded that treatment was effective in improving 
quality of life in severe and moderate OSA, but there 
was insufficient evidence for the effectiveness of 
CPAP in mild OSA [81]. More recent data showed 
that CPAP treatment significantly improved quality of 
life compared with sham treatment in 223 mild-
moderate patients (AHI 5–30/h) [82]. In addition, 
CPAP treatment was associated with significant 
improvements in quality of life in female OSA 
patients on a number of measures including daytime 
functioning, activity levels, daytime sleepiness, mood 
disturbances, and impact of sickness on daily life 
[63]. Campos-Rodriguez et al. recently published the 
first study to review the quality of life impact of CPAP 
treatment in women with moderate-to-severe OSA. 
Compared with the control group, the CPAP group 
had significantly greater improvements in all quality 
of life measures, including sleepiness 
(𝑝 < 0.001), mood (𝑝 = 0.012), anxiety (𝑝 = 0.014), 
and depression (𝑝 = 0.016) [83]. 
Craig et al. randomized 391 non-sleepy mild OSA 
patients 
toCPAPtherapyorstandardcarefor6monthsandfoundt
hat CPAP improved daytime sleepiness (based on ESS 
scores), objective sleepiness, and self-assessed 
health status (SF36), but not vascular health risk [84]. 
Interestingly, Craig et al. found no relationship 
between OSA severity and improved quality of life, 
indicating that the severity of OSA may not 
accurately predict CPAP effectiveness. In 2016, the 
American Thoracic Society again reviewed the 
evidence available for CPAP treatment of mild OSA. 
They concluded that patients with sleepiness may 
benefit from treatment and that CPAP may also 
improve quality of life. They found that there was 
still insufficient evidence to understand the impact of 
mild OSA treatment on cardiovascular events, stroke, 
and arrhythmias [17]. 
8.1. Gender Differences in OSA Treatment. Sex 
differences in the response to different OSA 
treatment strategies have not been extensively 
studied to date. The limited data available indicate 
that usage is similar between males and females. A 
review of a database of 4281 patients found that 
average daily CPAP usage in male patients was 
slightly higher than in female patients; however, 
average usage time in both genders was high 
(377±94 versus 370±96 min) [85]. A similar analysis 
followed up a group of 708 women for a median of 
6.2 (4.2– 7.7) years. Overall long-term compliance 
with treatment was good in female patients, with 
median daily usage of 6 hours per day (interquartile 
range 4–7); 82.8% of patients were still using CPAP 
BioMed Research International 162 
162 
 
after 5 years, and 79.9% were still on CPAP at 10 
years [86]. 
Clinical trials have indicated that males require 
higher CPAP pressure than females, after adjusting 
for baseline OSA severity and BMI [87, 88]. However, 
there do not appear to be differences between men 
and women in the types of interfaces used for CPAP 
or overall satisfaction with mask treatment [89]. 
Given that there are marked differences between 
men and women in the physiology and presentation 
of OSA, it is possible that treatment options 
specifically targeting female presentations of OSA 
may result in better treatment outcomes for these 
patients [85, 87, 88]. One recent bench test has 
found that there are significant differences in the 
way commercially available CPAP devices respond to 
flow limitation common in female patients [90]. 
Personalized medicine has not made major inroads 
into OSA, despite the potentially different gender 
and potential symptom specific phenotypes [91]. 
One commercially available CPAP device contains an 
algorithm which aims to address female-specific OSA 
characteristics. This device was tested in a 
randomized, double-blind, crossover clinical trial and 
was found to be as effective as standard CPAP, with a 
significant reduction in residual flow limitation and 
lower mean pressures [92]. An ongoing clinical study 
is investigating the use of this device on quality of life 
in women, with outcome measures including daily 
functioning, sleepiness, depression, sexual function, 
and sleep quality (NCT02400073). 
Non-CPAP treatments have rarely been studied for 
gender specific effects. Mild patients are often 
instructed to lose weight; however, this may be more 
beneficial for males than females based on the fat 
distribution in the upper airway of males [93]. 
Mandibular Advancement Devices (MADs) are a 
treatment option for those with mild-moderate OSA 
or those who have rejected CPAP. One large study 
found that female gender was a predictor of MAD 
treatment success, particularly when OSA was mild 
[94]. However, more research is needed in this area. 
9. Conclusion 
A growing body of evidence suggests that there are 
substantial differences between females and males 
in the symptoms, diagnosis, and consequences of 
OSA. The majority of existing data relate to 
populations with a predominance of males, 
particularly with respect to treatment. Better 
knowledge of gender differences in OSA will help to 
improve the awareness and diagnosis of OSA in 
women, and the development and availability of 
therapeutic options that take into account 
differences in the physiology and presentation of 
OSA in women could have the potential to improve 
outcomes for these patients. 
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ABSTRACT 
Historically OSA has been regarded as a male disease. Therefore, much of our knowledge comes from 
studies with largely male populations. Growing evidence suggests that there are significantly different 
gender aspects of OSA. The symptoms of OSA may manifest differently in female patients, and females tend 
to be diagnosed and treated less often, despite reporting worse quality of life outcomes. Comparisons of 
polysomnography data have shown that women appear to have less severe OSA overall with a higher 
incidence of flow limitation and REM related events. Severe OSA in women appears to be associated with 
cardiovascular morbidity and mortality, and effective treatment may reduce this risk. Researchers are 
beginning to understand more about gender differences in OSA, and the optimal treatment for these 
patients, although more research in this field is still needed. 
PREVALENCE 
Obstructive sleep apnea (OSA) is a condition during which the upper airway closes repetitively during 
sleep. Airway closures are identified as either apneas (full upper airway closure) or hypopnoea as (partial 
Gr   up SM 
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upper airway closure), where the event is associated with oxygen desaturation and /or arousal from sleep. 
The count of events per hour; the apnea hypopnea index (AHI), indicates the severity of the disorder.  
The estimated prevalence of OSA changes depending on which scoring criteria are used. Table 1 displays 
the estimated population prevalence of OSA in males and females. 
Table 1: Estimated population prevalence of OSA. 
Study Mild OSA (AHI ≥ 5) Moderate to severe OSA (AHI ≥ 15) 
 Males Females Males Females 
Young et al (1993) [2] 24% 9% 9% 4% 
Redline et al (1994) [5]* - - 26% 13% 
Bixleret al (1998, 2001) [64,65] 17% - 7% 2% 
Duran et al (2001) [66] 26.2% 28% 14% 7% 
Peppard et al (2013) [67] - - 13.5% 6% 
Franklin et al (2013) [33]^# - 50% - 26% 
Heinzeret al (2015)# 34% 38% 49.7% 23.4% 
*Respiratory Disturbance Index (RDI) rather than AHI given. 
^ Women aged 20-70 years. 
#An updated scoring criteria (AASM 2012) was used. 
The prevalence of OSA has been increasingly steadily, in part due to the global rise in obesity, and also 
due to an update to the recommended OSA scoring rules which were published in 2012 and allow a more 
liberal scoring of hypopnoeas [1]. 
CLINICAL FEATURES  
While the prevalence of OSA in males is reported to be higher than that of females, there is a much higher 
discrepancy between the genders in the clinical population. OSA is estimated to have a male to female ratio 
of between 3:1 and 5:1 in the general population and between 8:1 and 10:1 in some clinical populations [2-
5].  
It has been hypothesised that the large discrepancy between the population prevalence of OSA, and the 
clinical populations is due to women being frequently misdiagnosed [4,6]. Women often present with 
different symptoms than what are considered the “typical” symptoms of sleep apnea [4,7]. The typical 
symptoms that men with sleep apnea present with are snoring, witnessed apneas and excessive daytime 
sleepiness. However approximately 40% of women with an AHI ≥ 15 do not report any of the classic OSA 
[8]. Instead women are likely to complain of insomnia, fatigue, daytime tiredness, headaches, muscle pain 
and depression [4,9,10].  As a result, women are frequently misdiagnosed with depression or another 
illness [4,9]. In addition, women typically have lower scores than men on the Epworth sleepiness scale 
(ESS), a questionnaire designed to evaluate daytime sleepiness which is often used as a screening tool for 
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OSA [11,12]. The ESS has not been validated for use in female OSA patients, and indeed in population based 
studies OSA has not been strongly associated with daytime sleepiness in female patients [11,12]. It is 
hypothesized that women may use different words to describe sleepiness, and answer questions on 
sleepiness differently from men. Or they may have a higher threshold for sleepiness or simply be less 
inclined to complain about it [4]. 
Men often attend clinical appointments with their partner, whereas women are more likely to attend on 
their own [3,4]. This may mean that perhaps apneas in women are less frequently reported [3], or that male 
partners tend to be less concerned about the events [13]. It has also been hypothesized that women may 
be reluctant to complain about disturbed sleep and their own snoring, if they consider it unladylike or 
embarrassing [4]. 
Regardless of the symptoms which patients present with, Young and colleagues found that even when 
women did report the same classic symptoms of OSA, such as snoring, witnessed apneas and excessive 
daytime sleepiness, they were still less likely to be referred to sleep clinics than men. They raised the issue 
that physicians tend to disregard these typical symptoms in women [6]. Similar results were recently 
reported by Lindberg et al, who found that women were underrepresented at sleep clinics, and despite 
similar symptoms to males, less likely to be diagnosed or treated with OSA [14]. 
GENDER DIFFERENCES IN POLYSOMNOGRAPHY  
Recent studies have shown that the polysomnography (PSG) features of female OSA are different from 
male OSA. Overall, women have less severe OSA with lower AHIs [15] and shorter apneas [16]. Although 
overall women have lower AHIs than males, research has shown that women are more symptomatic at 
lower AHI’s than males with a similar diseases severity [6]. 
One reason women are more symptomatic may be because women have more episodes of upper airway 
resistance [17]. Obstructive events can be thought of as a continuum of partial to complete upper airway 
obstruction. Upper airway resistance occurs early in this spectrum, and refers to incidences where there 
are increases in resistance to airflow in the upper airway during sleep, presenting as flow limitation on a 
PSG [18].This upper airway narrowing has the potential to increase work of breathing, cause arousals and 
disrupted sleep, and effect daytime cognitive function [18]. Upper airway resistance alone, without 
complete obstructive apnea, has been shown to produce clinical symptoms such as daytime fatigue and 
depression [19]. 
As females may have multiple episodes of upper airway resistance without frank apneas, the AHI value 
may not give the physician a true indication of the degree of sleep fragmentation a patient is experiencing. 
As a result, episodes during sleep where the flow is reduced; respiratory effort increases; and the episode 
is terminated by an arousal have been coined Respiratory Effort Related Arousals (RERAs) [18]. The 
importance of measuring and reporting on RERAs has been emphasised by a task force of the American 
Academy of Sleep Medicine (AASM) in 2007[20]. Updates to the recommended scoring criteria by the AASM 
in 2012 meant that hypopnoeas could be defined by an arousal only, with no requirement for oxygen 
desaturation [1]. This broader definition means that less RERAs are scored and more female patients may 
now be diagnosed with OSA, who previously may not have met the requirements for hypopnoeas. This is 
likely reflected in the increase in the prevalence of female OSA seen in recent studies. 
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Women often have events mainly occurring during REM sleep [15]. Body position is far less important 
for the severity of OSA in women, while with men the severity is more based on position than sleep state 
[15]. In fact a study by O’Connor and colleagues found that in a group of 830 patients, positional OSA  was 
almost exclusively a male presentation [15]. 
Sleep architecture is also different in healthy men and women with sleep apnea. A study of 307 patients 
by Valencia-Flores and colleagues found that women took longer to fall asleep than males. Once women 
were asleep, they then had fewer awakenings from sleep, and had slower wave (deep) sleep than males 
[21]. 
GENDER DIFFERENCES IN PATHOPHYSIOLOGY 
In women, the neck and upper airway are smaller in size than in men [4]. MRI imaging has shown that 
the airway length, the tongue, the soft palate, and the total amount of soft tissue in the throat are all smaller 
in women than men [22]. Although common sense would dictate that a smaller airway size would collapse 
more easily than a larger one, this isn’t the case. The pharyngeal critical closing pressure, or Pcrit, is lower 
in women with sleep apnea than men with the same severity of obstructive sleep apnea, meaning that the 
airway of males is more collapsible than that of females [4,23].  
Obstructive sleep apnea has long been associated with obesity, and in both genders increased body mass 
index indicates a higher severity of the disease [24]. However women with OSA are typically more obese 
than men who have the same AHI [9]. One possible explanation for this is the differences in fat distributions 
between the genders. Men tend to put on weight in the upper body and trunk, including the upper airway 
soft tissue structures – the tongue, soft palate, and lateral pharyngeal walls; whereas when women put on 
weight it tends to be deposited in the lower body and extremities [4]. Newman and colleagues showed that 
small weight changes influence sleep disordered breathing in men more than in women as men may reduce 
fatty tissue in the upper airway more readily [25]. Fat distribution also affects the lungs in different ways 
between men and women. Women are better able to cope with an increased chest wall load, because with 
increased obesity women have improved chemosensitivity responses to hypoxia and hypercapnia [22]. 
Respiratory stability refers to efficacy of gas exchange, blood circulation and the functioning of central 
and peripheral chemoreceptors. There are distinctive differences between the efficacy of respiratory 
stability in men and women [4]. The response to low oxygen in the blood (hypoxia) declines in men during 
sleep compared with their awake values, whereas in women the hypoxia response is similar between sleep 
and wake [26]. Men have been shown to have a more significant ventilatory response to high levels of 
carbon dioxide in the blood (hypercapnia) [27]. Zhou and colleagues showed that men and women require 
different levels of carbon dioxide in the blood to cause respiratory instability, and that men are more 
susceptible to hypocapnic dysfunction during NREM sleep than women. This may be due to the notion that 
women preserve ventilation output during hypocapnia more efficiently than men [28]. Taken together, this 
may mean that women are better able to stabilise their breathing during sleep, leading to less severe apneas 
with minimal desaturation. 
There may also be gender differences in the arousal response patients have to apneas. Jordan and 
colleagues found that during NREM men had a higher ventilatory response to apneas, but then they 
developed a greater hypoventilation when they went back to sleep, especially in the supine position. This 
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prolonged hypoventilation often leads to ventilatory instability upon returning to sleep. The result can be 
a cycle of respiratory instability leading to consecutive apneas during sleep. Jordan and colleagues 
hypothesised that this may play a role in explaining why sleep apnea is more severe in men [29]. However 
the same authors also found that loop gain was not different in males and females matched for AHI and 
BMI, and therefore respiratory control stability may be less significant than reduced upper airway 
collapsibility in female patients [30]. 
The prevalence of sleep apnea increases in post-menopausal women [9]. One reason for this increase 
may be that menstrual hormones play a role in the distribution of body fat. Post menopausal women have 
more body fat than menstruating women, and that body fat is distributed in similar areas to males, which 
is the upper body, specifically the trunk and neck [31]. A second reason that post menopausal women have 
increased incidence of sleep apnea may be due to the hormone progesterone. Progesterone is a known 
respiratory stimulant which increases chemoreceptor responses to hypercapnia and hypoxia and has also 
been shown to increase upper airway muscle tone [32]. 
HEALTH CONSEQUENCES OF OSA IN FEMALES 
In the past, obstructive sleep apnoea (OSA) has been primarily considered a male disorder, and as a 
result clinical trial populations were comprised almost entirely of males [33]. Recently studies have focused 
more specifically on the unique consequences of OSA in female patients.  
Several comparisons of women and men with untreated OSA have found that women experience a 
worsened quality of life. Women experience more mood disturbances such as anxiety and depression, 
report lower quality of life scores on a range of questionnaires, display increased daytime fatigue, reduced 
sleep quality and worsened neurobehavioral symptoms [34-37]. This worsened quality of life found in 
female patients may well be a reflection of the more severe flow limitation and sleep fragmentation seen in 
many women patients. Basically sleep physiology tells us that constant arousals during sleep in healthy 
subjects severely impacts daytime cognitive performance [38]. And indeed arousals from sleep without 
corresponding oxygen desaturation have been associated with a range of consequences including tiredness, 
fatigue and sleepiness [39]; significant daytime impairment, difficulty completing tasks, depressed mood 
and insomnia [40]. 
Women with OSA were also found to be more likely to develop hypothyroidism and arthropathy, as well 
as experience lower perceived health status, overuse psychoactive drugs, and experience increased 
healthcare costs of 1.3 times compared with men with OSA [36]. 
Yaffee al. studied a group of women with sleep disordered breathing (SDB) and found that they were 
more likely to develop cognitive impairment or dementia than those without the condition. They found that 
cognitive issues were more likely to develop in those with increased oxygen desaturation and higher 
periods of time spent in apnea or hypopnoea [41]. Further research undertaken by Macey and colleagues 
discovered that female OSA patients experienced more brain white matter injury than their male 
counterparts [35]. It is hypothesised, although not yet known, that this change in white matter structure 
may be responsible for the worsened quality of life reported by women.  
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Endothelial function, peak blood flow, systemic inflammation, and digital vascular function have been 
found to be more impaired in females than males with OSA [42-44]. These blunted responses may mean 
that women with OSA are more susceptible to the adverse cardiovascular consequences of OSA than males 
[44]. The association between OSA and hypertension in females is not conclusive, with some studies 
showing no association [45,46], and some studies finding an association in peri-menopausal and older 
females [47,48]. The largest dataset published to date included 1 704 905 patients with OSA and 1 704 417 
matched controls. The authors reported that hypertension was more prevalent in women with OSA than 
males with OSA, with an overall odds ratio of developing hypertension of 2.14 in the OSA group compared 
with controls [49].  
The same data set found that congestive heart failure was strongly associated with OSA in both sexes 
compare with controls (p<0.000) with no clear sex differences [49]. A prospective study by Campos-
Rodriguez et al. evaluated the long term outcomes of OSA in a group of treated and nontreated female 
patients. They found that severe OSA was associated with increased cardiovascular mortality risk (adjusted 
HR 3.50, 95% CI 1.23-9.98), and that adequate CPAP treatment may reduce this risk [10].  
THE ROLE OF PREGNANCY  
Pregnancy may also increase the risk of developing OSA. During a typical pregnancy, elevation of the 
diaphragm leads to reduced functional residual capacity, the upper airway narrows, neck circumference 
enlarges, nasal patency is reduced, and there is substantial weight gain. All of these factors suggest 
pregnancy may induce or exacerbate OSA [4]. Conversely, pregnant women may be more protected from 
OSA, with increased levels of female sexual hormones stimulating respiration [50]. 
While the effect of OSA on pregnancy outcome is not completely understood, some studies have found 
that OSA is associated with higher rates of pre-eclampsia and intra-uterine growth retardation [51]. An 
ongoing study in this area will enrol 3702 women to understand the prevalence and outcomes of OSA 
during pregnancy [52]. Preliminary data from this group found that OSA affects 8.1% of pregnant women 
by the second trimester, and that there was an association between OSA and hypertension and diabetes in 
this group [53]. 
TREATMENT OF OSA IN FEMALES 
The treatment of choice for OSA is continuous positive airway pressure (CPAP). CPAP attaches to the 
user with a mask and tubing, and circulates air to increase pressure in the upper airway. The result is a 
pneumatic splint which holds the airway open and prevents collapse. Effective treatment with CPAP has 
been shown to improve symptoms and reduce health risks in OSA patients [54]. 
Personalized medicine has not yet made major inroads into OSA treatments. However due to the 
different structures and pathologies involved in the disease, personalized diagnostic methods and 
treatments should be introduced as a way to improve patient care [55]. Sex differences in the use and 
response to CPAP devices are one example of personalized treatment which has not been extensively 
studied to date. A review of a database of 4281 patients found that average daily CPAP usage in male 
patients was slightly higher than in female patients, however usage in both genders was high (377 ± 94 vs. 
370 ± 96) [56]. A similar analysis followed a group of 708 women for a median of 6.2 (4.2-7.7) years. Overall 
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long term compliance to treatment was good in female patients, with a median daily usage of 6 (IQR 4-7) 
hours per day. 82.8% were still using CPAP after 5 years, and 79.9% were still on CPAP at 10 years [57]. 
The first study to investigate the role of CPAP therapy on quality of life in only female patients has 
recently been published. The authors studied 307 women with moderate to severe OSA and found that 
three months CPAP use improved quality of life, anxiety, depression, mood and daytime symptoms 
compared with controls [58]. 
Few studies have focused on the physiological differences in women when considering treatments. 
Clinical trial data suggest that men require higher pressures during CPAP therapy than females, after 
adjusting for baseline OSA severity or BMI [56,59,60]. One recent bench test has found that there are 
significant differences in the way commercially available CPAP devices respond to flow limitation common 
in female patients [61]. One CPAP device contains an algorithm which aims to address female specific OSA 
characteristics. This device was tested in a randomised, double-blind, cross-over clinical trial and was found 
to be as efficacious as a standard CPAP with a significant reduction in residual flow limitation and lower 
mean pressures [62]. An on-going clinical study is investigating the use of this device on quality of life in 
women, with outcome measures including daily functioning; sleepiness; depression; sexual function and 
sleep quality (clinicaltrials.gov registration: NCT02400073). 
Non CPAP treatments have rarely been studied for gender specific effects. Weight loss is a common 
recommendation for mild patients; however this may be more beneficial to males than females based on 
the fat distribution in the upper airway of males [25]. Mandibular Advancement Devices (MADs) are a 
treatment option for those with mild-moderate OSA or those who have rejected CPAP. One large study 
found female gender was a predictor of treatment success, particularly in the mild group [63]. However 
more research is needed in this area. 
CONCLUSION 
Historically, our understandings of OSA and its treatments have been largely focused on male patients. 
There are clear gender differences in all aspects of OSA, including prevalence; symptoms; clinical 
recognition; anatomy (Including the upper airway, as well as obesity and fat distribution); physiology & 
pathophysiology (Including sleep architecture & respiratory stability) and the influence of hormones. 
Knowledge is coming to light that there may also be differences in long term consequences and 
cardiovascular outcomes of female OSA. Additionally, there may be requirements for gender specific 
treatment options. More research is required to complete our understanding of the gender differences in 
OSA and the optimal treatment for patients.  
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ABSTRACT  
Evidence-based treatment of mild obstructive sleep apnea (OSA) is hindered by a lack of research, 
specifically whether continuous positive airway pressure (CPAP) treatment is beneficial in this group. 
In addition, definitions of respiratory events are not always consistent. The American Academy of 
Sleep Medicine (AASM) definition of hypopnea was revised in 2012, resulting in a significant increase 
in the number of patients meeting diagnostic criteria for mild OSA. The MERGE study is a multicenter, 
randomized, controlled clinical trial designed to investigate the efficacy of CPAP treatment in mild 
OSA, focusing on the AASM 2012 criteria to define disease severity. Patients with mild OSA, defined 
using both AASM 2007 and 2012 criteria, will be randomized to receive 3 months’ treatment with 
either standard care (sleep hygiene counseling) alone or CPAP plus standard care. The primary 
outcome is change in the Energy and Vitality subscale of the Short Form-36 from baseline to three 
months in patients with mild OSA (apnea-hypopnea index 5–15/h) based on the AASM 2012 scoring 
criteria. The MERGE study will be the first randomized controlled trial to investigate the impact of 
CPAP treatment on symptoms and quality of life in patients with mild OSA according to the AASM 
2012 criteria. It is hoped that the findings will provide evidence to inform physicians and policy makers 
about how to manage mild OSA in clinical practice. 
 
Keywords: continuous positive airway pressure; obstructive sleep apnea; quality of life; study design; 
randomized controlled trial; treatment adherence  
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1. Introduction 
The severity of obstructive sleep apnea (OSA) is conventionally defined using the number of 
disordered breathing events per hour of sleep (the apnea-hypopnea index [AHI]): mild when the AHI 
is 5–<15/h, moderate when AHI 15–<30/h, or severe when AHI is ≥30/h. However, the definition of 
AHI has evolved over time making development of clear guidelines difficult. 
Moderate and severe OSA have been associated with increased risk of motor vehicle 
accidents, impaired cognitive function, reduced quality of life (QoL), and diseases such as 
hypertension, diabetes, stroke and cardiovascular morbidity (52, 54-57). In this setting, continuous 
positive airway pressure (CPAP) is an effective treatment, improving symptoms and reducing health 
risks (54, 57-61). Despite this, mild OSA has not been extensively studied. There is some evidence 
that low levels of sleep-disordered breathing have a negative impact on hypertension (104, 105), 
cognitive function (106, 107), QoL (95, 108), and the risk of motor vehicle accidents (109). However, 
there is no agreement on the best approach to treating mild OSA (95, 172). In terms of QoL, there is a 
lack of data on the effectiveness of CPAP in mild OSA (58), but it may be useful in this setting if QoL 
is impaired and other treatments have failed (234), or in the presence of sleepiness (95). 
Interpretation of data from studies evaluating CPAP in patients with mild OSA is complicated 
by the fact that definitions of hypopneas have changed over time. The 2007 American Academy of 
Sleep Medicine (AASM) criteria defined hypopnea as a ≥30% decrease in oronasal airflow from 
baseline for ≥10 seconds with oxygen desaturation of ≥4% (1). In 2012, the AASM modified these 
criteria to allow scoring based on arousal only or with ≥3% oxygen desaturation (1) (Table 1). The 
rationale for updating the criteria was that some patients who experience frequent respiratory events 
and arousals (insufficient to cause significant hypoxia) were not captured using the 2007 criteria but 
may benefit from diagnosis and treatment (1). The change in scoring criteria markedly increases the 
number of patients achieving the diagnostic criteria for OSA, potentially by up to 40% (4, 5). 
The 2012 change to hypopnea scoring criteria remains controversial, partly due to the lack of 
objective evidence that patients with mild OSA based on these criteria will benefit from treatment. To 
date, no adequately powered randomized controlled trials have studied the benefits of CPAP 
treatment in this expanded group of mild OSA patients. Therefore, the minimum degree of OSA likely 
to benefit from CPAP therapy has not yet been defined.  
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The majority of studies conducted in mild OSA have used sleepiness as the primary endpoint. 
However, the term “sleepiness” may not adequately capture the feelings of general tiredness, fatigue, 
poor sleep, insomnia, and lack of energy often reported by patients with mild OSA (11, 90, 95). 
Therefore, the MERGE study has been designed to evaluate the effects of CPAP treatment on QoL in 
patients with mild OSA, using outcomes such as energy and vitality that may reflect patient-relevant 
improvements.   
 
2. Methods 
2.1 Study overview 
The MERGE study is a multicenter, randomized, controlled clinical trial (NCT02699463) 
designed to measure the response to CPAP using a patient-centered outcome, the Energy and 
Vitality subscale of the Short Form-36 (SF-36). A number of other QoL measures have also been 
included (e.g. fatigue, depression, anxiety and insomnia) in order to better understand the impact of 
treatment on OSA symptoms in patients diagnosed with mild disease. Patients will be provided with 
support to optimize adherence to CPAP, and a health economic analysis is included. The first patient 
was randomized in November 2016, and the study completed recruitment in February 2019. 
 
2.2 Setting 
 Recruitment to the MERGE study is via the UK respiratory sleep network 
(Table 2), which has delivered other randomized controlled trials in the UK (61, 175, 235, 236). The 
MERGE study is a collaboration with industry, which has provided equipment, funding and ongoing 
study support. Eleven centers throughout the UK are recruiting to the study. Each site has completed 
standardized study training, and sites communicate regularly, both by phone and in-person meetings, 
to share experiences and best practice findings.  
 
2.3 Eligibility criteria 
Patients are screened for OSA by their local sleep service using a home sleep test 
(polygraphy; Apnealink Air, ResMed). Those with an AHI of 5-15/h based on automated analysis 
using AASM 2007 criteria or an AHI 0-4.9/h using AASM 2007 but ≥5/h using AASM 2012 scoring and 
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who meet all other selection criteria (Table 3) are eligible for inclusion (Figure 1). Patients who 
provide informed consent have their polygraphy data uploaded to a central study server. 
 
2.4 Randomization 
Randomization (1:1 ratio) to standard care (sleep hygiene counseling) alone, or standard care 
plus auto-adjusting CPAP (AirSense 10 AutoSet; or AirSense 10 AutoSet for Her, ResMed)) is 
performed centrally using a computer-generated schedule, with stratification by age, gender, and 
body mass index (BMI).  
 
2.5 Blinding 
Neither the patients nor the investigators can be blinded due to the nature of the study 
interventions. However, assessment of sleep studies is automated (unbiased and consistent), and 
research staff assessing outcomes are independent from the study and study sponsor.  
 
3. Treatment intervention 
3.1 Standard care 
All patients are given sleep hygiene counseling, based on national guidelines and 
recommendations from the UK National Health Service. Patients receive standardized information on 
healthy sleep behaviors, such as spending adequate amounts of time in bed, and setting up a 
bedroom that is conducive to sleep. Patients are given a take-home sheet summarizing the main 
points of the consultation, and will receive a telephone call from a Central Support Laboratory three 
days later for a review of sleep hygiene behaviors.  
 
3.2 Auto-adjusting CPAP 
All patients use CPAP for a one-hour run-in at their local site as part of their eligibility testing. 
During this test, CPAP is slowly increased from 4 to 10cm H2O. Patients are able to change the CPAP 
mask and test different comfort and humidification settings. Participants randomized to the CPAP 
group are given CPAP education by the local clinical team and then provided with an auto-adjusting 
CPAP device for home use (AirSense 10/AirSense 10 for Her; ResMed). CPAP patients also receive 
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a phone call from the central laboratory after 3 days, with a focus on CPAP usage and 
troubleshooting any issues identified by the patient. During study therapy, changes to CPAP settings 
will be made based on standard clinical practice by the Central Support Laboratory.  
 
3.2.1 Supporting CPAP adherence 
A Central Support Laboratory has been set up in order to assist CPAP patients. Throughout 
the study, patients in the CPAP group are monitored using a telemedicine solution (AirView patient 
management system, ResMed). The online system receives data wirelessly from registered devices 
each day after overnight use. These data are regularly monitored by the Central Support Laboratory 
(at least twice per week). The Central Support Laboratory intervenes when compliance is low (<4 
h/night) for ≥3 consecutive nights, or when other issues are identified (e.g. high mask leak [>24 L/min] 
or suboptimal treatment [residual AHI ≥5/h]). If issues are identified, the Central Support Laboratory 
contacts the patient to discuss the issues and troubleshoot potential solutions. Contact is made via 
email, phone or video calls. Face-to-face visits are organized with the local sleep service if necessary. 
Patients are encouraged to contact the Central Support Laboratory at any time if they have any 
concerns. In addition to the ability to contact the Central Support Laboratory with any CPAP-related 
issues, patients are encouraged to use a web-based application (myAir, ResMed), which wirelessly 
collects data from the patient’s device and provides automated feedback, education, resources and 
coaching tips direct to the patient. 
 
4. Data collection and measures 
 At the first study visit, medical history and information on gender, age, 
ethnicity, height, weight, and neck circumference are collected, and patients are asked which 
symptoms prompted them to visit their health care provider. Patients also complete a range of QoL 
questionnaires: Short Form-36 (SF-36; 8 scales, and 2 domains [physical and mental composite]); 
Epworth Sleepiness Scale (ESS); Fatigue Severity Scale (FSS); Functional Outcomes of Sleep 
Questionnaire (FOSQ); Hospital Anxiety and Depression Scale (HADS); Insomnia Severity Index 
(ISI); and EuroQol five dimensions (EQ-5D). At the final study visit after 3 months’ treatment with 
standard care or standard care + CPAP, patients return to their local sleep service for the final study 
 182 
 
visit where they complete the same group of questionnaires as at baseline. Those in the treatment 
group will be asked if they wish to continue CPAP therapy.  
All sleep studies are scored using automated scoring algorithms based on both AASM 2007 
and AASM 2012 criteria. AASM 2007 scoring is done via AirView software (ResMed). This scoring 
algorithm has been shown to be consistent with manual polysomnography (PSG) scoring in several 
studies (189, 190, 237-241)_ENREF_11_ENREF_12_ENREF_15_ENREF_16. AASM 2012 scoring is 
done by an algorithm (ResMed) that is being concurrently validated in another clinical trial 
(clinicaltrials.gov ID: NCT03470493).  
 
5. Outcomes 
5.1 Primary outcomes 
 The primary endpoint is change from baseline to 3 months in the Energy and 
Vitality component of the SF-36 questionnaire in patients with mild OSA based on the AASM 2012 
scoring criteria.  
 
5.2 Secondary outcomes 
 Secondary endpoints are change from baseline to 3 months in patients with 
mild OSA based on either the AASM 2012 or AASM 2007 criteria in the following QoL measures: SF-
36; ESS; FSS; FOSQ; HADS; ISI; and EQ-5D.  
 
5.3 Health economics analysis 
The main objective of the health economics analysis will be to determine the cost 
effectiveness of CPAP treatment versus standard care for the management of mild OSA over an 
individual’s lifetime from the perspective of the publicly funded healthcare system. A Markov model 
will be developed, including health outcomes (health utility values, deaths) and costs over an 
individual’s life time using data collected within the trial and from published literature. The base case 
model will include two health states: mild OSA (treated with CPAP or standard of care) and death, 
with cycle lengths of 1 year. Various scenarios will be modelled including a number of relevant health 
states (stroke, cardiovascular disease, motor vehicle collision). Secondary objectives of the health 
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economic analysis are: to compare different utility-based QoL questionnaires and scoring algorithms 
(SF-6D and SF-12 utility scores taken from the SF-36, EQ-5D, and SF-12 utility mapping to EQ-5D) 
using patient-level data collected within the clinical study; and to calculate incremental cost-
effectiveness ratios for CPAP treatment versus standard care based on different utility-based QoL 
questionnaire and scoring algorithms. 
 
5.4 Sample size 
The sample size calculation was based on data from mild OSA patients in the Multicentre 
Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) study (175), 80% power and a 
two-sided significance level of 5%. It was calculated that a total of 224 patients (112 per group) would 
be required to detect a difference of 6.6 in mean score change (baseline to 3 months) on the Energy 
and Vitality subscale of the SF-36 questionnaire between the two treatment groups (CPAP mean 
10.817.0; standard care mean 4.218.1). Assuming a 10% dropout rate and enrolment of patients 
who meet the mild OSA criteria based on AASM 2007 but not 2012 criteria, target recruitment is set at 
300 participants. 
 
5.5 Statistical analysis 
 All statistical analyses will be performed on an intention-to-treat (ITT) basis 
including all randomized patients, using a Type 1 error rate of 0.05, unless otherwise specified. The 
ITT population will be divided into two overlapping subgroups: all randomized patients with mild OSA 
based on the AASM 2012 criteria, and those with mild OSA based on the 2007 criteria. Comparison of 
the CPAP and standard care groups at baseline will be performed using a student’s t-test or Wilcoxon 
signed rank test for continuous measures and Fisher’s exact test for categorical or binary measures, 
as appropriate. 
Homogeneity of the primary outcome across study sites will be assessed using a mixed-
effects regression model. The effect of a treatment-by-site interaction will be tested at a significance 
level of 0.10. The primary endpoint will be analyzed using a mixed-effects repeated measures model 
to account for missing values. In the case that the primary endpoint is not homogeneous across study 
sites, a treatment-by-visit-by-site interaction will be included in the model. Results will be presented as 
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the mean between-group difference in the change in Energy and Vitality score from baseline to 3 
months (adjusted for baseline score, as appropriate) with the associated 95% confidence interval (CI) 
and p-value. A sensitivity analysis of the primary outcome will be generated to include any baseline 
and demographic variables that were imbalanced between treatment groups using a mixed-effects 
repeated measures model to adjust the primary results for these factors.  
All secondary outcome measures for all randomized patients who complete the 3-month study 
visit will be analyzed in the same way as the primary outcome. These secondary analyses will be 
considered exploratory and no formal adjustments for multiple significance testing will be made.  
 
6. Protection of human subjects 
This study protocol has been approved by the Institutional Review Boards at each of the study 
centers. The study steering committee meet regularly and review any adverse events. All patients 
provide written informed consent prior to enrolment in the study. 
 
7. Discussion  
There is a need for reliable data on the effectiveness of CPAP treatment in patients with mild 
OSA, particularly as defined by the AASM 2012 scoring criteria and with a focus on patient-centered 
outcomes (e.g. QoL). The MERGE study has been designed to help address this data gap. We 
hypothesize that some patients with mild OSA will experience improved QoL during CPAP therapy, 
including those with disease severity defined using only the AASM 2012 criteria. If this is the case, the 
MERGE study results will provide evidence to support the consideration of CPAP for all patients with 
OSA, including those with the mildest disease. 
The SF-36 is a well validated and widely used generic QoL questionnaire (242). It has been 
used in previous studies to detect reduced QoL in OSA patients (243). One consideration when 
designing the MERGE study was whether SF-36 baseline values would actually be normal in patients 
with mild OSA, therefore excluding the possibility of any improvement with CPAP therapy. In a 
previous study of mild OSA patients, baseline FOSQ scores were within the normal range and did not 
improve significantly during CPAP therapy, although 62% of patients wanted to continue treatment at 
the end of the study (172). Those findings may also reflect the difficulty in measuring specific QoL 
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issues in patients with mild OSA, such as lack of energy and motivation rather than overt sleepiness. 
Therefore, we chose to use the Energy and Vitality dimension of the SF-36, as the primary endpoint in 
our study because this has consistently been shown to be the most sensitive dimension of the SF-36 
for measuring QoL improvements in mild OSA patients (174, 175, 244-246). Normative scores for the 
Energy and Vitality dimension of the SF-36 are reported to be 60.9 for the United States general 
population (247). For example, in a population of 90 OSA subjects, the mean SF-36 Energy and 
Vitality score before and after CPAP treatment was 40.1620.89 and 60.6820.58, respectively, which 
gave a normalized effect size of 0.98 (243). For patients in the CPAP treatment group of the MOSAIC 
study, who were considered non-sleepy at baseline, the SF-36 Energy and Vitality score effect size 
was 0.3 compared with control (mean scores at baseline and 6 months of 49.822.4 and 60.620.9, 
respectively) (175)); these figures were used in the sample size calculation for the MERGE study. The 
CPAP Apnea Study North American Program (CATNAP) trial included a large proportion of sleepy 
mild OSA patients and found that the SF-36 Energy and Vitality subscale showed an adjusted mean 
change from baseline of 12.7 with CPAP versus 6.1 in the sham CPAP group (174).  
Another consideration when designing the MERGE study was whether patients with mild OSA 
would tolerate, and therefore adhere to, CPAP therapy. A review of the evidence shows that CPAP 
can be used successfully by some asymptomatic patients. In a 12-month study of CPAP use in 
asymptomatic, non-sleepy patients with OSA, mean adherence was 4.7±2 h/night (248). At 4-year 
follow-up, those still using CPAP had median device usage of 5 h/night (interquartile range [IQR] 
2.18–6.25) and 64% had usage of >4 h/night (249). In the MOSAIC trial 71% of patients wanted to 
continue CPAP despite reporting normal levels of sleepiness at the beginning of the study (175). 
Taken together, these data suggest that mild asymptomatic patients may benefit from treatment e.g.: 
improvement in snoring, emotional wellbeing, relationships, and functioning (driving, working, study). 
Historically, clinical trials testing the efficacy of CPAP treatment have reported lower than 
desirable CPAP adherence (i.e. <4 h/night) (250-252). Factors that have shown to impact adherence 
include equipment (e.g. device, interface) (222), remote monitoring (253) and clinical support (254, 
255). Given that regular and ongoing usage is required for the benefits of therapy to be realized (227, 
231, 256-258), maximizing adherence to CPAP is a major focus of the MERGE study. Firstly, patients 
unable to tolerate a 1-hour CPAP trial are not included in the study. In addition, patients get regular 
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support from the Central Support Laboratory and telemonitoring solutions during the study, with the 
goal of maximizing device usage. 
The use of automated versus manual scoring of the diagnostic sleep study (polygraphy) was 
considered carefully when the MERGE trial was designed. The decision to use automated scoring 
was based on the reliability and repeatability of this approach (259). Specifically, the automated 
algorithm for scoring using AASM 2007 criteria has been validated in multiple studies (192, 195-197). 
Scoring based on the AASM 2012 criteria in MERGE uses a new algorithm (ResMed) that is 
concurrently being validated against PSG (clinicaltrials.gov ID: NCT03470493). To score hypopneas 
with arousal (and 3% oxygen desaturation), the new algorithm uses surrogate arousal measures that 
utilize airflow shape information and machine learning techniques. Surrogate arousal measures have 
found to accurately estimate arousals from sleep (198, 199). All automated scoring using the AASM 
2012 algorithm is reviewed by an expert to check for software errors in the scoring decisions. The 
choice was made not to use PSG in the MERGE study due to the pragmatic nature of home sleep 
testing and the desire to replicate common clinical practice in the UK National Health Service.  
In this study we defined the mild patient group as those with an AHI of 5-15, rather than 5- 
<15. This was to ensure that those patients who are borderline mild (with an AHI between 15 and 16), 
who switch between mild-moderate categories on a regular basis (and therefore may not be offered 
treatment based on a one-night sleep study) were included in the analysis.  
 
Conclusions 
The definition of mild OSA, which was revised in 2012 in an attempt to recognize the 
potentially detrimental effects of repetitive breathing-related arousals from sleep, is complex. An 
unintended outcome of the updated classification is that some healthcare professionals and providers 
have taken the decision not to offer CPAP treatment for mild OSA diagnosed based on AASM 2012 
criteria due to a lack of evidence that treatment of mild OSA could be beneficial. The MERGE study is 
a randomized controlled study that will assess, for the first time, whether CPAP treatment can 
improve quality of life in patients with mild OSA diagnosed using the AASM 2012 scoring criteria. The 
results of the study will indicate the clinical applicability of the updated scoring criteria and provide 
guidance for sleep professionals about disease classification and effective treatment options for 
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patients with mild OSA. If CPAP treatment is effective, the MERGE study will demonstrate the 
feasibility of a clinical model of assessment, treatment implementation, and ongoing CPAP therapy 
support in mild OSA patients.  
 
Study Steering Committee 
Mary J Morrell (chief investigator), John Stradling (chairperson), Alison Wimms, Julia Kelly, Peter 
Calverley (independent member), Sonya Craig, Alison McMillan, John O’Reilly, and Chris Turnbull.  
 
Acknowledgements 
This study is funded and sponsored by ResMed. Statistical analysis is conducted by Leslee Willes, 
Willes Consulting Group, Inc., Encinitas, California, U.S. Health economics analysis is conducted by 
Erika Penz, Department of Medicine, University of Saskatchewan, Canada. Editing assistance was 
provided by Nicola Ryan, independent medical writer, funded by ResMed.  
ResMed algorithm design and quality control was conducted by Ce Zhan, Dinesh Ramanan, Faizan 
Javed, Gordon Malouf, and Jeff Armitstead, ResMed Ltd, Sydney. Review of automated scoring was 
conducted by Peter Bateman, independent contractor, Stephen Emegbo, Aintree University Hospital, 
and Ana Gaspar, Lister Hospital, UK. 
 
Author contributions: The first draft of the manuscript was prepared by Alison Wimms, who 
designed the study in collaboration with all authors (Study Steering Committee). The manuscript was 
reviewed and edited by all the authors. All authors made the decision to submit the manuscript for 
publication and assume responsibility for the accuracy, completeness and fidelity of this report to the 
study protocol. 
 
Funding and management: This study was sponsored by ResMed Ltd, Sydney, Australia. The Chief 
Investigator and study team are based at National Heart and Lung Institute, Imperial College London, 
Royal Brompton and Harefield NHS Foundation Trust, London, UK. The study is managed by Oxford 
Respiratory Trials Unit, University of Oxford, UK. Statistical analysis is managed by Willes Consulting 
Group, Inc., California, U.S. 
 
 188 
 
References 
1. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, 
Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM, American Academy of Sleep 
M. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the 
Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task 
Force of the American Academy of Sleep Medicine. Journal of clinical sleep medicine : JCSM : 
official publication of the American Academy of Sleep Medicine 2012; 8: 597-619. 
2. Iber C A-IS, Chesson AL Jr., Quan SF; for the American Academy, Medicine. oS. The AASM manual 
for the scoring of sleep and associated events: rules, terminology and technical 
specifications. 1st ed. Westchester, IL. American Academy of Sleep Medicine 2007. 
3. Force. AAoSMT. Sleep-related breathing disorders in adults: recommendations for syndrome 
definition and measurement techniques in clinical research. The Report of an American 
Academy of Sleep Medicine Task Force. Sleep Breath 1999; 22: 667-689. 
4. Guilleminault C, Hagen CC, Huynh NT. Comparison of hypopnea definitions in lean patients with 
known obstructive sleep apnea hypopnea syndrome (OSAHS). Sleep Breath 2009; 13: 341-
347. 
5. BaHammam AS, Obeidat A, Barataman K, Bahammam SA, Olaish AH, Sharif MM. A comparison 
between the AASM 2012 and 2007 definitions for detecting hypopnea. Sleep Breath 2014; 
18: 767-773. 
6. Ruehland WR, Rochford PD, O'Donoghue FJ, Pierce RJ, Singh P, Thornton AT. The new AASM 
criteria for scoring hypopneas: impact on the apnea hypopnea index. Sleep 2009; 32: 150-
157. 
7. Ho V, Crainiceanu CM, Punjabi NM, Redline S, Gottlieb DJ. Calibration Model for Apnea-Hypopnea 
Indices: Impact of Alternative Criteria for Hypopneas. Sleep 2015; 38: 1887-1892. 
8. Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. 
The upper airway resistance syndrome. Chest 1993; 104: 781-787. 
9. Lavie P. Who was the first to use the term Pickwickian in connection with sleepy patients? History 
of sleep apnoea syndrome. Sleep medicine reviews 2008; 12: 5-17. 
10. Cracowski C, Pepin JL, Wuyam B, Levy P. Characterization of obstructive nonapneic respiratory 
events in moderate sleep apnea syndrome. American journal of respiratory and critical care 
medicine 2001; 164: 944-948. 
11. Pepin JL, Guillot M, Tamisier R, Levy P. The upper airway resistance syndrome. Respiration 2012; 
83: 559-566. 
12. Ayappa I, Norman RG, Krieger AC, Rosen A, O'Malley R L, Rapoport DM. Non-Invasive detection 
of respiratory effort-related arousals (REras) by a nasal cannula/pressure transducer system. 
Sleep 2000; 23: 763-771. 
 189 
 
13. Hoffstein V. Chapter 83 Snoring and Upper Airway Resistance. In: Kryger M, Roth D, Dement w, 
editors. Principles and Practice of Sleep Medicine. Philadelphia: Elsevier Saunders; 2005. p. 
1001-1012. 
14. International Classification of Sleep Disorders: Diagnostic and Coding Manual (ICD-2). 2005. 
American Academy of Sleep Medicine. 2005. 
15. Franklin KA, Sahlin C, Stenlund H, Lindberg E. Sleep apnoea is a common occurrence in females. 
Eur Respir J 2012. 
16. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered 
breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-1235. 
17. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased Prevalence of Sleep-
Disordered Breathing in Adults. Am J Epidemiol 2013; 1779: 1006-1014. 
18. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, 
Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J. Prevalence of sleep-
disordered breathing in the general population: the HypnoLaus study. The Lancet 
Respiratory medicine 2015. 
19. Redline S, Kump K, Tishler PV, Browner I, Ferrette V. Gender differences in sleep disordered 
breathing in a community-based sample. American journal of respiratory and critical care 
medicine 1994; 149: 722-726. 
20. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. 
Prevalence and severity. American journal of respiratory and critical care medicine 1998; 
157: 144-148. 
21. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, Kales A. Prevalence of sleep-
disordered breathing in women: effects of gender. American journal of respiratory and 
critical care medicine 2001; 163: 608-613. 
22. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical 
features in a population-based sample of subjects aged 30 to 70 yr. American journal of 
respiratory and critical care medicine 2001; 163: 685-689. 
23. Lin CM, Davidson TM, Ancoli-Israel S. Gender differences in obstructive sleep apnea and 
treatment implications. Sleep medicine reviews 2008; 12: 481-496. 
24. Valipour A. Gender-related differences in the obstructive sleep apnea syndrome. Pneumologie 
(Stuttgart, Germany) 2012; 66: 584-588. 
25. Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, Almeida-Gonzalez C, Catalan-
Serra P, Montserrat JM. Cardiovascular mortality in women with obstructive sleep apnea 
with or without continuous positive airway pressure treatment: a cohort study. Ann Intern 
Med 2012; 156: 115-122. 
 190 
 
26. Cairns A, Poulos G, Bogan R. Sex differences in sleep apnea predictors and outcomes from home 
sleep apnea testing. Nature and science of sleep 2016; 8: 197-205. 
27. Hilmisson H, Sveinsdottir E, Lange N, Magnusdottir S. Insomnia symptoms in primary care: A 
prospective study focusing on prevalence of undiagnosed co-morbid sleep disordered 
breathing. European journal of internal medicine 2019. 
28. Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P. Gender-related differences 
in symptoms of patients with suspected breathing disorders in sleep: a clinical population 
study using the sleep disorders questionnaire. Sleep 2007; 30: 312-319. 
29. Ye L, Pien GW, Ratcliffe SJ, Weaver TE. Gender differences in obstructive sleep apnea and 
treatment response to continuous positive airway pressure. Journal of clinical sleep medicine 
: JCSM : official publication of the American Academy of Sleep Medicine 2009; 5: 512-518. 
30. Macey PM, Kumar R, Yan-Go FL, Woo MA, Harper RM. Sex differences in white matter alterations 
accompanying obstructive sleep apnea. Sleep 2012; 35: 1603-1613. 
31. Baldwin CM, Kapur VK, Holberg CJ, Rosen C, Nieto FJ. Associations between gender and 
measures of daytime somnolence in the Sleep Heart Health Study. Sleep 2004; 27: 305-311. 
32. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 
1991; 14: 540-545. 
33. Chiner E, Arriero JM, Signes-Costa J, Marco J, Fuentes I. [Validation of the Spanish version of the 
Epworth Sleepiness Scale in patients with a sleep apnea syndrome]. Arch Bronconeumol 
1999; 35: 422-427. 
34. Chervin RD, Aldrich MS, Pickett R, Guilleminault C. Comparison of the results of the Epworth 
Sleepiness Scale and the Multiple Sleep Latency Test. Journal of psychosomatic research 
1997; 42: 145-155. 
35. Young T. Rationale, design and findings from the Wisconsin Sleep Cohort Study: Toward 
understanding the total societal burden of sleep disordered breathing. Sleep Med Clin 2009; 
4: 37-46. 
36. Morrell MJ, Finn L, McMillan A, Peppard PE. The impact of ageing and sex on the association 
between sleepiness and sleep disordered breathing. European Respiratory Journal 2012; 40: 
386-393. 
37. Franklin KA, Sahlin C, Stenlund H, Lindberg E. Sleep apnoea is a common occurrence in females. 
The European respiratory journal 2013; 41: 610-615. 
38. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to 
patients with multiple sclerosis and systemic lupus erythematosus. Archives of neurology 
1989; 46: 1121-1123. 
39. Kim SA, Koo BB, Kim DE, Hwangbo Y, Yang KI. Factors affecting fatigue severity in patients with 
obstructive sleep apnea. The clinical respiratory journal 2017; 11: 1045-1051. 
 191 
 
40. Pallansch J, Li Y, Bena J, Wang L, Foldvary-Schaefer N. Patient-Reported Outcomes in Older 
Adults With Obstructive Sleep Apnea Treated With Continuous Positive Airway Pressure 
Therapy. Journal of clinical sleep medicine : JCSM : official publication of the American 
Academy of Sleep Medicine 2018; 14: 215-222. 
41. Wang Y, Ai L, Luo J, Li R, Chai Y, He X, Cao Y, Li Y. Effect of adherence on daytime sleepiness, 
fatigue, depression and sleep quality in the obstructive sleep apnea/hypopnea syndrome 
patients undertaking nasal continuous positive airway pressure therapy. Patient preference 
and adherence 2017; 11: 769-779. 
42. Gavrilov YV, Shkilnyuk GG, Valko PO, Stolyarov ID, Ivashkova EV, Ilves AG, Nikiforova IG, 
Shchelkova OY, Vasserman LI, Vais EE, Valko Y. Validation of the Russian version of the 
Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients. Acta 
neurologica Scandinavica 2018; 138: 408-416. 
43. Rosti-Otajarvi E, Hamalainen P, Wiksten A, Hakkarainen T, Ruutiainen J. Validity and reliability of 
the Fatigue Severity Scale in Finnish multiple sclerosis patients. Brain and behavior 2017; 7: 
e00743. 
44. Jason LA, Evans M, Brown M, Porter N, Brown A, Hunnell J, Anderson V, Lerch A. Fatigue Scales 
and Chronic Fatigue Syndrome: Issues of Sensitivity and Specificity. Disability studies 
quarterly 2011; 31. 
45. A.J W, A M, Benjafield AV. Screening questionnaires and symptoms in female obstructive sleep 
apnea patients. . Journal of Sleep Research 2018; 27: 103. P161. 
46. Quintana-Gallego E, Carmona-Bernal C, Capote F, Sanchez-Armengol A, Botebol-Benhamou G, 
Polo-Padillo J, Castillo-Gomez J. Gender differences in obstructive sleep apnea syndrome: a 
clinical study of 1166 patients. Respir Med 2004; 98: 984-989. 
47. Young T, Hutton R, Finn L, Badr S, Palta M. The gender bias in sleep apnea diagnosis. Are women 
missed because they have different symptoms? Arch Intern Med 1996; 156: 2445-2451. 
48. Ambrogetti A, Olson LG, Saunders NA. Differences in the symptoms of men and women with 
obstructive sleep apnoea. Aust N Z J Med 1991; 21: 863-866. 
49. Collop NA, Adkins D, Phillips BA. Gender differences in sleep and sleep-disordered breathing. 
Clinics in chest medicine 2004; 25: 257-268. 
50. Tantrakul V, Park CS, Guilleminault C. Sleep-disordered breathing in premenopausal women: 
differences between younger (less than 30 years old) and older women. Sleep medicine 
2012; 13: 656-662. 
51. Lindberg E, Benediktsdottir B, Franklin KA, Gislason T, Mathias H, Christer J, Rain J, Johnannessen 
A, Gomez Real F, Schunssen V. Gender differences in sleep disordered breathing. Presented 
at the European Thoracic Society, Amsterdam ID: PA2377 2015. 
52. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet 2014; 383: 736-747. 
 192 
 
53. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive 
Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine 
Systematic Review, Meta-Analysis, and GRADE Assessment. Journal of Clinical Sleep 
Medicine 2019; 15: 301-334. 
54. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, Malhotra A, 
Martinez-Garcia MA, Mehra R, Pack AI, Polotsky VY, Redline S, Somers VK. Sleep Apnea: 
Types, Mechanisms, and Clinical Cardiovascular Consequences. Journal of the American 
College of Cardiology 2017; 69: 841-858. 
55. Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of Positive 
Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A 
Systematic Review and Meta-analysis. Jama 2017; 318: 156-166. 
56. Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type 2 diabetes: interacting 
epidemics. Chest 2008; 133: 496-506. 
57. Pamidi S, Wroblewski K, Stepien M, Sharif-Sidi K, Kilkus J, Whitmore H, Tasali E. Eight Hours of 
Nightly Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea 
Improves Glucose Metabolism in Patients with Prediabetes. A Randomized Controlled Trial. 
American journal of respiratory and critical care medicine 2015; 192: 96-105. 
58. Gay P, Weaver T, Loube D, Iber C. Evaluation of positive airway pressure treatment for sleep 
related breathing disorders in adults. Sleep 2006; 29: 381-401. 
59. Lewis EF, Wang R, Punjabi N, Gottlieb DJ, Quan SF, Bhatt DL, Patel SR, Mehra R, Blumenthal RS, 
Weng J, Rueschman M, Redline S. Impact of continuous positive airway pressure and oxygen 
on health status in patients with coronary heart disease, cardiovascular risk factors, and 
obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) 
analysis. Am Heart J 2017; 189: 59-67. 
60. Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with 
obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive 
airway pressure: an observational study. The Lancet 2005; 365: 1046-1053. 
61. McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Davies RJ, Nunn AJ, Stradling JR, 
Riha RL, Morrell MJ. Continuous positive airway pressure in older people with obstructive 
sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. The Lancet 
Respiratory Medicine 2014. 
62. Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, Ensrud KE, Ancoli-Israel S, Stone KL. Sleep-
disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older 
women. Jama 2011; 306: 613-619. 
63. Macey PM, Prasad JP, Ogren JA, Moiyadi AS, Aysola RS, Kumar R, Yan-Go FL, Woo MA, Albert 
Thomas M, Harper RM. Sex-specific hippocampus volume changes in obstructive sleep 
apnea. NeuroImage Clinical 2018; 20: 305-317. 
 193 
 
64. Steinke E, Palm Johansen P, Fridlund B, Brostrom A. Determinants of sexual dysfunction and 
interventions for patients with obstructive sleep apnoea: a systematic review. Int J Clin Pract 
2016; 70: 5-19. 
65. Liu L, Kang R, Zhao S, Zhang T, Zhu W, Li E, Li F, Wan S, Zhao Z. Sexual Dysfunction in Patients 
with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. The journal of sexual 
medicine 2015; 12: 1992-2003. 
66. Subramanian S, Bopparaju S, Desai A, Wiggins T, Rambaud C, Surani S. Sexual dysfunction in 
women with obstructive sleep apnea. Sleep Breath 2010; 14: 59-62. 
67. Petersen M, Kristensen E, Berg S, Giraldi A, Midgren B. Sexual function in female patients with 
obstructive sleep apnea. The journal of sexual medicine 2011; 8: 2560-2568. 
68. Greenberg-Dotan S, Reuveni H, Simon-Tuval T, Oksenberg A, Tarasiuk A. Gender differences in 
morbidity and health care utilization among adult obstructive sleep apnea patients. Sleep 
2007; 30: 1173-1180. 
69. Campos-Rodriguez F, Martinez-Garcia M, Cruz-Moron I, Almeida-Gonzalez C, Catalan-Serra P, JM 
M. Cardiovascular mortality in women with OSA with or without CPAP treatment- A cohort 
study. AnnInternMed 2012; 156: 115-122. 
70. Mokhlesi B, Ham SA, Gozal D. The effect of sex and age on the comorbidity burden of OSA: an 
observational analysis from a large nationwide US health claims database. The European 
respiratory journal 2016. 
71. Faulx MD, Larkin EK, Hoit BD, Aylor JE, Wright AT, Redline S. Sex influences endothelial function 
in sleep-disordered breathing. Sleep 2004; 27: 1113-1120. 
72. Macey PM, Kumar R, Woo MA, Yan-Go FL, Harper RM. Heart rate responses to autonomic 
challenges in obstructive sleep apnea. PLoS One 2013; 8: e76631. 
73. Weinberger SE, Weiss ST, Cohen WR, Weiss JW, Johnson TS. Pregnancy and the lung. The 
American review of respiratory disease 1980; 121: 559-581. 
74. Izci B, Martin SE, Dundas KC, Liston WA, Calder AA, Douglas NJ. Sleep complaints: snoring and 
daytime sleepiness in pregnant and pre-eclamptic women. Sleep Med 2005; 6: 163-169. 
75. Pien GW, Fife D, Pack AI, Nkwuo JE, Schwab RJ. Changes in symptoms of sleep-disordered 
breathing during pregnancy. Sleep 2005; 28: 1299-1305. 
76. Mabry RL. Rhinitis of pregnancy. Southern medical journal 1986; 79: 965-971. 
77. Pilkington S, Carli F, Dakin MJ, Romney M, De Witt KA, Dore CJ, Cormack RS. Increase in 
Mallampati score during pregnancy. British journal of anaesthesia 1995; 74: 638-642. 
78. Franklin KA, Holmgren PA, Jonsson F, Poromaa N, Stenlund H, Svanborg E. Snoring, pregnancy-
induced hypertension, and growth retardation of the fetus. Chest 2000; 117: 137-141. 
 194 
 
79. Bourjeily G, Danilack VA, Bublitz MH, Lipkind H, Muri J, Caldwell D, Tong I, Rosene-Montella K. 
Obstructive sleep apnea in pregnancy is associated with adverse maternal outcomes: a 
national cohort. Sleep medicine 2017; 38: 50-57. 
80. Felder JN, Baer RJ, Rand L, Jelliffe-Pawlowski LL, Prather AA. Sleep Disorder Diagnosis During 
Pregnancy and Risk of Preterm Birth. Obstetrics and gynecology 2017; 130: 573-581. 
81. Facco FL, Parker CB, Reddy UM, Silver RM, Louis JM, Basner RC, Chung JH, Schubert FP, Pien GW, 
Redline S, Mobley DR, Koch MA, Simhan HN, Nhan-Chang CL, Parry S, Grobman WA, Haas 
DM, Wing DA, Mercer BM, Saade GR, Zee PC. NuMoM2b Sleep-Disordered Breathing study: 
objectives and methods. Am J Obstet Gynecol 2015; 212: 542 e541-127. 
82. Facco FL. LB2: Prospective study of the association between sleep disordered breathing and 
hypertensive disorders of pregnancy and gestational diabetes. American Journal of 
Obstetrics and Gynecology 2015; 212: S424-S425. 
83. Facco FL, Parker CB, Reddy UM, Silver RM, Koch MA, Louis JM, Basner RC, Chung JH, Nhan-Chang 
CL, Pien GW, Redline S, Grobman WA, Wing DA, Simhan HN, Haas DM, Mercer BM, Parry S, 
Mobley D, Hunter S, Saade GR, Schubert FP, Zee PC. Association Between Sleep-Disordered 
Breathing and Hypertensive Disorders of Pregnancy and Gestational Diabetes Mellitus. 
Obstetrics and gynecology 2017; 129: 31-41. 
84. Young T, Finn L. Epidemiological insights into the public health burden of sleep disordered 
breathing: sex differences in survival among sleep clinic patients. Thorax 1998; 53 Suppl 3: 
S16-19. 
85. Gold AR, Dipalo F, Gold MS, O'Hearn D. The symptoms and signs of upper airway resistance 
syndrome: a link to the functional somatic syndromes. Chest 2003; 123: 87-95. 
86. Powers CR, Frey WC. Maintenance of wakefulness test in military personnel with upper airway 
resistance syndrome and mild to moderate obstructive sleep apnea. Sleep Breath 2009; 13: 
253-258. 
87. So SJ, Lee HJ, Kang SG, Cho CH, Yoon HK, Kim L. A Comparison of Personality Characteristics and 
Psychiatric Symptomatology between Upper Airway Resistance Syndrome and Obstructive 
Sleep Apnea Syndrome. Psychiatry investigation 2015; 12: 183-189. 
88. Kokturk O, Baha A, Kanbay A. A new approach in the diagnosis of upper airway resistance 
syndrome (UARS): PAP method. Tuberkuloz ve toraks 2015; 63: 31-36. 
89. Kristo DA, Lettieri CJ, Andrada T, Taylor Y, Eliasson AH. Silent upper airway resistance syndrome: 
prevalence in a mixed military population. Chest 2005; 127: 1654-1657. 
90. Stoohs RA, Knaack L, Blum HC, Janicki J, Hohenhorst W. Differences in clinical features of upper 
airway resistance syndrome, primary snoring, and obstructive sleep apnea/hypopnea 
syndrome. Sleep medicine 2008; 9: 121-128. 
91. Guilleminault C, Chowdhuri S. Upper airway resistance syndrome is a distinct syndrome. 
American journal of respiratory and critical care medicine 2000; 161: 1412-1413. 
 195 
 
92. Baldwin CM, Griffith KA, Nieto FJ, O'Connor GT, Walsleben JA, Redline S. The association of sleep-
disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health 
Study. Sleep 2001; 24: 96-105. 
93. Kushida CA, Nichols DA, Holmes TH, Quan SF, Walsh JK, Gottlieb DJ, Simon RD, Jr., Guilleminault 
C, White DP, Goodwin JL, Schweitzer PK, Leary EB, Hyde PR, Hirshkowitz M, Green S, McEvoy 
LK, Chan C, Gevins A, Kay GG, Bloch DA, Crabtree T, Dement WC. Effects of continuous 
positive airway pressure on neurocognitive function in obstructive sleep apnea patients: The 
Apnea Positive Pressure Long-term Efficacy Study (APPLES). Sleep 2012; 35: 1593-1602. 
94. Quan SF, Budhiraja R, Batool-Anwar S, Gottlieb DJ, Eichling P, Patel S, Shen W, Walsh JK, Kushida 
CA. Lack of Impact of Mild Obstructive Sleep Apnea on Sleepiness, Mood and Quality of Life. 
Southwest journal of pulmonary & critical care 2014; 9: 44-56. 
95. Chowdhuri S, Quan SF, Almeida F, Ayappa I, Batool-Anwar S, Budhiraja R, Cruse PE, Drager LF, 
Griss B, Marshall N, Patel SR, Patil S, Knight SL, Rowley JA, Slyman A, Apnea ATSAHCoMOS. 
An Official American Thoracic Society Research Statement: Impact of Mild Obstructive Sleep 
Apnea in Adults. American journal of respiratory and critical care medicine 2016; 193: e37-
54. 
96. Lloyd-Owen SJ, Donaldson GC, Ambrosino N, Escarabill J, Farre R, Fauroux B, Robert D, 
Schoenhofer B, Simonds AK, Wedzicha JA. Patterns of home mechanical ventilation use in 
Europe: results from the Eurovent survey. The European respiratory journal 2005; 25: 1025-
1031. 
97. Guilleminault C, Stoohs R, Shiomi T, Kushida C, Schnittger I. Upper airway resistance syndrome, 
nocturnal blood pressure monitoring, and borderline hypertension. Chest 1996; 109: 901-
908. 
98. Bao G, Guilleminault C. Upper airway resistance syndrome--one decade later. Current opinion in 
pulmonary medicine 2004; 10: 461-467. 
99. Guilleminault C, Kirisoglu C, Poyares D, Palombini L, Leger D, Farid-Moayer M, Ohayon MM. 
Upper airway resistance syndrome: a long-term outcome study. J Psychiatr Res 2006; 40: 
273-279. 
100. Anttalainen U, Polo O, Vahlberg T, Saaresranta T. Women with partial upper airway obstruction 
are not less sleepy than those with obstructive sleep apnea. Sleep Breath 2013; 17: 873-876. 
101. Fogel RB, Trinder J, White DP, Malhotra A, Raneri J, Schory K, Kleverlaan D, Pierce RJ. The effect 
of sleep onset on upper airway muscle activity in patients with sleep apnoea versus controls. 
The Journal of physiology 2005; 564: 549-562. 
102. Palombini LO, Tufik S, Rapoport DM, Ayappa IA, Guilleminault C, de Godoy LB, Castro LS, 
Bittencourt L. Inspiratory flow limitation in a normal population of adults in Sao Paulo, Brazil. 
Sleep 2013; 36: 1663-1668. 
103. Hosselet J, Ayappa I, Norman RG, Krieger AC, Rapoport DM. Classification of sleep-disordered 
breathing. American journal of respiratory and critical care medicine 2001; 163: 398-405. 
 196 
 
104. Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, Skatrud J. Population-based study of 
sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997; 157: 
1746-1752. 
105. Torres G, Sanchez-de-la-Torre M, Barbe F. Relationship Between OSA and Hypertension. Chest 
2015; 148: 824-832. 
106. Redline S, Strauss ME, Adams N, Winters M, Roebuck T, Spry K, Rosenberg C, Adams K. 
Neuropsychological function in mild sleep-disordered breathing. Sleep 1997; 20: 160-167. 
107. Leng Y, McEvoy CT, Allen IE, Yaffe K. Association of Sleep-Disordered Breathing With Cognitive 
Function and Risk of Cognitive Impairment: A Systematic Review Meta-analysis. JAMA 
neurology 2017. 
108. Gall R, Isaac L, Kryger M. Quality of life in mild obstructive sleep apnea. Sleep 1993; 16: S59-61. 
109. Tregear S, Reston J, Schoelles K, Phillips B. Obstructive sleep apnea and risk of motor vehicle 
crash: systematic review and meta-analysis. Journal of clinical sleep medicine : JCSM : official 
publication of the American Academy of Sleep Medicine 2009; 5: 573-581. 
110. Asker M, Asker S, Kucuk U, Kucuk HO. An overlooked cause of resistant hypertension: upper 
airway resistance syndrome - preliminary results. Clinics (Sao Paulo, Brazil) 2014; 69: 731-
734. 
111. Lofaso F, Coste A, Gilain L, Harf A, Guilleminault C, Goldenberg F. Sleep fragmentation as a risk 
factor for hypertension in middle-aged nonapneic snorers. Chest 1996; 109: 896-900. 
112. Stradling JR, Barbour C, Glennon J, Langford BA, Crosby JH. Which aspects of breathing during 
sleep influence the overnight fall of blood pressure in a community population? Thorax 
2000; 55: 393-398. 
113. Calero G, Farre R, Ballester E, Hernandez L, Daniel N, Montserrat Canal JM. Physiological 
consequences of prolonged periods of flow limitation in patients with sleep apnea hypopnea 
syndrome. Respir Med 2006; 100: 813-817. 
114. Exar EN, Collop NA. The upper airway resistance syndrome. Chest 1999; 115: 1127-1139. 
115. Guilleminault C, Poyares D, Rosa A, Huang YS. Heart rate variability, sympathetic and vagal 
balance and EEG arousals in upper airway resistance and mild obstructive sleep apnea 
syndromes. Sleep medicine 2005; 6: 451-457. 
116. Lofaso F, Goldenberg F, d'Ortho MP, Coste A, Harf A. Arterial blood pressure response to 
transient arousals from NREM sleep in nonapneic snorers with sleep fragmentation. Chest 
1998; 113: 985-991. 
117. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal 
subjects. Chest 2010; 137: 95-101. 
 197 
 
118. Lee SA, Amis TC, Byth K, Larcos G, Kairaitis K, Robinson TD, Wheatley JR. Heavy snoring as a 
cause of carotid artery atherosclerosis. Sleep 2008; 31: 1207-1213. 
119. Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Snoring is not associated with 
all-cause mortality, incident cardiovascular disease, or stroke in the Busselton Health Study. 
Sleep 2012; 35: 1235-1240. 
120. Gold AR, Gold MS, Harris KW, Espeleta VJ, Amin MM, Broderick JE. Hypersomnolence, insomnia 
and the pathophysiology of upper airway resistance syndrome. Sleep medicine 2008; 9: 675-
683. 
121. Guilleminault C, Do Kim Y, Chowdhuri S, Horita M, Ohayon M, Kushida C. Sleep and daytime 
sleepiness in upper airway resistance syndrome compared to obstructive sleep apnoea 
syndrome. The European respiratory journal 2001; 17: 838-847. 
122. Stoohs RA, Philip P, Andries D, Finlayson EV, Guilleminault C. Reaction time performance in 
upper airway resistance syndrome versus obstructive sleep apnea syndrome. Sleep medicine 
2009; 10: 1000-1004. 
123. O'Connor C, Thornley KS, Hanly PJ. Gender differences in the polysomnographic features of 
obstructive sleep apnea. American journal of respiratory and critical care medicine 2000; 
161: 1465-1472. 
124. Ware JC, McBrayer RH, Scott JA. Influence of sex and age on duration and frequency of sleep 
apnea events. Sleep 2000; 23: 165-170. 
125. Valencia-Flores M, Bliwise DL, Guilleminault C, Rhoads NP, Clerk A. Gender differences in sleep 
architecture in sleep apnoea syndrome. J Sleep Res 1992; 1: 51-53. 
126. Callop N CD. Snoring and sleep disordered breathing. In: Lee-Chiong T Jr SM, Carskadon M, 
editor. Sleep Medicine. Philadelphia: Hanley & Belfus; 2002. p. 349-355. 
127. Mohsenin V. Effects of gender on upper airway collapsibility and severity of obstructive sleep 
apnea. Sleep medicine 2003; 4: 523-529. 
128. Jordan AS, Wellman A, Edwards JK, Schory K, Dover L, MacDonald M, Patel SR, Fogel RB, 
Malhotra A, White DP. Respiratory control stability and upper airway collapsibility in men 
and women with obstructive sleep apnea. J Appl Physiol 2005; 99: 2020-2027. 
129. Trinder J, Kay A, Kleiman J, Dunai J. Gender differences in airway resistance during sleep. J Appl 
Physiol (1985) 1997; 83: 1986-1997. 
130. Thurnheer R, Wraith PK, Douglas NJ. Influence of age and gender on upper airway resistance in 
NREM and REM sleep. J Appl Physiol 2001; 90: 981-988. 
131. Leech JA, Onal E, Dulberg C, Lopata MA. A comparison of men and women with occlusive sleep 
apnea syndrome. Chest 1988; 94: 983-988. 
 198 
 
132. Tishler PV, Larkin EK, Schluchter MD, Redline S. Incidence of sleep-disordered breathing in an 
urban adult population: the relative importance of risk factors in the development of sleep-
disordered breathing. Jama 2003; 289: 2230-2237. 
133. Whittle AT, Marshall I, Mortimore IL, Wraith PK, Sellar RJ, Douglas NJ. Neck soft tissue and fat 
distribution: comparison between normal men and women by magnetic resonance imaging. 
Thorax 1999; 54: 323-328. 
134. Collins LC, Hoberty PD, Walker JF, Fletcher EC, Peiris AN. The effect of body fat distribution on 
pulmonary function tests. Chest 1995; 107: 1298-1302. 
135. Harik-Khan RI, Wise RA, Fleg JL. The effect of gender on the relationship between body fat 
distribution and lung function. J Clin Epidemiol 2001; 54: 399-406. 
136. Buyse B, Markous N, Cauberghs M, Van Klaveren R, Muls E, Demedts M. Effect of obesity 
and/or sleep apnea on chemosensitivity: differences between men and women. Respir 
Physiol Neurobiol 2003; 134: 13-22. 
137. White DP, Douglas NJ, Pickett CK, Weil JV, Zwillich CW. Sexual influence on the control of 
breathing. J Appl Physiol 1983; 54: 874-879. 
138. Zhou XS, Shahabuddin S, Zahn BR, Babcock MA, Badr MS. Effect of gender on the development 
of hypocapnic apnea/hypopnea during NREM sleep. J Appl Physiol 2000; 89: 192-199. 
139. Jordan AS, Eckert DJ, Catcheside PG, McEvoy RD. Ventilatory response to brief arousal from 
non-rapid eye movement sleep is greater in men than in women. American journal of 
respiratory and critical care medicine 2003; 168: 1512-1519. 
140. Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the 
Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2003; 167: 1181-1185. 
141. Dancey DR, Hanly PJ, Soong C, Lee B, Hoffstein V. Impact of menopause on the prevalence and 
severity of sleep apnea. Chest 2001; 120: 151-155. 
142. Krishnan V, Collop N. Chapter 14 Gender differences in obstructive sleep apnea. In: Kushida C, 
editor. Obstructive sleep apnea: diagnosis and treatment. New York: Informa Healthcare; 
2007. p. 247-260. 
143. Andersen ML, Bittencourt LR, Antunes IB, Tufik S. Effects of progesterone on sleep: a possible 
pharmacological treatment for sleep-breathing disorders? Current medicinal chemistry 2006; 
13: 3575-3582. 
144. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. 
Am J Clin Nutr 1992; 55: 950-954. 
145. Tremollieres FA, Pouilles JM, Ribot CA. Relative influence of age and menopause on total and 
regional body composition changes in postmenopausal women. American journal of 
obstetrics and gynecology 1996; 175: 1594-1600. 
 199 
 
146. Li Y, Ye J, Li T, Lin N, Wang Z, Liang C, Sperry A, Han D. Anatomic predictors of retropalatal 
mechanical loads in patients with obstructive sleep apnea. Respiration 2011; 82: 246-253. 
147. Tamisier R, Pepin JL, Wuyam B, Smith R, Argod J, Levy P. Characterization of pharyngeal 
resistance during sleep in a spectrum of sleep-disordered breathing. J Appl Physiol (1985) 
2000; 89: 120-130. 
148. Gold AR, Marcus CL, Dipalo F, Gold MS. Upper airway collapsibility during sleep in upper airway 
resistance syndrome. Chest 2002; 121: 1531-1540. 
149. Gleadhill IC, Schwartz AR, Schubert N, Wise RA, Permutt S, Smith PL. Upper airway collapsibility 
in snorers and in patients with obstructive hypopnea and apnea. Am Rev Respir Dis 1991; 
143: 1300-1303. 
150. Tamisier R, Wuyam B, Nicolle I, Pepin JL, Orliaguet O, Perrin CP, Levy P. Awake flow limitation 
with negative expiratory pressure in sleep disordered breathing. Sleep medicine 2005; 6: 
205-213. 
151. Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev 
2010; 90: 47-112. 
152. Loube DI, Andrada TF. Comparison of respiratory polysomnographic parameters in matched 
cohorts of upper airway resistance and obstructive sleep apnea syndrome patients. Chest 
1999; 115: 1519-1524. 
153. Guilleminault C, Li K, Chen NH, Poyares D. Two-point palatal discrimination in patients with 
upper airway resistance syndrome, obstructive sleep apnea syndrome, and normal control 
subjects. Chest 2002; 122: 866-870. 
154. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal of obstructive sleep apnoea by 
continuous positive airway pressure applied through the nares. Lancet (London, England) 
1981; 1: 862-865. 
155. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with 
obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive 
airway pressure: an observational study. Lancet (London, England) 2005; 365: 1046-1053. 
156. Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. 
The impact of continuous positive airway pressure on blood pressure in patients with 
obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled 
randomized trials. Arch Intern Med 2007; 167: 757-764. 
157. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of 
mild to moderate obstructive sleep apnea reduces cardiovascular risk. American journal of 
respiratory and critical care medicine 2007; 176: 1274-1280. 
158. Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in 
obstructive sleep apnoea/hypopnoea syndrome. Thorax 2004; 59: 618-622. 
 200 
 
159. Mohsenin V. Gender differences in the expression of sleep-disordered breathing : role of upper 
airway dimensions. Chest 2001; 120: 1442-1447. 
160. Ye L, Pien G, Ratcliffe S, Weaver T. Gender differences in Obstructive Sleep Apnea and 
Treatment Responses to Continuous Positive Airway Pressure. Journal of clinical sleep 
medicine : JCSM : official publication of the American Academy of Sleep Medicine 2009; 5: 
512-518. 
161. Edwards C, Mukherjee S, Simpson L, Palmer LJ, Almeida OP, Hillman DR. Depressive Symptoms 
before and after Treatment of Obstructive Sleep Apnea in Men and Women. Journal of 
clinical sleep medicine : JCSM : official publication of the American Academy of Sleep 
Medicine 2015; 11: 1029-1038. 
162. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. 
Journal of general internal medicine 2001; 16: 606-613. 
163. Campos-Rodriguez F, Queipo-Corona C, Carmona-Bernal C, Jurado-Gamez B, Cordero-Guevara J, 
Reyes-Nunez N, Troncoso-Acevedo F, Abad-Fernandez A, Teran-Santos J, Caballero-
Rodriguez J, Martin-Romero M, Encabo-Motino A, Sacristan-Bou L, Navarro-Esteva J, 
Somoza-Gonzalez M, Masa JF, Sanchez-Quiroga MA, Jara-Chinarro B, Orosa-Bertol B, 
Martinez-Garcia MA. Continuous Positive Airway Pressure Improves Quality of Life in 
Women with OSA. A Randomized-controlled Trial. American journal of respiratory and 
critical care medicine 2016. 
164. Campos-Rodriguez F, Gonzalez-Martinez M, Sanchez-Armengol A, Jurado-Gamez B, Cordero-
Guevara J, Reyes-Nunez N, Troncoso MF, Abad-Fernandez A, Teran-Santos J, Caballero-
Rodriguez J, Martin-Romero M, Encabo-Motino A, Sacristan-Bou L, Navarro-Esteva J, 
Somoza-Gonzalez M, Masa JF, Sanchez-Quiroga MA, Jara-Chinarro B, Orosa-Bertol B, 
Martinez-Garcia MA, Spanish Sleep N. Effect of continuous positive airway pressure on blood 
pressure and metabolic profile in women with sleep apnoea. The European respiratory 
journal 2017; 50. 
165. Champagne KA, Kimoff RJ, Barriga PC, Schwartzman K. Sleep disordered breathing in women of 
childbearing age & during pregnancy. The Indian journal of medical research 2010; 131: 285-
301. 
166. Guilleminault C, Kreutzer M, Chang JL. Pregnancy, sleep disordered breathing and treatment 
with nasal continuous positive airway pressure. Sleep medicine 2004; 5: 43-51. 
167. Poyares D, Guilleminault C, Hachul H, Fujita L, Takaoka S, Tufik S, Sass N. Pre-eclampsia and 
nasal CPAP: part 2. Hypertension during pregnancy, chronic snoring, and early nasal CPAP 
intervention. Sleep medicine 2007; 9: 15-21. 
168. Woehrle H, Graml A, Weinreich G. Age- and gender-dependent adherence with continuous 
positive airway pressure therapy. Sleep medicine 2011; 12: 1034-1036. 
169. Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nunez N, Caballero-Martinez I, Almeida-
Gonzalez CV, Catalan-Serra P, Pena-Grinan N. Long-term CPAP compliance in females with 
obstructive sleep apnoea. The European respiratory journal 2013. 
 201 
 
170. Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of 
sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch 
Intern Med 2005; 165: 2408-2413. 
171. Marklund M, Stenlund H, Franklin KA. Mandibular advancement devices in 630 men and 
women with obstructive sleep apnea and snoring: tolerability and predictors of treatment 
success. Chest 2004; 125: 1270-1278. 
172. Monasterio C, Vidal S, Duran J, Ferrer M, Carmona C, Barbe F, Mayos M, Gonzalez-Mangado N, 
Juncadella M, Navarro A, Barreira R, Capote F, Mayoralas LR, Peces-Barba G, Alonso J, 
Montserrat JM. Effectiveness of continuous positive airway pressure in mild sleep apnea-
hypopnea syndrome. American journal of respiratory and critical care medicine 2001; 164: 
939-943. 
173. Montserrat JM, Ferrer M, Hernandez L, Farre R, Vilagut G, Navajas D, Badia JR, Carrasco E, De 
Pablo J, Ballester E. Effectiveness of CPAP treatment in daytime function in sleep apnea 
syndrome: a randomized controlled study with an optimized placebo. American journal of 
respiratory and critical care medicine 2001; 164: 608-613. 
174. Weaver TE, Mancini C, Maislin G, Cater J, Staley B, Landis JR, Ferguson KA, George CF, Schulman 
DA, Greenberg H, Rapoport DM, Walsleben JA, Lee-Chiong T, Gurubhagavatula I, Kuna ST. 
Continuous positive airway pressure treatment of sleepy patients with milder obstructive 
sleep apnea: results of the CPAP Apnea Trial North American Program (CATNAP) randomized 
clinical trial. Am J Respir Crit Care Med 2012; 186: 677-683. 
175. Craig SE, Kohler M, Nicoll D, Bratton DJ, Nunn A, Davies R, Stradling J. Continuous positive 
airway pressure improves sleepiness but not calculated vascular risk in patients with 
minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. 
Thorax 2012; 67: 1090-1096. 
176. Kohler M, Craig S, Pepperell JC, Nicoll D, Bratton DJ, Nunn AJ, Leeson P, Stradling JR. CPAP 
Improves Endothelial Function in Patients With Minimally Symptomatic OSA: Results From a 
Subset Study of the MOSAIC Trial. Chest 2013; 144: 896-902. 
177. Littner MR. Mild obstructive sleep apnea syndrome should not be treated. Con. Journal of 
clinical sleep medicine : JCSM : official publication of the American Academy of Sleep 
Medicine 2007; 3: 263-264. 
178. Brown LK. Mild obstructive sleep apnea syndrome should be treated. Pro. Journal of clinical 
sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2007; 
3: 259-262. 
179. Yoshida K. Oral device therapy for the upper airway resistance syndrome patient. J Prosthet 
Dent 2002; 87: 427-430. 
180. Rees K, Wraith PK, Berthon-Jones M, Douglas NJ. Detection of apnoeas, hypopnoeas and 
arousals by the AutoSet in the sleep apnoea/hypopnoea syndrome. The European 
respiratory journal 1998; 12: 764-769. 
 202 
 
181. Teschler H, Wessendorf TE, Farhat AA, Konietzko N, Berthon-Jones M. Two months auto-
adjusting versus conventional nCPAP for obstructive sleep apnoea syndrome. The European 
respiratory journal 2000; 15: 990-995. 
182. Teschler H, Berthon-Jones M, Thompson AB, Henkel A, Henry J, Konietzko N. Automated 
continuous positive airway pressure titration for obstructive sleep apnea syndrome. 
American journal of respiratory and critical care medicine 1996; 154: 734-740. 
183. Deacon NL, Jen R, Li Y, Malhotra A. Treatment of Obstructive Sleep Apnea. Prospects for 
Personalized Combined Modality Therapy. Annals of the American Thoracic Society 2016; 13: 
101-108. 
184. Pack AI. Application of P4 Medicine to Obstructive Sleep Apnea: A Roadmap for Improving 
Care? Annals of the American Thoracic Society 2016. 
185. Lee MH, Lee SA, Lee GH, Ryu HS, Chung S, Chung YS, Kim WS. Gender differences in the effect of 
comorbid insomnia symptom on depression, anxiety, fatigue, and daytime sleepiness in 
patients with obstructive sleep apnea. Sleep Breath 2014; 18: 111-117. 
186. Quintana-Gallego E, Carmona-Bernal C, Capote F, Sánchez-Armengol Á, Botebol-Benhamou G, 
Polo-Padillo J, Castillo-Gómez J. Gender differences in obstructive sleep apnea syndrome: a 
clinical study of 1166 patients. Respiratory Medicine 2004; 98: 984-989. 
187. Shepertycky MR, Banno K, Kryger MH. Differences between men and women in the clinical 
presentation of patients diagnosed with obstructive sleep apnea syndrome. Sleep 2005; 28: 
309-314. 
188. Nigro CA, Dibur E, Malnis S, Grandval S, Nogueira F. Validation of ApneaLink Ox for the diagnosis 
of obstructive sleep apnea. Sleep Breath 2013; 17: 259-266. 
189. Nigro CA, Malnis S, Dibur E, Rhodius E. How reliable is the manual correction of the autoscoring 
of a level IV sleep study (ApneaLink) by an observer without experience in 
polysomnography? Sleep Breath 2012; 16: 275-279. 
190. Nigro CA, Dibur E, Grandval S, Nogueira F. Indication of CPAP in Patients with Suspected 
Obstructive Sleep Apnea, Based on Clinical Parameters and a Novel Two-Channel Recording 
Device (ApneaLink): A Pilot Study. Sleep disorders 2012; 2012: 346181. 
191. Nigro CA, Dibur E, Aimaretti S, Gonzalez S, Rhodius E. Comparison of the automatic analysis 
versus the manual scoring from ApneaLink device for the diagnosis of obstructive sleep 
apnoea syndrome. Sleep Breath 2011; 15: 679-686. 
192. Ragette R, Wang Y, Weinreich G, Teschler H. Diagnostic performance of single airflow channel 
recording (ApneaLink) in home diagnosis of sleep apnea. Sleep Breath 2010; 14: 109-114. 
193. Nigro CA, Serrano F, Aimaretti S, Gonzalez S, Codinardo C, Rhodius E. Utility of ApneaLink for 
the diagnosis of sleep apnea-hypopnea syndrome. Medicina (B Aires) 2010; 70: 53-59. 
 203 
 
194. Weinreich G, Armitstead J, Topfer V, Wang YM, Wang Y, Teschler H. Validation of ApneaLink as 
screening device for Cheyne-Stokes respiration. Sleep 2009; 32: 553-557. 
195. Ng SS, Chan TO, To KW, Ngai J, Tung A, Ko FW, Hui DS. Validation of a portable recording device 
(ApneaLink) for identifying patients with suspected obstructive sleep apnoea syndrome. 
Internal medicine journal 2009; 39: 757-762. 
196. Chen H, Lowe AA, Bai Y, Hamilton P, Fleetham JA, Almeida FR. Evaluation of a portable 
recording device (ApneaLink) for case selection of obstructive sleep apnea. Sleep Breath 
2009; 13: 213-219. 
197. Erman MK, Stewart D, Einhorn D, Gordon N, Casal E. Validation of the ApneaLink for the 
screening of sleep apnea: a novel and simple single-channel recording device. Journal of 
clinical sleep medicine : JCSM : official publication of the American Academy of Sleep 
Medicine 2007; 3: 387-392. 
198. Adler D, Bridevaux PO, Contal O, Georges M, Dupuis-Lozeron E, Claudel E, Pepin JL, Janssens JP. 
Pulse wave amplitude reduction: a surrogate marker of micro-arousals associated with 
respiratory events occurring under non-invasive ventilation? Respir Med 2013; 107: 2053-
2060. 
199. Delessert A, Espa F, Rossetti A, Lavigne G, Tafti M, Heinzer R. Pulse wave amplitude drops 
during sleep are reliable surrogate markers of changes in cortical activity. Sleep 2010; 33: 
1687-1692. 
200. Vat S, Haba-Rubio J, Tafti M, Tobback N, Andries D, Heinzer R. Scoring criteria for portable 
monitor recordings: a comparison of four hypopnoea definitions in a population-based 
cohort. Thorax 2015; 70: 1047-1053. 
201. Berry RB PS, Kantner G et al. Validation of a Home Sleep Apnea Testing Device for the Diagnosis 
of Sleep Disordered Breathing based on AASM 2012 guidelines. Sleep 2019; 
42(Supplement_1): A186-A 2019. 
202. Sushmita Pamidi, Indu Ayappa, John Kimoff, Luciana Palombini, David M. Rapoport, Redline S. 
Non-Invasive Identification of Inspiratory Flow Limitation in Sleep Studies. Working Group 
for the ATS 2015 Workshop 2015. 
203. Araghi MH, Jagielski A, Neira I, Brown A, Higgs S, Thomas GN, Taheri S. The complex 
associations among sleep quality, anxiety-depression, and quality of life in patients with 
extreme obesity. Sleep 2013; 36: 1859-1865. 
204. Cooksey JA, Balachandran JS. Portable Monitoring for the Diagnosis of OSA. Chest 2016; 149: 
1074-1081. 
205. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, Sanchez-de-la-Torre A, 
Duran-Cantolla J, Egea CJ, Salord N, Monasterio C, Teran J, Alonso-Alvarez ML, Munoz-
Mendez J, Arias EM, Cabello M, Montserrat JM, De la Pena M, Serrano JC, Barbe F, Masa JF. 
Conventional Polysomnography is Not Necessary for the Management of Most Patients with 
Suspected Obstructive Sleep Apnea. American journal of respiratory and critical care 
medicine 2017. 
 204 
 
206. Chai-Coetzer CL, McEvoy RD. The Debate Should Now Be Over. Simplified Cardiorespiratory 
Sleep Tests are a Reliable, Cost-saving Option for Diagnosing Obstructive Sleep Apnea. 
American journal of respiratory and critical care medicine 2017. 
207. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel D, Sateia M, 
Schwab R. Clinical guidelines for the use of unattended portable monitors in the diagnosis of 
obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American 
Academy of Sleep Medicine. Journal of clinical sleep medicine : JCSM : official publication of 
the American Academy of Sleep Medicine 2007; 3: 737-747. 
208. Rosen IM, Kirsch DB, Chervin RD, Carden KA, Ramar K, Aurora RN, Kristo DA, Malhotra RK, 
Martin JL, Olson EJ, Rosen CL, Rowley JA. Clinical Use of a Home Sleep Apnea Test: An 
American Academy of Sleep Medicine Position Statement. Journal of Clinical Sleep Medicine 
2017; 13: 1205-1207. 
209. https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. Decision 
Memo for SLEEP TESTING for Obstructive SLEEP Apnea (OSA) (CAG-00405N). June 2017]. 
210. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical 
Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American 
Academy of Sleep Medicine Clinical Practice Guideline. Journal of clinical sleep medicine : 
JCSM : official publication of the American Academy of Sleep Medicine 2017; 13: 479-504. 
211. Stöberl AS, Schwarz EI, Haile SR, Turnbull CD, Rossi VA, Stradling JR, Kohler M. Night-to-night 
variability of obstructive sleep apnea. J Sleep Res 2017; 26: 782-788. 
212. Jayaraman G, Majid H, Surani S, Kao C, Subramanian S. Influence of gender on continuous 
positive airway pressure requirements in patients with obstructive sleep apnea syndrome. 
Sleep Breath 2011; 15: 781-784. 
213. Yukawa K, Inoue Y, Yagyu H, Hasegawa T, Komada Y, Namba K, Nagai N, Nemoto S, Sano E, 
Shibusawa M, Nagano N, Suzuki M. Gender differences in the clinical characteristics among 
Japanese patients with obstructive sleep apnea syndrome. Chest 2009; 135: 337-343. 
214. Ralls FM, Grigg-Damberger M. Roles of gender, age, race/ethnicity, and residential 
socioeconomics in obstructive sleep apnea syndromes. Current opinion in pulmonary 
medicine 2012; 18: 568-573. 
215. JC W, RH M, JA S. Influence of Sex and Age on Duration and Frequency of Sleep Apnea Events. 
Sleep 2000; 23. 
216. Rigau J, Montserrat JM, Wohrle H, Plattner D, Schwaibold M, Navajas D, Farre R. Bench model 
to simulate upper airway obstruction for analyzing automatic continuous positive airway 
pressure devices. Chest 2006; 130: 350-361. 
217. Farre R, Montserrat JM, Rigau J, Trepat X, Pinto P, Navajas D. Response of automatic continuous 
positive airway pressure devices to different sleep breathing patterns: a bench study. 
American journal of respiratory and critical care medicine 2002; 166: 469-473. 
 205 
 
218. Isetta V, Montserrat JM, Santano R, Wimms AJ, Ramanan D, Woehrle H, Navajas D, Farre R. 
Novel Approach to Simulate Sleep Apnea Patients for Evaluating Positive Pressure Therapy 
Devices. PLoS One 2016; 11: e0151530. 
219. Brown LK. Autotitrating CPAP: how shall we judge safety and efficacy of a "black box"? Chest 
2006; 130: 312-314. 
220. Pevernagie DA, Proot PM, Hertegonne KB, Neyens MC, Hoornaert KP, Pauwels RA. Efficacy of 
flow- vs impedance-guided autoadjustable continuous positive airway pressure: a 
randomized cross-over trial. Chest 2004; 126: 25-30. 
221. Nolan GM, Ryan S, O'Connor T M, McNicholas WT. Comparison of three auto-adjusting positive 
pressure devices in patients with sleep apnoea. The European respiratory journal 2006; 28: 
159-164. 
222. Wimms AJ, Richards GN, Benjafield AV. Assessment of the impact on compliance of a new CPAP 
system in obstructive sleep apnea. Sleep Breath 2013; 17: 69-76. 
223. Meurice JC, Paquereau J, Denjean A, Patte F, Series F. Influence of correction of flow limitation 
on continuous positive airway pressure efficiency in sleep apnoea/hypopnoea syndrome. 
The European respiratory journal 1998; 11: 1121-1127. 
224. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep 
apnea syndrome in middle-aged men and women. Sleep 1997; 20: 705-706. 
225. McArdle N, King S, Shepherd K, Baker V, Ramanan D, Ketheeswaran S, Bateman P, Wimms A, 
Armitstead J, Richards G, Hillman D, Eastwood P. Study of a Novel APAP Algorithm for the 
Treatment of Obstructive Sleep Apnea in Women. Sleep 2015; 38: 1775-1781. 
226. Weaver TE. Relationship Between Hours of CPAP Use and Achieving Normal Levels of Sleepiness 
and Daily Functioning. SLEEP   2007; 30: 711-719. 
227. Antic NA, Catcheside P, Buchan C, Hensley M, Naughton MT, Rowland S, Williamson B, Windler 
S, McEvoy RD. The effect of CPAP in normalizing daytime sleepiness, quality of life, and 
neurocognitive function in patients with moderate to severe OSA. Sleep 2011; 34: 111-119. 
228. Zhang XB, Lin QC, Zeng HQ, Jiang XT, Chen B, Chen X. Erectile Dysfunction and Sexual Hormone 
Levels in Men With Obstructive Sleep Apnea: Efficacy of Continuous Positive Airway 
Pressure. Archives of sexual behavior 2016; 45: 235-240. 
229. Yilmaz Z, Sirinocak PB, Voyvoda B, Ozcan L. Sexual Dysfunction in Premenopausal Women With 
Obstructive Sleep Apnea. Urology journal 2017; 14: 5051-5056. 
230. Koseoglu N, Koseoglu H, Itil O, Oztura I, Baklan B, Ikiz AO, Esen AA. Sexual function status in 
women with obstructive sleep apnea syndrome. The journal of sexual medicine 2007; 4: 
1352-1357. 
231. Stradling JR, Davies RJ. Is more NCPAP better? Sleep 2000; 23 Suppl 4: S150-153. 
 206 
 
232. Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nunez N, Caballero-Martinez I, Almeida-
Gonzalez CV, Catalan-Serra P, Pena-Grinan N. Long-term CPAP compliance in females with 
obstructive sleep apnoea. The European respiratory journal 2013; 42: 1255-1262. 
233. Ackermann S, Rasch B. Differential effects of non-REM and REM sleep on memory 
consolidation? Current neurology and neuroscience reports 2014; 14: 430. 
234. guidance NNIfHaCETa. Continuous positive airway pressure for the treatment of obstructive 
sleep apnoea/hypopnoea syndrome. 2008; nice.org.uk/guidance/ta139 [accessed 12 Sep 
2017]. 
235. West SD, Prudon B, Hughes J, Gupta R, Mohammed SB, Gerry S, Stradling JR. Continuous 
positive airway pressure effect on visual acuity in patients with type 2 diabetes and 
obstructive sleep apnoea: a multicentre randomised controlled trial. The European 
respiratory journal 2018; 52. 
236. Quinnell TG, Bennett M, Jordan J, Clutterbuck-James AL, Davies MG, Smith IE, Oscroft N, 
Pittman MA, Cameron M, Chadwick R, Morrell MJ, Glover MJ, Fox-Rushby JA, Sharples LD. A 
crossover randomised controlled trial of oral mandibular advancement devices for 
obstructive sleep apnoea-hypopnoea (TOMADO). Thorax 2014; 69: 938-945. 
237. Areias V, Romero J, Cunha K, Faria R, Mimoso J, Gomes V, Brito U. Sleep apnea-hypopnea 
syndrome and acute coronary syndrome - an association not to forget. Revista portuguesa 
de pneumologia 2012; 18: 22-28. 
238. Byun MK, Park SC, Chang YS, Kim YS, Kim SK, Kim HJ, Chang J, Ahn CM, Park MS. Associations of 
moderate to severe asthma with obstructive sleep apnea. Yonsei medical journal 2013; 54: 
942-948. 
239. Eroshina EV, Kalinkin AL, Sidorenko BA. [The diagnostic efficiency of the methods of separate 
and combined registration of oronasal airflow and pulse oximetry for detection of the 
obstructive sleep apnea/hypopnea syndrome]. Kardiologiia 2013; 53: 77-82. 
240. Gantner D, Ge JY, Li LH, Antic N, Windler S, Wong K, Heeley E, Huang SG, Cui P, Anderson C, 
Wang JG, McEvoy D. Diagnostic accuracy of a questionnaire and simple home monitoring 
device in detecting obstructive sleep apnoea in a Chinese population at high cardiovascular 
risk. Respirology (Carlton, Vic) 2010; 15: 952-960. 
241. Mason RH, West SD, Kiire CA, Groves DC, Lipinski HJ, Jaycock A, Chong VN, Stradling JR. High 
prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina 
2012; 32: 1791-1798. 
242. Patel AA, Donegan D, Albert T. The 36-item short form. The Journal of the American Academy of 
Orthopaedic Surgeons 2007; 15: 126-134. 
243. Jenkinson C, Stradling J, Petersen S. Comparison of three measures of quality of life outcome in 
the evaluation of continuous positive airways pressure therapy for sleep apnoea. J Sleep Res 
1997; 6: 199-204. 
 207 
 
244. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways 
pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006: 
Cd001106. 
245. Jenkinson C, Davies RJ, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic 
nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised 
prospective parallel trial. Lancet 1999; 353: 2100-2105. 
246. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of 
continuous positive airway pressure in obstructive sleep apnea and heart failure. American 
journal of respiratory and critical care medicine 2004; 169: 361-366. 
247. Thumboo J, Cheung YB, Machin D, Feng PH, Boey ML, Thio ST, Fong KY. Does being bilingual in 
English and Chinese influence changes in quality of life scale scores? Evidence from a 
prospective, population based study. Quality of life research : an international journal of 
quality of life aspects of treatment, care and rehabilitation 2005; 14: 529-538. 
248. Barbe F, Duran-Cantolla J, Capote F, de la Pena M, Chiner E, Masa JF, Gonzalez M, Marin JM, 
Garcia-Rio F, de Atauri JD, Teran J, Mayos M, Monasterio C, del Campo F, Gomez S, de la 
Torre MS, Martinez M, Montserrat JM. Long-term effect of continuous positive airway 
pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181: 
718-726. 
249. Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C, Barcelo A, 
Chiner E, Masa JF, Gonzalez M, Marin JM, Garcia-Rio F, Diaz de Atauri J, Teran J, Mayos M, 
de la Pena M, Monasterio C, del Campo F, Montserrat JM. Effect of continuous positive 
airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy 
patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 307: 2161-
2168. 
250. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, 
Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, 
Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS, 
Investigators S, Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive 
Sleep Apnea. N Engl J Med 2016; 375: 919-931. 
251. McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Davies RJ, Nunn AJ, Stradling 
JR, Riha RL, Morrell MJ. Continuous positive airway pressure in older people with obstructive 
sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. The Lancet 
Respiratory Medicine 2014; 2: 804-812. 
252. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, Levy P, Simonds 
AK, Somers VK, Zannad F, Teschler H. Adaptive Servo-Ventilation for Central Sleep Apnea in 
Systolic Heart Failure. N Engl J Med 2015; 373: 1095-1105. 
253. Fox N, Hirsch-Allen AJ, Goodfellow E, Wenner J, Fleetham J, Ryan CF, Kwiatkowska M, Ayas NT. 
The impact of a telemedicine monitoring system on positive airway pressure adherence in 
patients with obstructive sleep apnea: a randomized controlled trial. Sleep 2012; 35: 477-
481. 
 208 
 
254. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to 
improve usage of continuous positive airway pressure machines for adults with obstructive 
sleep apnoea. Cochrane Database Syst Rev 2009: CD007736. 
255. Lewis KE, Bartle IE, Watkins AJ, Seale L, Ebden P. Simple interventions improve re-attendance 
when treating the sleep apnoea syndrome. Sleep medicine 2006; 7: 241-247. 
256. Barnes M, Houston D, Worsnop CJ, Neill AM, Mykytyn IJ, Kay A, Trinder J, Saunders NA, Douglas 
McEvoy R, Pierce RJ. A randomized controlled trial of continuous positive airway pressure in 
mild obstructive sleep apnea. Am J Respir Crit Care Med 2002; 165: 773-780. 
257. Weaver TE, Maislin G, Dinges DF, Bloxham T, George CF, Greenberg H, Kader G, Mahowald M, 
Younger J, Pack AI. Relationship between hours of CPAP use and achieving normal levels of 
sleepiness and daily functioning. Sleep 2007; 30: 711-719. 
258. Zimmerman ME, Arnedt JT, Stanchina M, Millman RP, Aloia MS. Normalization of memory 
performance and positive airway pressure adherence in memory-impaired patients with 
obstructive sleep apnea. Chest 2006; 130: 1772-1778. 
259. Bruyneel M, Libert W, Ameye L, Ninane V. Comparison between home and hospital set-up for 
unattended home-based polysomnography: a prospective randomized study. Sleep medicine 
2015; 16: 1434-1438. 
 
  
 209 
 
TABLES 
Table 1. American Academy of Sleep Medicine (AASM) hypopnea scoring criteria 
Recommended hypopnea definition 
AASM 2007 criteria AASM 2012 criteria 
≥30% decrease in oronasal airflow from baseline AND ≥30% decrease in oronasal airflow from baseline AND 
Event duration ≥10 seconds AND Event duration ≥10 seconds AND 
Oxygen desaturation of ≥4%  Oxygen desaturation of ≥3% OR arousal 
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Table 2. MERGE sites participating in the UK Respiratory Sleep network 
Site Principal Investigator(s) 
National Heart and Lung Institute, Imperial College London 
Royal Brompton and Harefield Hospitals, London 
Prof Mary Morrell (MERGE CI) 
Dr Julia Kelly 
Dr Shirmila Withana 
Aintree University Hospital, Liverpool Dr John O'Reilly, Dr Sonya Craig 
Oxford Centre for Respiratory Medicine, Oxford Dr Annabel Nickol, Dr Chris Turnbull 
Freeman Hospital, Newcastle Dr Sophie West 
Lister Hospital, Stevenage Dr Alison McMillan 
Guys & St Thomas Hospital, London Dr Brian Kent 
Derriford Hospital, Plymouth Dr Neil Ward 
Taunton and Somerset Hospital, Taunton Dr Justin Pepperell 
Blackpool Teaching Hospital, Blackpool Dr Mohammad Paracha 
Tayside Health Board, Ninewells Hospital, Dundee  Dr Will Anderson 
Papworth Hospital, Cambridge Dr Tim Quinnell 
CI, chief investigator. 
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Table 3. Patient selection criteria for the MERGE study 
Inclusion Criteria 
• Age ≥18 and ≤80 years 
• Ability and willingness to provide written informed consent 
• AHI 5-15/h as per AASM 2007 scoring criteria (or AHI ≥5/h based on AASM 2012 
criteria if AHI was 0-4/h using AASM 2007 criteria) 
• Ability to tolerate a one-hour long CPAP run-in test 
Exclusion Criteria 
• Unstable cardiac disease 
• Inability to give fully informed consent 
• Supplemental oxygen 
• Secondary sleep pathology (e.g. periodic limb movement syndrome, narcolepsy, 
circadian disorder, obesity hypoventilation syndrome) 
• Epworth Sleepiness Scale score ≥15, or concerns about sleepy driving from physician/ 
sleep lab staff 
• Body mass index ≥40 kg/m2 
• Previous CPAP usage 
AASM, American Academy of Sleep Medicine; CPAP, continuous positive airway pressure.  
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FIGURES 
Fig. 1. MERGE study flow chart. AASM, American Academy of Sleep Medicine; AHI, apnea-
hypopnea index; CPAP, continuous positive airway pressure;  
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Study of a Novel APAP Algorithm for the Treatment of 
Obstructive Sleep Apnea in Women 
Nigel McArdle, MD1,2; Stuart King, BAppSc1,2; Kelly Shepherd, PhD1,2; Vanessa Baker, BHSc1,2; 
Dinesh Ramanan, M Biomed Eng3; Sahisha Ketheeswaran, BBiomedSc3; Peter Bateman, RN3; 
Alison Wimms, MScMed3; Jeff Armitstead, PhD3; Glenn Richards, MB ChB3; David Hillman, 
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Study Objectives: To assess the efficacy of a novel female-specific autotitrating continuous positive 
airway pressure (CPAP) algorithm (AutoSet for her, AfH) in premenopausal women relative to a 
standard autotitrating algorithm (AutoSet, S9) (ResMed Ltd., Bella Vista, New South Wales, Australia). 
Design: Prospective randomised crossover noninferiority trial. 
Setting: Tertiary hospital sleep clinic and university research sleep laboratory. 
Participants: 20 female patients with obstructive sleep apnea (OSA) established on long-term CPAP 
treatment. 
Interventions: Treatment with 1 night each of AfH and AutoSet while monitored with overnight 
laboratory-based polysomnography (PSG); order randomly allocated. 
Measurements and Results: The primary outcome variables were the apnea-hypopnea index (AHI) 
and 3% oxygen desaturation index (ODI 3%) determined from PSG. Treatment efficacy on the AfH 
night was noninferior to the AutoSet night as assessed by median (IQR) AHI (1.2 [0.60– 1.85]/h versus 
1.15 [0.40–2.85]/h, respectively, P = 0.51) and 3% ODI (0.85 [0.25–1.5]/h versus 0.5 [0.25–2.55]/h, 
respectively, P = 0.83). Other PSG measures were similar, except for the percentage of the night 
spent in flow limitation, which was lower on the AfH (0.14%) than the AutoSet night (0.19%, P = 
0.007). The device-downloaded 95th centile pressure on the AfH night was also lower than on the 
AutoSet night (10.6 ± 1.7 versus 11.6 ± 2.6 cmH2O, respectively; mean difference [95% confidence 
interval]: −1.1 [−2.13 to −0.01] cm H2O). 
Conclusion: Among premenopausal women a novel female-specific autotitrating algorithm (AfH) is as 
effective as the standard AutoSet algorithm in controlling obstructive sleep apnea (OSA). The new 
algorithm may reduce flow limitation more than the standard algorithm and achieve control of OSA at a 
lower (95th centile) pressure. 
Keywords: apnea-hypopnea index, automatic positive airway pressure algorithm, continuous positive 
airway pressure, obstructive sleep apnea, positive airway pressure titration, premenopausal women 
Citation: McArdle N, King S, Shepherd K, Baker V, Ramanan D, Ketheeswaran S, Bateman P, 
Wimms A, Armitstead J, Richards G, Hillman D, Eastwood P. Study of a novel APAP algorithm for the 
treatment of obstructive sleep apnea in women. SLEEP 2015;38(11):1775–1781. 
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INTRODUCTION 
Obstructive sleep apnea (OSA) is a common disorder 
characterized by repetitive collapse of the upper airway 
during sleep and associated nocturnal hypoxia and sleep 
fragmentation. It is a disorder that has widespread 
effects on health and is associated with reduced quality 
of life,1 neurocognitive impairment (including increased 
risk of motor vehicle accidents2), and increased 
cardiovascular morbidity and mortality; from ischemic 
heart disease, congestive heart failure, and stroke.3–5 
Early studies of OSA report a high male predominance, 
with male-to-female ratios ranging between 10:1 and 
60:1 in clinic populations.6 Hence, OSA is traditionally 
thought of as a predominantly male disorder and 
treatment options have often been developed and 
tested in male study populations. More recently, several 
studies have reported a male-to-female ratio closer to 
3:1,7,8 and indicate that women may present  
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with different clinical features8 and have different 
polysomnographic (PSG) patterns of obstructive sleep 
disordered breathing compared to men. In particular, 
PSG studies show a relative rapid eye movement (REM) 
predominance to obstructive events9 and milder disease 
(i.e., lower apnea-hypopnea index; AHI) in women 
compared to men.10,11 Women with obstructive sleep 
apnea are also less likely to manifest complete upper 
airway collapse (apneas)12 and more likely to have flow 
limitation, which can manifest as an upper airway 
resistance syndrome (UARS).11 These sex differences may 
affect therapeutic decisions and therapeutic 
effectiveness. 
The gold-standard treatment for moderate and severe  
OSA is continuous positive airway pressure (CPAP),13 
which acts as a pneumatic splint to maintain patency of 
the upper airway. Long-term treatment may be 
delivered using a standard CPAP device at a set “fixed” 
pressure, or using automatic positive airway pressure 
(APAP) devices that vary the pressure throughout the 
night based on device-monitored physiological signals. 
The pressure response in these APAP devices is 
controlled by a computerized algorithm. ResMed 
Corporation has recently developed a female-specific 
‘AutoSet for Her’ (AfH) algorithm; designed to optimize 
the pressure response to the specific patterns of 
obstructive sleep disordered breathing seen in women. 
The AfH algorithm is adapted from the S9 AutoSet 
algorithm (ResMed Ltd., Bella Vista, Sydney) with a 
number of modifications, including an increased 
sensitivity  
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to flow limitation, an optimized internal gain (a slower, 
and lower, pressure rise and decay in response to flow 
limitation), a lower cap on the pressure response to 
obstructive apneas, and an adaptive minimum pressure. 
We sought to assess the efficacy of this new algorithm in 
premenopausal women by comparing it to the standard 
ResMed S9 AutoSet algorithm. The primary aim of the 
study was to assess the efficacy of the AfH algorithm, 
based on a priori PSG outcome measures of the AHI and 
the 3% oxygen desaturation index (3% ODI). Secondary 
aims were to compare objective sleep quality measures 
and patient symptomatic responses between the 2 study 
nights. We hypothesized that the efficacy (AHI and 3% 
ODI) of the AfH algorithm would be noninferior to the 
standard AutoSet (ResMed) algorithm and speculated 
that its use would be associated with advantages in 
terms of patient comfort. 
METHODS 
Overview 
A double-blind randomized crossover study design was 
used (Figure 1), which required participants to undergo 
2 overnight laboratory-based PSGs, 1 night using an 
APAP device set in the AfH mode and the other night set 
in the standard AutoSet algorithm mode. 
Study Participants 
Inclusion criteria comprised premenopausal females 
aged 18 y or older; current positive airway pressure 
(CPAP or APAP) therapy use, where “current” was 
defined as on therapy for at least 1 mo prior to study 
entry; availability of a diagnostic PSG; diagnosis of mild-
moderate OSA (5 < AHI ≤ 30); and willingness and ability 
to give written informed consent 
Exclusion criteria comprised current use of bilevel 
positive airway pressure treatment; current use of 
supplemental oxygen; pregnancy; a preexisting lung 
disease or condition that would predispose the 
participant to pneumothorax (e.g., chronic obstructive 
pulmonary disease, lung cancer; pulmonary fibrosis; 
recent (< 2 y) pneumonia or lung infection; other lung 
injury); and any individual whom the researcher believes 
is unsuitable for inclusion because that person does not 
comprehend English or is unable to provide written 
Figure 1 —Study flow. Questionnaire asks about sleep quality  
And comfort using the device. PSG, polysomnography. 
Premenopausal Women Established  
on CPAP Treatment 
Questionnaire Questionnaire 
Laboratory PSG:  
AutoSet for Her 
Laboratory PSG:  
Standard AutoSet  
Laboratory PSG:  
AutoSet for Her 
Laboratory PSG:  
Standard AutoSet  
Questionnaire  Questionnaire 
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informed consent or physically unable to comply with 
the protocol. 
Potential participants were identified from the Sleep 
Clinic database, contacted by phone and asked if they 
wished to take part in the study. The study was 
approved by the Institutional Review Boards of the 
University of Western Australia and Sir Charles Gairdner 
Hospital. Written informed consent was obtained prior 
to participation in the study. The trial was registered 
with ClinicalTrials.gov (Clinical Trials Registry number: 
NCT01826513). 
Study Protocol 
A double-blind randomized crossover study design was 
used (Figure 1). Participants spent 1 night using an APAP 
device set in the AfH mode and another night set in the 
standard AutoSet algorithm mode. An in-house 
questionnaire asking about sleep quality and comfort 
using the device was completed after each study night. 
The studies were done on consecutive nights, apart 
from one patient whose studies were separated by 2 
nights. One member of the research team randomly 
determined the order of the nights, concealed the codes 
using opaque envelopes, and allocated device modes to 
each participant. Neither the patient nor the overnight 
research staff was able to ascertain the device mode 
because the device appeared identical irrespective of 
the algorithm used. Furthermore, all outcome analyses 
were performed by one sleep scientist, blinded to the 
study arm (i.e., scoring of respiratory events was 
performed without access to the pressure signal to 
ensure full blinding, i.e., using other respiratory signals, 
including mask flow signal). Self-reported menopause 
status, medical history, and concomitant medications 
were recorded. Comorbidities were identified based on 
reported history or treatment for the condition. 
CPAP 
During the study nights the device was set to a pressure 
range of 4–20 cm H2O, and the ramp set at the patients’ 
usual value (AutoSet night) or automatic with a 
maximum of 30 min (AfH night). All other settings (e.g., 
humidification) were set as per the patients’ usual device 
and the patient used his or her own mask and chin strap 
(if required) on both study nights. The device was set by 
research staff in the evening prior to arrival of overnight 
staff to ensure the latter were blinded to the algorithm 
used. 
PSG 
In-laboratory PSG was performed using the 
Compumedics Grael HD-PSG (Compumedics Ltd., 
Abbotsford, Australia), which recorded the following 
signals: F3-M2, F4-M1, C3M2, C4-M1, O1-M2, O2-M1 
electroencephalogram, bilateral electrooculograms, 
submental electromyogram, electrocardiogram, device 
analog outputs (i.e., mask pressure, unintentional leak 
and flow), oximetry (averaged over three beats, sampling 
256 Hz), ribcage and abdominal movement (respiratory 
inductance plethysmography), body position, sound 
intensity (dB), and bilateral tibial electromyogram. 
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Questionnaire 
Symptomatic responses to therapy, including questions 
about participant’s perception of their sleep on the 
device and quality of sleep, were assessed in the 
morning after each study night using a Likert scale (see 
supplemental material). 
Data Analyses 
PSGs were manually scored at the study site by 
experienced sleep scientists according to standard 
criteria (AASM 2012).14 Flow limitation was assessed by 
the site using the sponsor’s  
(ResMed Ltd.) flow limitation tool to perform automatic 
analyses of high-fidelity flow signals (25 Hz). The flow 
limitation tool utilizes the shape, tidal volume, and duty 
cycle (ratio of inspiratory time to total breath time) of 
each breath and automatically identifies whether each 
breath is flow limited or not. 
Statistical Analyses 
Statistical analyses were performed using SigmaStat 
version 3.5 (Systat, Richmond, CA, USA). Parametric data 
were described using means and standard deviations 
(SDs) and paired comparisons were performed using 
paired t tests and  
95th percentile confidence intervals (95% CIs) were 
reported. Nonparametric variables were described using 
medians and interquartile ranges and paired 
comparisons made with the Wilcoxon signed-rank test. 
Statistical significance was considered to occur when P < 
0.05. 
Sample Size Calculation 
We tested the hypothesis that the AfH algorithm was not 
worse (but not necessarily better) than the standard 
AutoSet algorithm. Hence, the null Hypothesis (H0) was: 
AfH is inferior to standard AutoSet and the alternate 
Hypothesis (H1) was: AfH is noninferior to standard 
AutoSet. The expected  
AHI difference (mu) is 0 events/h and the NonInferiority 
Margin (delta) is 0.75 events/h (a difference of 1 event/h 
is seen as clinically significant: 0.75 events/h was chosen 
to ensure any relevant AHI change was observed). 
Unpublished data from a trial15 supported by the 
sponsor showed that the SD of such a dataset is 1.06 
events/h. Based on a power of  
80% and two-sided alpha of 0.05 (one-sided alpha of 
0.025 used in this noninferiority trial), the sample size 
(for paired Trial)16 = (Z(1 − a.2) + Z(1 − b))2) * (SD / (mu 
− delta))2. Using our data, the sample size = (1.96 + 0.85)2 
* (1.06 / (0 − 0.75))2 = 15.8. On this basis, and allowing 
for potential dropouts, we chose a sample size of 20 for 
the study. 
RESULTS 
Patient Characteristics 
Twenty women participated in the study and all 
completed the protocol. Participants were 
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premenopausal, obese (body mass index; BMI = 38.5 ± 
7.5 kg/m2), predominantly Caucasian  
Table 1—Baseline characteristics of study participants. 
Premenopausal  
Baseline Characteristics Women, n = 20  
 Age, y  44.6 ± 5.1  
 BMI, kg/m2  38.5 ± 7.5 
 Self-reported ethnicity  9:1 
(Caucasian: Australian aboriginal) 
 History of hypertension 6 (30%) 
 History of hyperlipidemia 4 (20%) 
 History of diabetes 3 (15%) 
 History of hypothyroidism 5 (25%) 
 Diagnostic AHI, events/h 19.1 ± 8.7  
Average duration of positive airway therapy, moa 23.3 ± 
34.5  
 CPAP, cm H2O b 11.0 ± 2.0  
Data presented as mean ± standard deviation, ratio or 
number (percentage). aData missing in one. bData for 18 
participants receiving long-term fixed pressure CPAP (two 
participants were receiving automatic positive airway 
pressure as long-term therapy). AHI, apneahypopnea 
index; CPAP, continuous positive airway pressure. 
females aged 44.6 ± 5.1 y, most of whom received a 
diagnosis of moderately severe OSA (AHI = 19.1 ± 8.7 
events/h) (Table 1). Three participants were recruited 
with severe OSA after a decision was made by the study 
investigators to modify the protocol to assist with 
recruitment. This protocol variation was considered to 
be safe and was approved by the local ethics review 
board. Participants had a higher prevalence of 
cardiovascular risk factors (Table 1) than are typical for 
similar aged women in the community but similar to that 
expected in an OSA sleep clinic population. None had 
severe cardiac or pulmonary comorbidities. Participants 
had been using CPAP treatment for an average of 23 mo 
with a mean fixed CPAP pressure of 11.0 ± 2.0 cm H2O, 
apart from two patients who had been using an APAP 
device (Table 1). The majority of patients were using a 
nasal mask (55%), with the remainder using nasal pillows 
(35%) or a full face mask (15%). 
Outcomes 
Treatment efficacy on the AfH night was noninferior to 
the AutoSet night as assessed by AHI (1.2 [0.60–1.85]/h 
versus 1.15 [0.40–2.85]/h, P = 0.51) and 3% ODI (0.5 
[0.25–2.55]/h versus 0.85 [0.25– 1.5]/h, P = 0.83) (Figure 
2 and Table 2). In comparison with the patients’ 
diagnostic AHI there was a statistically and clinically 
significant reduction in AHI with treatment using the 
AfH (diagnostic versus AfH: 19.07 versus 1.2/h, P < 
0.001) and AutoSet algorithms (diagnostic versus 
AutoSet: 19.07 versus 1.15/h, P < 0.001). Percentage of 
breaths with flow limitation during sleep was 
significantly less using the AfH algorithm (0.14%) than 
the AutoSet (0.20%, P = 0.02) (Table 2). Other PSG 
measures of sleep quality were similar between study 
nights (Table 2, all P > 0.05). The downloaded 95th 
centile pressure from the device on the AfH study night 
was lower than on the AutoSet night (10.56 ± 1.7 versus 
11.63 ± 2.6 cmH2O; mean difference (95% CI): −1.1 
(−2.13 to −0.01) cm H2O). The downloaded median 
pressure delivered by the AfH device was similar to that 
delivered by the AutoSet (P > 0.05). The downloaded 
median  
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leak from the device was similar on the AfH and AutoSet 
nights (P > 0.05), as was the 95th centile leak (AfH: 9.0 ± 
9.6 l/min, AutoSet: 12.6 ± 15.6 l/min, P > 0.05). Symptom 
response to the treatment nights and device tolerance 
were similar following a night using the AfH compared to 
AutoSet (all P > 0.05) (Table 3). 
DISCUSSION 
This study among premenopausal women shows the AfH 
algorithm to be as efficacious as the standard AutoSet 
algorithm, according to overnight full PSG evaluation. 
Compared to a diagnostic study night (i.e., without 
treatment) both algorithms reduced the AHI to ‘well 
controlled’ (P < 0.001), confirming that these are 
suitable algorithms for CPAP treatment of OSA. In 
addition, sleep efficiency was high on the AfH and 
AutoSet nights and other PSG measures of sleep quality 
were similar on both nights and similar to the quoted 
normal ranges for middle-aged females.17,18 Notably, 
there was a statistically significant reduction in flow 
limitation (% of breaths), achieved at a lower (95th 
centile) pressure, on the AfH night compared to the 
AutoSet night. 
Many of the early studies showing a high prevalence of 
OSA among males, compared to females, used clinic-
based samples.6,8 By contrast, community studies7,19,20 
have consistently shown male-to- female ratios to range 
from 2:1 to 4:1, suggesting clinical underrecognition of 
OSA in females, perhaps because females report less 
classic OSA symptoms such as snoring19,21 and witnessed 
apneas22 and for other sociocultural reasons.22 The 
historically high male prevalence in clinical samples has 
resulted in most treatment options being developed and 
tested in predominantly male study samples. Moreover, 
several recent studies have reported sex-specific 
differences in the patterns of sleep and sleep disordered 
breathing, particularly among premenopausal 
Figure 2 —Comparison of efficacy outcomes during standard 
AutoSet  vs AutoSe  for Her (AfH) treatment nights. 
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women.9,10,23 These differences raise the possibility that 
tailoring OSA treatment according to sex-specific 
patterns of obstructive sleep disordered breathing may 
improve the efficacy of APAP treatment. The current 
device was, therefore, designed and developed to 
provide a female-specific APAP algorithm (AfH) with 
the aim of targeting the breathing abnormalities 
characteristic of female patients. 
The primary aim of the current study was to test the 
hypothesis that the efficacy of the new AfH algorithm is 
noninferior to the standard AutoSet algorithm. The AHI 
and ODI were chosen as the primary outcome measures. 
AHI is the standard accepted metric used to determine 
severity of OSA and the ODI may have particular 
usefulness as a predictor of OSA-related vascular and 
metabolic consequences.24 On both measures the new 
AfH algorithm performed similarly to the standard 
AutoSet algorithm, as assessed by the gold standard of 
laboratory-based PSG. This finding supports the use of 
the AfH algorithm as a new efficacious treatment option 
for mild moderate OSA among premenopausal patients. 
The AfH algorithm has been designed to be more 
sensitive to flow limitation by responding to the first 
identified flow-limited breath rather than requiring three 
consecutive flow-limited breaths, as occurs with the 
standard AutoSet algorithm. The basis for this change is 
the increasing evidence that inspiratory flow limitation is 
more prevalent in women compared to men. For example, 
a recent study among consecutive sleep clinic patients 
referred for evaluation of sleep disordered breathing 
found women to have more UARS than OSA, whereas 
among men the prevalence of OSA was greater than 
UARS.11 Similarly, women attending a sleep clinic appear 
to have fewer episodes of complete upper airway 
collapse (lower ratio of apneas to hypopneas) compared 
to men.12 The precise mechanisms underlying these 
findings have yet to be resolved, but are most likely 
related to complex sex-related differences in the 
structure and function of the upper airway. For example, 
comparisons between men and women, matched for 
BMI, found the critical airway closing pressure (Pcrit) 
was lower in women compared to men without 
differences in respiratory control stability.25 Overall, 
these studies indicate that women have a less collapsible 
upper airway, making obstructive apneas less likely and 
predisposing to partial airway collapse (hypopnoeas) and 
flow limited breathing abnormalities during sleep. 
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Despite the percentage residual flow limitation being low 
with both algorithms, the current study showed 
improved control of flow limitation on the AfH night 
(Table 2). It is unknown whether a reduction from 0.20 to 
0.14% flow-limited breaths using AfH, compared to 
standard AutoSet, is of clinical significance. However, the 
participants were compliant users, established on CPAP 
treatment, who had excellent control of their OSA using 
APAP, producing ‘floor effects’ that limit the possibility 
of showing large improvements in disease control with 
the new algorithm. Studies on consecutive CPAP naïve 
patients in the standard clinical setting are needed to 
assess the potential magnitude of improvement in flow 
limitation obtainable from the AfH algorithm. 
Table 2—Polysomnographic sleep characteristics during standard Autoset and AutoSet for her (AfH) treatment nights. 
Polysomnographic Characteristic Standard AutoSET, n = 20   AfH, n = 20  95% CI for Mean Difference  P  
 Total sleep time 383.8 ± 48.5 388.4 ± 56.0 −32.5 to 23.3 0.74 
 Sleep efficiency, %  84.1 ± 7.1  84.2 ± 9.2  −5.2 to 5.0 0.96  
 Sleep latency, min  16.2 ± 17.2  19.1 ± 15.6  −10.2 to 4.5  0.43 
 Wake after sleep onset, min 52.9 ± 31.8 52.8 ± 39.6 −22.9 to 23.0 0.99 
 Time N1, % 10.2 (8.7–15.5) 11.0 (9.3–14.2) 0.78 
 Time N2, %  51.4 (47.6–53.1) 51.4 (39.8–54.6) 0.73  
 Time N3, %  21.5 ± 8.2  22.4 ± 11.7  −3.7 to 1.8  0.49  
 Time REM, %  15.4 ± 7.1  16.6 ± 7.0  −4.9 to 2.5  0.52 
 Arousal number index, events/h 12.3 ± 6.4 11.7 ± 4.2 −1.16 to 2.47 0.46 
 AHI, events/h slept 1.15 (0.40–2.85) 1.20 (0.60–1.85) 0.51 
 Obstructive apnea index, events/h 0 (0–0) 0 (0–0) 0.81 
 Central apnea index, events/h 0.50 ± 0.68 0.38 ± 0.48 −0.15 to 0.37 0.39 
 Central apnea number 1 (0–5.5)  1 (0–4.5) 0.24 
 Hypopnea index, events/h 0.50 (0.20–1.7) 0.80 (0.25–1.35) 0.65 
 RERAS, number/h 0.75 (0.4–1.45) 0.80 (0.45–1.60) 0.50 
 Flow limitation, % of breaths  0.202 ± 0.151 0.145 ± 0.093 0.010 to 0.102 0.02 
 Mean SpO2, %  97 (96–97) 96 (96–97) 0.16 
 Lowest SpO2,% 91.65 ± 2.23 91.10 ± 0.56 −0.68 to 1.78 0.36 
 ODI 3%, events/h slept 0.85 (0.25–1.5) 0.5 (0.5–2.55) 0.83 
 ODI 4%, events/h slept 0.25 (0–0.55) 0.2 (0–0.55) 0.97 
AHI, apnea-hypopnea index; CI, confidence interval; N1, stage N1 sleep; N2, stage N2 sleep; N3, stage N3 sleep; ODI 3%, 
oxygen desaturation index of 3% or more; ODI 4%, oxygen desaturation index of 4% or more; REM, rapid eye movement 
sleep; RERAS, respiratory event-related arousals; SpO2, oxygen saturation. 
Table 3—Subjective feedback from participants after standard Autoset and Autoset for her (AfH) treatment nights. 
Mean Difference and 95% Cl  
Questionnaire Response  Standard AutoSet, n = 20  AfH, n = 20 for Mean Difference P  
 Comfort of breathing  8.0 (7.125–9.4)  8.0 (7.0–9.25)  0.67  
 Ease of falling asleep  7.9 ± 1.8  7.0 ± 2.3  0.58 (−0.78 to 1.94) 0.38 
 Sleep disturbance  9 (7.25–9.4)  8 (6.5–9.0)  0.12  
 Feeling of being refreshed  7.6 ± 1.6  6.4 ± 2.2  1.3 (−0.1 to 2.7) 0.07  
An in-house questionnaire asked for responses using an 11-point Likert rating scale (questionnaire provided in supplemental 
material). Data presented as mean ± standard deviation, or median (Interquartile range). CI, confidence interval. 
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Another novel feature of the AfH algorithm is a moving 
minimum AutoSet pressure (i.e., a minimum pressure is 
set to which pressure decreases during sleep periods 
devoid of respiratory events). If apneas occur within a 
short time period the minimum AfH pressure will 
automatically increase and the pressure will not decline 
below this level for the remainder of the night’s therapy. 
The purpose of this is to minimize inappropriate 
pressure decreases during REM sleep that could occur 
with the standard AutoSet algorithm. It is possible, for 
example, that the standard AutoSet algorithm pressure 
could decay below the critical closing airway pressure 
during REM sleep, which can result in several apneas at 
the beginning of REM sleep until the device responds 
with appropriate pressure increases. This could be 
particularly important in women, who have been shown 
to have a predominance of REM-related OSA compared 
to men.9 During REM sleep CPAP pressures may need to 
be higher to maintain patency of the upper airway 
secondary to a REM-related reduction in the tone of 
upper airway muscles. It is also possible that this 
algorithm feature could reduce pressure variability, 
contribute to longer REM sleep, and reduce REM-related 
respiratory events. However, the current study did not 
find any statistically significant differences on these 
measures, although it was not designed or statistically 
powered to detect these differences and larger studies 
would be needed in order to demonstrate any such 
changes. 
In order to prevent an excessive pressure rise, the AfH 
algorithm does not increase pressure above 12 cm H2O 
in response to detected apneas (but pressure can 
increase above 12 cm H2O if other respiratory events are 
present). Furthermore, the AfH algorithm increases 
pressure in response to flow limitation at a slower rate 
and to a lesser extent than the standard AutoSet 
algorithm (similarly the decay in the gain is lower). These 
features are in response to previous studies that have 
shown that women tend to have less severe OSA, for a 
given BMI, compared to men,9–11 and that women appear 
to require lower CPAP pressures than men as 
determined by manual attended laboratory PSG 
titration.26 The current study supports the use of this AfH 
pressure algorithm strategy among premenopausal 
female patients with OSA because equivalent control of 
apneas and hypopneas and improved control of flow 
limitation was achieved at a lower 95th centile pressure 
than the standard AutoSet algorithm. The 95th centile 
pressure is an important index of pressure requirements 
as it is the value commonly used when setting a fixed 
pressure from an AutoSet titration. 
CPAP devices often incorporate a ramp to increase 
pressure gradually when the device is first turned on; this 
aims to keep pressure low and more comfortable when 
falling asleep. The AfH algorithm incorporates a novel 
automatic ramp that keeps the pressure at a minimum 
until there are changes in the breathing pattern 
indicative of either sleep onset (based on regularity of 
the breaths); or three obstructive apneas or hypopneas 
occurring within 2 min; or five consecutive snore breaths. 
The algorithm will then ramp up to minimum therapy 
pressure within 1 min of the event occurring at a rate of 
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1 cm H2O/ min. Women with OSA have longer sleep 
latencies than men with OSA despite no difference in 
age, respiratory disturbance index, or oxygen 
saturation.27 Hence, the rationale of the AfH automatic 
ramp is to allow sufficient time for sleep onset by 
minimizing disturbance from increasing ramp pressure, 
while still responding to changes consistent with sleep or 
obstructive events as necessary. The participants’ sleep 
latency in the current study was not significantly different 
using the AfH and the standard AutoSet algorithm and 
similar to values reported in normal middle-aged 
women.18 
In practice, overall treatment effectiveness is 
determined not only by efficacy but also by compliance 
with therapy in the home environment. An in-house 
questionnaire indicated there were no significant 
differences in symptomatic report and tolerance of the 
AfH algorithm compared to the AutoSet algorithm. 
Further studies are needed to assess compliance in the 
home with the new AfH algorithm. 
The strengths of the current study include the use of a 
randomized controlled crossover design; with patients 
acting as their own controls to increase study power. In 
addition, the patients, therapists, and sleep data scorers 
were blinded to the study intervention. The gold 
standard of in-laboratory full PSG assessment was used 
to ascertain the primary study outcomes, and currently 
recommended definitions for respiratory events were also 
used. However, the study was not adequately powered 
to make conclusive statements about secondary 
outcomes.  
Although the study found reduced flow-limited breaths 
and lower pressure requirements using the AfH 
algorithm, it is unclear if these changes will translate 
into measureable clinical benefits to female OSA 
patients. Further studies, adequately powered for these 
outcomes, will be needed to answer these questions. 
In conclusion, the primary finding of this study is that the 
efficacy of a novel female-specific (AfH) algorithm 
among premenopausal women with OSA is noninferior 
to the standard AutoSet algorithm. The study also 
suggests the AfH algorithm results in superior control of 
flow limited breaths in premenopausal women 
compared to the AutoSet algorithm, and it achieves this 
at a lower 95th centile pressure. 
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Abstract 
Bench testing is a useful method to characterize the response of different automatic positive airway pressure (APAP) 
devices under well-controlled conditions. However, previous models did not consider the diversity of obstructive 
sleep apnea (OSA) patients’ characteristics and phenotypes. The objective of this proof-of-concept study was to 
design a new bench test for realistically simulating an OSA patient’s night, and to implement a one-night example of 
a typical female phenotype for comparing responses to several currently-available APAP devices. We developed a 
novel approach aimed at replicating a typical night of sleep which includes different disturbed breathing events, 
disease severities, sleep/wake phases, body postures and respiratory artefacts. The simulated female OSA patient 
example that we implemented included periods of wake, light sleep and deep sleep with positional changes and was 
connected to ten different APAP devices. Flow and pressure readings were recorded; each device was tested twice. 
The new approach for simulating female OSA patients effectively combined a wide variety of disturbed breathing 
patterns to mimic the response of a predefined patient type. There were marked differences in response between 
devices; only three were able to overcome flow limitation to normalize breathing, and only five devices were 
associated with a residual apnea-hypopnea index of <5/h. In conclusion, bench tests can be designed to simulate 
specific patient characteristics, and typical stages of sleep, body position, and wake. Each APAP device behaved 
differently when exposed to this controlled model of a female OSA patient, and should lead to further understanding 
of OSA treatment. 
 
Introduction 
Obstructive sleep apnea (OSA) is a prevalent breathing disorder and is considered a major public 
health issue, affecting 5–15% of the general population and increasing with both body mass index 
and age (up to at least 60–65 years) [1,2]. OSA is characterized by repetitive narrowing 
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and closure of the upper airway during sleep [3] that results in brain arousal, intermittent hypoxia, 
negative intrathoracic pressure swings, and increased sympathetic activity. OSA is associated with a 
reduction in quality of life, daytime sleepiness, traffic accidents, neurocognitive impairment, 
metabolic, cardiovascular disease [4] and malignancies [5]. 
The treatment of choice for OSA is the application of continuous positive airway pressure (CPAP) to 
the patient’s nose or mouth through a mask during sleep at home. This pressure in the mask is 
transmitted to the pharyngeal area, splinting the collapsible upper airway walls thereby avoiding 
obstruction. Auto-adjusting positive airway pressure (APAP) devices, which are increasingly being 
used, are driven by algorithms that measure abnormal sleep breathing events, analyze the patient’s 
breathing pattern and eventually increase the delivered pressure in response to airway obstruction, 
or decrease pressure when breathing is stable to increase patient comfort [6–11]. In theory, APAP 
devices should be ideal for treating a range of patients with different characteristics, and for 
effectively treating OSA despite within-night and night-to-night variations in the upper airway 
collapsibility experienced by each individual patient [12–16]. However, commercially available APAP 
devices contain undisclosed proprietary algorithms, and therefore the way that they measure and 
respond to specific breathing patterns varies [17]. In addition, some APAP manufacturers are 
introducing new algorithms based on specific patient characteristics. This move towards 
personalized medicine in the treatment of OSA means greater choice for patients and more 
variability in APAP algorithms. Therefore, understanding how each device responds to different OSA 
patterns requires comparative studies using well defined references. 
Bench testing is a useful method to characterize the response of different APAP algorithms under 
well-controlled conditions, thus avoiding the biological variability inherent in clinical trials. However, 
previously used bench test models have been based on subjecting the APAP device under test to a 
repetitive string of disturbed breathing patterns, without providing a sufficiently wide spectrum of 
events. These limitations mean that variety in patient characteristics and phenotypes, or the 
changes that occur during different sleep stages and body positions over the course of a night’s 
sleep, cannot be taken into consideration. This is particularly relevant given that different 
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subpopulations of OSA patients (e.g. children, men, women, the elderly) exhibit specific traits in 
their sleep-related breathing disorders [18]. 
Therefore, the aims of this proof-of-concept study were: 1) to design a new complex and versatile 
bench test approach for realistically simulating respiratory events throughout the course of the night 
in an OSA patient, mimicking breathing disturbances across different phenotypes, and 2) to 
implement a full night example of a female OSA phenotype and use this to compare the responses of 
several currently-available APAP devices. 
Materials and Methods 
The hardware of our new model was based on a previously described bench test [19]. This fully 
computer-driven model comprises a servo-controlled pump able to deliver a flow that replicates any 
breathing waveform stored in the computer. An obstruction valve allows the simulation of 
controlled obstructive events by imposing mechanical impedances previously recorded in patients 
with OSA. Two other valves can mimic leaks and mouth breathing, and a loudspeaker-in-box system 
can superimpose simulated snoring onto the breathing flow. The test bench is equipped with two 
sensors, one to measure pressure at the simulated patient entrance and one to measure the actual 
flow generated by the patient simulator. A calibrated leak based on a 4-mm internal diameter (ID) 
orifice [20] mimics the mask leak (exhalation port) in nasal masks. In previous studies, this system 
was fed by a collection of disturbed breathing events, such as obstructive and central apneas, 
hypopneas, flow limitation, mask leaks and mouth expiration [19,21]. 
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To design the new OSA simulator model we developed a novel approach aimed at realistically 
replicating a typical night of sleep for a female patient. With this aim, we considerably expanded our 
library of disturbed breathing patterns anonymously extracted from polysomnography recordings 
obtained from real OSA patients and we incorporated several new adjustable features into the 
simulator. Specifically, the new patient model can be set to react to the pressure delivered by the 
APAP device (PAP-responsive mode) or to reproduce a fixed scenario of disturbed breathing events 
(Steady mode), depending on the device characteristics being tested. Moreover, the severity of the 
simulated OSA profile is now fully modifiable by changing the frequency and duration of each 
breathing event. Various artefacts were introduced into the event spectrum, such as changes in tidal 
volume and breath rate, to replicate typical events during wake such as irregular breathing, 
swallowing, moving and talking. By combining these new features, we aimed to create a new OSA 
model concept model that can realistically replicate a whole night of sleep, including phases of 
wake, rapid eye movement (REM) and non-REM sleep, and change in body position, each one 
designed to mimic different characteristics in terms of upper airway collapsibility. 
For this study specifically, as an example of an entire night of sleep-disordered breathing (SDB), the 
bench test model was set to simulate the disturbed patterns of a female OSA patient with the 
following characteristics: long sleep latency (45 min), low positive airway pressures (PAPs) required 
to overcome obstructive events, high proportion of flow limitation events versus apneas, higher 
apnea-hypopnea index (AHI) during REM sleep, and only minor positional effects on upper airway 
collapsibility. The features and structure of this female-specific OSA patient simulation are detailed 
in Table 1. The breathing pattern of the simulated patient depended on the PAP applied by the 
device under test, with a total duration of 4 hours and 15 minutes. APAP pressure values required to 
normalize breathing during each stage of the simulation are shown in Fig 1. The simulated night 
consisted of programming the different stages described in Table 1, starting with 45 minutes of 
simulated awake stage (sleep onset) followed by a succession of different sleep stages with the 
features detailed in Table 1 (e.g. breathing frequency, number and types of respiratory events) and a 
final awake short period. In this way we were able to model a patient exhibiting different sleep 
breathing characteristics throughout consecutive sleep stages. 
Ten different commercially available APAP devices were tested using the new bench test model and 
the female-specific simulation described above: AirSense 10 (A) and AirSense 10 AutoSet for Her (B) 
by ResMed; Dreamstar by Sefam (C); Icon by Fisher & Paykel (D); 
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Resmart by BMC (E); Somnobalance (F) and Prisma 20A (G) by Weinmann; System One by 
Respironics (H); iCH (I) and XT-Auto by Apex (J). Each APAP device was connected with its own tube 
to the bench model. Default APAP settings were used (minimum pressure 4 cmH2O, maximum 
pressure 20 cmH2O). Each device was tested twice and the results averaged to obtain the final 
values. 
Results 
The new OSA patient simulator could effectively combine a great variety of SDB elements to mimic 
the response of the predefined patient type. The responses of the assessed APAP devices to the new 
female-specific bench test model are summarized in Table 2. There was considerable variation 
among devices, particularly with respect to the mean and maximum nasal pressures applied, and the 
ability to overcome obstructive events and flow limitation, The residual AHI was calculated as the 
number of residual obstructive events per hour and the residual flow limitation was measured as the 
portion of the test in minutes (excluding the initial 45-minute wake period) that the simulated 
patient remained on flow limitation. 
Table 1. Description of the patient simulation implemented in the bench test model. 
Stage Duration AHI Features 
Sleep onset 45 min -  
   16 breaths/min 
   VT 500 mL 
   Random insertion of changes in breathing rate and VT, and swallowing 
Non-REM cycle 1 60 min 15/h  
   Body position: side 
   Apneas (0–5 cmH2O): event length 12 sec 
   Hypopneas (5–7 cmH2O): event length 16 sec 
   Flow limitation (7–9 cmH2O) 
   Normal breathing (>9 cmH2O) 
REM cycle 1 15 min 30/h  
   Apneas (0–8 cmH2O): event length 18 sec 
   Hypopneas (8–10 cmH2O): event length 16 sec 
   Flow limitation (10–12 cmH2O) 
   Normal breathing (>12 cmH2O) 
Non-REM cycle 2 45 min 15/h  
   Body position: side 
   Apneas (0–5 cmH2O): event length 12 sec 
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   Hypopneas (5–7 cmH2O): event length 16 sec 
   Flow limitation (7–10 cmH2O) 
   Normal breathing (>10 cmH2O) 
REM cycle 2 25 min 30/h  
   Apneas (0–7 cmH2O): event length 18 sec 
   Hypopneas (7–9 cmH2O): event length 16 sec 
   Flow limitation (9–11 cmH2O) 
   Normal breathing (>11 cmH2O) 
Non-REM cycle 3 30 min 15/h  
   Apneas (0–5 cmH2O): event length 18 sec 
   Hypopneas (5–7 cmH2O): event length 16 sec 
   Flow limitation (7–10 cmH2O) 
   Normal breathing (>10 cmH2O) 
REM cycle 3 30 min 30/h  
   Body position: supine 
   Apneas (0–9 cmH2O): event length 18 sec 
   Hypopneas (9–11 cmH2O): event length 16 sec 
   Flow limitation (11–13 cmH2O) 
   Normal breathing (>13 cmH2O) 
Awake 5 min - Normal breathing 
AHI: apnea-hypopnea index; REM: rapid eye movement; VT: tidal volume. 
 
Breathing normalization with a residual AHI <5/h was only achieved with devices A, B and D; devices 
E, H, I and J were associated with more than five residual events per hour. Pressure changes of each 
device throughout the whole test are displayed in Fig 1. 
Considering the 45-minute wake period, there was significant variation in the behaviour of the 
different devices. Table 3 shows the pressure values reached by each tested device at the end of the 
simulated wake period. Device C did not increase the pressure during wake periods. 
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Fig 1. Pressure trends over a full simulated night (grey line) for all APAP devices tested. A device that delivered pressures above the blue 
line achieves full breathing normalization, while if it delivered pressures just above the red line only obstructive apneas were overcome. 
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Table 2. Reponses of automatic CPAP devices to a specific simulated OSA patient. 
Device Pmax 
cmH2O 
Pmean 
cmH2O  
Residual AHI 
AHI,/h 
Overcome obstructive 
events? 
Overcome flow limitation? Residual flow 
limitation, min (% 
sleep time) 
A 18.65 13.25 0.7 Yes Yes 4 (2%) 
B 15.4 11.8 0.7 Yes Yes 4 (2%) 
C 11.4 6.75 16.5 No No 24 (12%) 
D 15.3 11.3 0.6 Yes Yes 24.5 (12%) 
E 11.35 7.7 11.9 No No 81 (40%) 
F 12.6 9.5 2.4 Yes No 167 (81%) 
G 12.1 10.05 1.6 Yes No 122 (60%) 
H 12.45 7.75 10 No No 76 (37%) 
I 10.6 8.3 6.5 Yes No 142 (69%) 
J 10.1 8.2 8.5 No No 132.5 (65%) 
AHI: apnea-hypopnea index; Pmax: maximum positive airway pressure applied; Pmean: mean positive airway pressure; A: AirSense 10 by 
ResMed; B: AirSense 10 AutoSet for Her by ResMed; C: Dreamstar by Sefam; D: Icon by Fisher & Paykel; E: Resmart by BMC; F:  
omnobalance by Weinmann; G: Prisma 20A by Weinmann; H: System One by Respironics; I: iCH by Apex; J: XT-Auto by Apex. 
 
Three devices (A, B and E) displayed only mild pressure increases (<2 cmH2O). Moderate pressure 
increases (2.5–3 cmH2O) were displayed by three devices (H, I and J), and significant pressure 
increases (>7 cmH2O) were seen from three devices (D, F and G). Three examples of different 
responses during the simulated wake period are presented in Fig 2, together with the flow signal 
generated by the simulator during the initial awake phase, which consisted of normal breathing with 
some events inserted simulating flow alterations due to irregular breathing (E) and swallowing (S). 
Devices A, B and D contain algorithms aimed at automatically detecting sleep onset (for A, B 
AutoRamp mode and for D SenseAwake mode). Devices A and B showed similar pressure increases 
with AutoRamp mode turned off, while device D responded with higher pressure increases when the 
SenseAwake mode turned off. 
To assess whether the observed variations in pressure during wake had an influence on the results 
of testing, a subset of devices that showed a moderate to significant pressure increase during sleep 
onset (D, G, H and I) were retested without the wake phase of the test. In this 
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Table 3. Pressure values reached by each device after 45 minutes of simulated wake. 
Device APAP pressure after 45 mins of simulated wake (cmH2O) 
A 5.4 (5.8 with AutoRamp OFF) 
B 4.8 (5.2 with AutoRamp OFF) 
C 4.0 
D 11.2 (14.5 with SenseAwake OFF) 
E 4.6 
F 11.8 
G 11.7 
H 6.5 
I 6.8 
J 6.9 
A: AirSense 10 by ResMed; B: AirSense 10 AutoSet for Her by ResMed; C: Dreamstar by Sefam; D: Icon by Fisher & Paykel; E: Resmart by 
BMC; F: Somnobalance by Weinmann; G: Prisma 20A by Weinmann; H: System One by Respironics; I: iCH by Apex; J: XT-Auto by Apex. 
 
 
Fig 2. Pressure trends for three different APAP devices tested during the initial 45-minute simulated wake period. Device A (black line) 
showed a mild pressure increase (< 2 cmH2O), device I (dark grey line) showed a moderate pressure increase (2.5–3 cmH2O), while device 
D (light grey line) showed a high pressure increase (>7 cmH2O) in response to the breathing pattern simulating 45 minutes of wake period 
(blue line). E: erratic breathing; S: swallowing. 
 
doi:10.1371/journal.pone.0151530.g002 
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additional analysis (Table 4), the responses of the tested devices were relatively similar to the ones 
in the previous tests that included the 45-minute sleep onset phase. The largest change was seen in 
device D, where the residual AHI increased from 0.6 to 6 events per hour. 
Discussion 
We successfully developed and carried out a proof-of-concept test of a novel optimized bench 
model easily adaptable to simulate different SDB patterns found in OSA, including periods of wake, 
periods representing different sleep stages and phases of more or less severe SDB events. This tool 
can be useful to objectively evaluate bench test performance of different APAP devices with realistic 
breathing patterns covering a wide range of patient phenotypes. In its “Steady mode”, the simulator 
could also assess the capacity of APAP, as well as CPAP, devices to estimate treatment duration and 
detect residual respiratory events of a fixed predefined disturbed breathing scenario. 
The presentation and severity of OSA varies greatly depending on patient characteristics such as 
gender, age, body mass index, and craniofacial structure [18,22]. Specific patient 
Table 4. Results of device re-testing without the sleep onset period. 
Device Pmax 
cmH2O 
Pmean 
cmH2O 
Residual AHI, 
/h 
Overcome  
events 
Overcome 
flow 
limitation 
 Residual flow limitation, min 
(% sleep time) 
D 14.6 8.95 6 Yes Yes  9 (4%) 
G 11.65 9.25 2.6 Yes No  164 (80%) 
H 11.45 7.35 6.6 No No  70 (34%) 
I 11.3 7.9 9.6 Yes No  107.5 (52%) 
AHI: apnea-hypopnea index; NA: not available; Pmax: maximum positive airway pressure applied; Pmean: mean positive airway pressure; D: 
Icon by Fisher & Paykel; G: Prisma 20A by Weinmann; H: System One by Respironics; I: iCH by Apex. 
 
subgroups have been gaining a lot of attention recently because of their clinical relevance. At one 
end of the age spectrum, elderly patients tend to present with severe OSA and snoring becomes less 
common. In addition, the frequency of central events increases, although obstructive events still 
predominate [23]. In contrast, children with OSA have frequent snoring, restless sleep, mouth 
breathing, apneas, gasping, and laboured or paradoxical breathing [24]. With the growing trend 
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towards personalized therapy, specific patient breathing patterns will be increasingly studied as 
manufacturers work to design the most optimal treatment for each phenotype. 
One good example of this is OSA in females versus males. It is well-known that the 
polysomnographic features of female OSA are different from those of male OSA. Overall, women 
have less severe OSA with, on average, a lower AHI [25] and shorter apneas [26]. Women also have 
more episodes of upper airway events during REM sleep [25]. Body position is far less important for 
the severity of OSA in women, while OSA severity in men is based more on position than sleep state 
[25]. Furthermore, women may take longer to fall asleep, but have fewer awakenings during sleep 
[27]. Regardless of the patient’s gender, there is also significant night-to-night variation in OSA, 
based on factors such as body posture, sleep stages, and previous drug or alcohol intake [28]. 
Besides OSA pathophysiology, gender influences also patients’ PAP requirements [29], as generally 
female patients require lower pressures. Such considerable variability between phenotypes 
highlights the relevance of the simulation approach taken in this study. In our optimized bench test 
we implemented a dynamic pattern (“PAP-responsive”) simulating a female patient phenotype 
(although an individual male patient may also present with this OSA pattern), which included long 
periods of flow limitation, low AHI, and short, low-severity obstructive events. Only three of the 
APAP devices tested were able to achieve full breathing normalization by overcoming all types of 
disturbed events including flow limitation. Considering the potential for increased flow limitation in 
female patients, which may lead to breathing disturbances, the effectiveness of treatment in 
patients presenting with a high component of flow limitation should be carefully examined. 
Published data comparing different APAP algorithms is scarce, particularly for devices recently 
launched into the market. Pevernagie et al examined two APAP devices and found that the residual 
apnea-hypopnea index (AHI) was lower during use of one device compared with the other 
(3.5±5.6/h vs 9.9±31.0/h), and that the amount of snoring during the night was significantly higher 
with one device [30]. A similar study by Nolan et al compared three commercially available devices. 
The authors found that mean pressure and patient compliance were significantly lower on one of 
the APAP devices [17]. Differences between algorithms combined with a lack of information 
regarding how different auto-adjusting devices work has led to the perception that auto-adjusting 
devices are a ‘black box’ which should be used with caution [31]. In this study, we also found 
considerable variation among devices in both the magnitude of response to obstructive events, the 
time taken to increase pressure during disrupted breathing, and device behaviour during the 
simulated wake period. With the exception of one device, which did not increase the pressure at all, 
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most devices at least slightly increased pressure during simulated wakefulness. Some devices 
showed quite an intense pressure response during the wake period of the test, with one reaching 
almost 14 cmH2O and two reaching 12 cmH2O. Due to the potential impact this could have on 
patient comfort, pressure changes during wake periods should be assessed in clinical practice, 
particularly in patients who report difficulties falling asleep while using PAP therapy or issues with 
comfort at higher PAP pressures. 
As stated above, our finding of considerable variability in the response of APAP devices when 
subjected to the same breathing pattern under well-controlled conditions is in agreement with 
previous reports [19,21,32]. These variations can be attributed to the individual algorithms within 
each APAP device. Each algorithm analyses flow and pressure to determine whether there is a 
breathing disturbance, and then initiates the most appropriate response to correct such a 
disturbance. For instance, it is interesting to note that, as we explained previously [21], the 
simulated hypopneas in our model were defined according to specific values of a flowlimitation 
pattern index initially introduced by Teschler et al [33]. Therefore, it could be possible that 
automatic CPAP devices set to detect hypopneas using this index, or something similar, could be 
more suitable for detecting our simulated events than other devices that use other metrics to define 
and detect hypopneas. Another reason for the observed different response in the automatic CPAP 
devices tested is that the optimal rate of pressure increase after detection of obstructive events has 
not been clinically defined. In fact, APAP devices are designed to normalize breathing at a rate which 
treats actual SDB, avoiding any response to false events, thereby unnecessarily modifying pressure. 
The results of this bench test have shown that, under well-controlled conditions, there are marked 
variations in response by different APAP devices, and that there may be high residual AHI or 
uncontrolled flow limitation in some female patients on some APAP devices. Therefore, all APAP 
devices should not be considered equal, and efficacy and patient comfort should be carefully 
examined following APAP initiation. 
It must be noted that our results are restricted to the specific patterns of disturbed breathing used 
in this bench test to simulate a specific OSA patient. It is possible that the response of the tested 
devices would have been different from the ones reported here if SBD was simulated using different 
patterns or patient phenotypes. In addition, a limitation of this study is that one device of each type 
was used. Hence, a more complete assessment would require testing of a larger number of each 
type of device randomly obtained from those available in the market. Finally, it should be stressed 
that although bench testing is a useful way to investigate the behaviour of different devices, testing 
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outcomes may vary in clinical practice due to the almost unlimited spectrum of events and 
phenotypes found in real life. Indeed, crucial factors such as changes in loop gain, and upper airway 
compliance and pharyngeal critical pressure are not considered in our model. Accordingly, bench 
testing should be considered as a preliminary assessment before clinical evaluation in patients. 
In conclusion, this study showed that a dynamic bench model tailored to represent specific OSA 
patient phenotypes, incorporating a variety of disturbed breathing events within the same simulated 
night, including different degrees of severity along sleep stages, and a period of wakefulness, can be 
useful to characterize treatment responses of commercially-available APAP devices. This 
demonstrates that bench testing can be modified to better represent a “real” patient, and that APAP 
devices can show markedly different responses to the same simulated breathing patterns. 
Realistically mimicking OSA patients during bench testing is useful as a first step to aid in the 
understanding of actual APAP device responses observed in the clinical setting, and can be helpful in 
selecting the device that best meets the individual needs of each patient, thereby improving comfort 
and increasing adherence to therapy, which is essential for effective treatment and reducing the 
consequences of OSA [34]. 
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